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The nucleolus is a multifunctional organelle that, in addition to its primary role in 
ribosome biogenesis, has emerged as a critical stress sensor and coordinator of stress 
response. However, the molecular nature of how nucleoli sense stress and coordinate 
downstream cellular consequence remains poorly understood. NF-κB signalling is a 
critical regulator of stress response. Many cellular stresses that disrupt nucleolar 
function also stimulate the NF-κB pathway. However, the role of NF-κB as a 
downstream effector of nucleolar stress has not yet been examined. Aspirin, a known 
chemopreventative agent, stimulates the NF-κB pathway to mediate apoptosis but the 
upstream mechanisms are unclear. In this thesis, I identified a novel nucleolar stress 
response pathway that culminates in activation of NF-κB signalling, and 
demonstrated the significance of this nucleolar pathway in the anti-tumour effects of 
aspirin. Using multiple approaches, I made the novel observations that disruption of 
the Pol I complex activates the cytoplasmic NF-κB signalling pathway. I show that 
multiple stress stimuli of NF-κB pathway induce degradation of the crucial Pol I 
complex component, rDNA transcription initiation factor IA (TIF-IA). I identified 
the tumour suppressor, p14ARF and the Pol I complex component, upstream binding 
factor (UBF) as mediators of this degradation. I revealed that inhibition of CDK4 
activity lies upstream of UBF/p14ARF-facilitated TIF-IA degradation. Furthermore, 
using different approaches I show that blocking aspirin/CDK4i-mediated degradation 
of TIF-IA blocks the effects of these agents on nucleolar morphology and NF-κB 
signalling. Finally, I show this nucleolar stress response pathway, containing a 
UBF/p14ARF/TIF-IA axis, is utilized by aspirin to kill colon cancer cells. Taken 
together, this data presented in this thesis advances understanding of nucleolar stress 
response, and has therapeutic implications with regard to the anti-tumour effects of 
aspirin. 






The nucleolus, a cell compartment in the nucleus, is essential for cell growth. It is 
dysfunctional in the majority of cancers and as such, is emerging as a target for 
cancer therapeutics. Cells are surrounded by a rapidly changing environment and 
exposed to numerous stress signals. The nucleolus acts as a central hub for 
converting these environmental stress signals to alterations of cellular function, but 
the mechanism underlying this role of nucleolus is largely unknown. Accumulating 
data from clinical trials have provided optimism regarding the potential role of 
aspirin as a cancer preventative agent, especially against colon cancer. However, the 
potential harm from aspirin-induced bleeding and the unclear mechanism of the anti-
tumour action of aspirin precludes its use as a chemopreventative agent.  
This thesis aims to illustrate how the nucleolus coordinates cellular stress response, 
and explore the role of nucleolar regulation in the anti-tumour effects of aspirin, with 
a view to identify molecular targets for further development of anti-tumour drugs. 
Generally, I show aspirin and other cellular stress signals induce significant changes 
to the morphology of the nucleolus, changing its size and number. I also show aspirin 
inhibits nucleolar function by reducing the protein level of a critical nucleolar 
protein—TIF-IA, reduction of which has been associated with cell death. Using 
biochemistry methods, I have revealed the molecular basis of aspirin-induced TIF-IA 
degradation and demonstrated that modifying this pathway to block degradation of 
TIF-IA blocks aspirin’s effects on nucleolus and colon cancer death. Therefore, in 
my PhD study, I define a cellular signalling pathway in the centre of nucleoli that is 
critical for the anti-tumour effects of aspirin in colorectal cancer. This could be an 
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The nucleolus is a distinct subnuclear organelle that is easily visible by phase 
contrast microscopy. In the past century, researchers have established the role of the 
nucleolus as the primary site of ribosome production and the mechanisms underlying 
the assembly, structure and function of nucleoli, and the pathways involved in 
ribosome biogenesis, have been comprehensively investigated. 
1.1.1 Assembly, structure and function 
The nucleolus was first formally documented between 1835-1839 by Wagner and 
Valentin independently. For the next century, due to the limitations of microscope 
technology, there were only occasional reports of the nucleolus in the broader 
context of cytological studies at that time. Then, from 1931-1934, Heitz and 
McClintock discovered that the nucleolus arises at a specific chromosomal locus. 
This discovery of nucleoli stationed at a genetic locus advanced nucleolar research in 
a way that proved nucleoli were cytogenetic entities rather than merely being an 
aspect of nuclear anatomy (Pederson, 2011). We now clearly know that nucleoli are 
not free-floating but anchored to specific genetic loci, which are termed nucleolar 
organizer regions (NORs), defined as clusters of head-to-tail tandem ribosomal DNA 
(rDNA) repeats. In humans, these repeat units are distributed on the short arms of 
five acrocentric chromosomes (chromosomes 13, 14, 15, 21 and 22) (Figure 1.1). 
Only a proportion of NORs are transcriptional active in many cell types due to 
epigenetic modulation of proteins (such as histones) and chromatin at the rDNA loci 
(McStay and Grummt, 2008). A single NOR is capable to form a functional 
nucleolus, and nucleoli assembled on different NOR always display distinct size and 
shape. Besides, it often happens that several active NORs coalesce together to 
assemble one nucleolus (Savino et al., 2001).  These properties of nucleolus 
assembly explain the diversity of this organelle.  
Another criteria contributing to the diversity of nucleolar structure is that the 
nucleolus undergoes ordered assembly/disassembly depending on the stage of cell 
division. It is disassembled at the onset of mitosis and assembled again upon 
completion of mitosis (Hernandez-Verdun, 2011). Nucleolar assembly is dependent 
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upon transcription of rDNA by the Polymerase I (Pol I) transcription machine and 
therefore, only occurs at active NORs. The minimal molecular requirement to drive 
assembly of a functional nucleolus was firstly investigated by Karpen et.al in 1988. 
In a research, they found rDNA transcription and ‘mininucleoli’ formation could be 
driven when an ectopic rDNA sequence was introduced into the genome of 
Drosophila melanogaster (Karpen et al., 1988). This finding was further deciphered 
by Brain McStay’s lab using a synthetic biology method. They artificially introduced 
DNA sequences from the ribosomal gene of Xenopus, which contained multiple 
binding sites for human upstream binding factor (UBF), into human chromosomes 
without a NOR. They found this rDNA fragment was sufficient to recruit 
endogenous UBF and other essential components of the Pol I transcriptional 
machinery. Importantly, these so-called ‘pseudo-NORs’ exhibited the same key 
features as an endogenous active NOR, although they were transcriptionally inactive 
and could not form functional nucleoli (Mais et al., 2005). They later expanded their 
finding by constructing a ‘neo-NOR’ which not only had a similar function to 
‘pseudo-NORs’ but was also transcriptionally active, produced mature rRNAs and 
formed functional neo-nucleoli. This ‘neo-NOR’ cassette, which contained UBF-
binding sites, human rDNA promoter and mouse rDNA transcription unit, can also 




The notion that the nucleolus is the site of ribosomal RNA synthesis and ribosome 
assembly came to light in the 1960s. In a landmark nucleolus meeting at Montevideo, 
Uruguay in 1965, a report from Donald Brown and John Gurdon demonstrated 
nucleoli are responsible for ribosome biosysthesis as they found anucleoate Xenopus 
embryos exhibit impairment of ribosome production and arrested in development 
when the maternal stock of ribosomes was exceeded. This finding, along with other 
data presented in this conference demonstrating DNA complementary to ribosomal 
RNA (rRNA) residues in the nucleolus, and that rRNA is generated from larger 
precursor molecules, established the role of the nucleolus as a ribosome production 
factory (Pederson, 2011). 
Following this meeting, the detailed molecular process of ribosome biosynthesis in 
the nucleolus was intensively addressed. In the past five decades, researchers have 
made significant progress in understanding the stages of pre-ribosomal particle 
assembly, determined a role for small nucleolar RNAs and ribonucleoproteins in 
rRNA processing and, with the help of electron microscopy, defined three distinct 
subregions of nucleoli. Basically, the nucleolus is tripartite in structure when 
observed under electron microscopy, which consists of fibrillar centres (FCs), dense 
fibrillar components (DFCs) and the surrounding granular component (GCs). As 
mentioned above ‘‘the nucleolus is an organelle formed by the act of building a 
ribosome’’, nucleoli locally concentrate the dedicated transcription and processing 
factors that are responsible for ribosome assembly, and the nucleolar tripartite 
structure is closely related to the complex and step-wise controlled ribosome 
assembly process. Each compartment reflects events related to ribosomal DNA 
transcription and ribosomal protein synthesis through enriching certain molecules 
involved in the process (Figure 1.2). Briefly, in FCs or at the boundary of FCs and 
DFCs, the initial 47S rRNA precursor is generated from Polymerase I (Pol I)-
dependent transcription of rDNA clusters on the transcriptional active NORs. In the 
DFCs, 47S rRNA is cleaved to form 28S, 18S and 5.8S rRNAs, which then undergo 
steps of post-transcriptional modifications through interacting with a number of 
Polymerase II (Pol II) transcribed small ribonucleoproteins (snoRNPs). Finally, in 
the GCs, modified rRNAs are assembled with Pol III transcribed 5S rRNA and a 
multiple ribosomal proteins and assembly factors generate the large pre-60S 
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ribosome (28S, 5.8S, 5S rRNAs) and small pre-40S ribosome (18S rRNA) subunits. 
These then interact with the export machinery and are transported to the cytoplasm 
where the mature functional ribosomes are ultimately formed after binding with 
message RNAs (mRNAs). 
 
1.1.2 rDNA transcription—the Pol I transcription machinery 
The initiation of ribosomal biosynthesis requires the active transcription of ribosomal 
DNA, which is dependent on the assembly of Pol I transcription initiation machinery 
(a multi-protein complex incorporating RNA polymerase I) on the promoter region 
of rDNA genes. 
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1.1.2.1 The formation of Pol I transcription machinery 
In mammals, binding of the two ancillary factors, upstream binding factor (UBF) and 
the promoter selectivity factor (termed SL1 in human, TIF-IB in mice), to the rDNA 
promoter, initiates the formation of the pre-initiation complex. UBF binds as a dimer 
to the upstream control element (UCE) and the GC-rich element in the core promoter 
of rDNA through its high mobility group (HMG) boxes. Like other sequence-
nonspecific high mobility group proteins (such as HMG1 and HMG2), the presence 
of the HMG box allows UBF to bend DNA and act as an architectural element to 
maintain chromatin/chromosomes structure. The UBF dimer interaction with the 
UCE enables a single turn of ~140 base pairs of enhancer DNA to form a 
nucleosome-like structure called the enhancosome. The formation of the 
enhancosome juxtaposes the precisely spaced UCE and core promoter to structurally 
support the assembly of the pre-initiation complex. Upon DNA binding of UBF, the 
promoter selectivity factor SL1/TIF-IB can interact with UBF and bind DNA 
cooperatively. SL1/TIF-IB is a protein complex of the TATA binding protein (TBP) 
and TBP-associated factors including TAFI110/95, TAFI68, TAFI48, TAFI35 and 
TAFI12 (Drygin et al., 2010). It confers promoter specificity and provides a crucial 
link between the rDNA promoter and core polymerase Pol I, which itself has no 
DNA binding activity, by interacting with a number of Pol I associated factors (like 
TIF-IA/RRN3 and PAF53) to recruit Pol I to the promoter. Pol I itself is a complex 
component, which in human has two distinct isoforms Pol I α and Pol I β. Although 
Pol I α comprises ~90% of cellular Pol I, it is Pol I β involved in the transcription 
initiation complex while Pol I α may play a more important role in transcription 
elongation (Russell and Zomerdijk, 2005).  
The assembly of the Pol I transcription pre-initiation machinery could be a stepwise 
process (subunits recruited to the promoter in order) or a pre-assembly process (all 
the factors assembled into a holoenzyme before docking at the promoter). It is still 
debatable with evidence for both hypotheses. The isolation and identification of a Pol 
I holoenzyme from mammalian (Hannan et al., 1999) (Seither et al., 1998) and 
Saccharomyces cerevisiae (Schneider and Nomura, 2004), containing Pol I and other 
core elements, has supported the scenario of a pre-assembly process. In contrast, 
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other reports have suggested the subunits are recruited to the promoter individually 
(Russell and Zomerdijk, 2005). In particular, experiments in live cells using 
fluorescence recovery after photobleaching (FRAP) methods have shown the 
individual dynamics of Pol I subunits and UBF as well as PAF53 and TIF-IA have 
distinct properties under conditions of different transcription levels (Gorski et al., 
2008).   
1.1.2.2 Regulation of Pol I transcription 
The production of ribosomes is the most energy consuming process in a cell. 
Therefore, there is a tight link between ribosome biogenesis, protein synthesis, cell 
growth and cell proliferation. The efficiency of protein synthesis is largely limited at 
the level of rDNA transcription or by the content of cellular rRNA, which means 
cells need to maintain a high rate of rRNA production to supply enough ribosomes 
for cell growth and metabolism. Therefore, the activity of rDNA transcription is 
efficiently controlled under changing cellular environment. Considering the nature of 
ribosomal DNA (hundreds copies of tandemly repeated rDNA genes), there are two 
possible models proposed for transcriptional regulation of rDNA.  
For long-term regulation, the number of transcriptionally active NORs engaged in 
active transcription is controlled at an epigenetic level through histone modification 
and DNA methylation (McStay and Grummt, 2008). In this process, several factors 
have been found to be involved in chromatin remodelling to alter the ratio of active 
to silent rDNA gene copies, including TTF-I (transcription termination factor I), CSB 
(cockayne syndrome protein B) and NoRC (nucleolar remodelling complex). It 
should be noted that UBF, as a member of Pol I transcription initiation complex, also 
plays an important role in regulating the condensation of chromatin structure through 
its HMG box DNA binding motifs (McStay and Grummt, 2008) (Grob et al., 2014; 
Mais et al., 2005).  
The epigenetic regulation of rDNA transcription accounts for the majority of species-
specific or tissue-specific transcription of rDNA genes, and functions throughout cell 
cycle progression, cell development and differentiation. However, given the high-
energy demand of cell metabolism and dramatic changes in the environment a cell 
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can potentially face, a more rapid, short-term rDNA transcription regulation model is 
required for finely adjusting transcription rates. In this short-term regulation system, 
the transcription rate of an individual active gene is changed by reversible, post-
translational modifications of Pol I transcription factors in response to various 
upstream signalling pathways. These modifications in turn affect the Pol I 
transcription initiation, elongation and rRNA processing and then results in different 
ribosomal production efficiency (Figure 1.3).  For example, the PI3K/AKT and 
RAS/RAF/MAPK/ERK pathways are well-known to regulate rDNA transcription in 
response to growth factors while an mTORC1 regulated pathway is known to play a 
central role in monitoring nutrient availability and regulating the rate of rDNA 
transcription. AMP dependent protein kinase (AMPK) is the critical energy sensor 
that transmits the cellular energy status to rDNA transcription outcome. These 
pathways can target multiple modification sites on crucial Pol I factors, like UBF, 
SL1 and TIF-IA, to change the activity of Pol I transcription (Reviewed by (Kusnadi 
et al., 2015)).   
 




Synthetic biology assays have revealed UBF is the minimal component to drive 
formation of the basal Pol I transcription machinery and assembly of a functional 
nucleolus. Therefore, it is anticipated that any modulation of UBF activity would be 
coupled with dramatic effects on the Pol I transcription activity. The activity of UBF 
is controlled by regulated phosphorylation. It is phosphorylated at serine residue 484 
by cdk4/cyclinD1 and cdk2/cyclin E upon serum stimulation (Voit et al., 1999) and 
phosphorylated at serine residue 388 by cdk2/cyclin E and cdk2/cyclin A during S 
phase of the cell cycle (Voit and Grummt, 2001). Under mitogenic stimulation, UBF 
is phosphorylated by ERK at threonine 117 and threonine 201 which are within 
HMG boxes 1 and 2 (Stefanovsky et al., 2001). The mTOR pathway is required for 
serum-induced activation of rDNA transcription via ribosomal protein S6 kinase 1 
(S6K1) phosphorylation of UBF on the carboxy-terminal activation domain (Hannan 
et al., 2003). These reports suggest that phosphorylation of UBF results in variation 
of Pol I activity through affecting its interaction with other Pol I factors or rDNA. 
Reports also suggest acetylation of UBF affects its activity. Acetyltransferase CBP 
activates Pol I transcription by acetylating UBF and reversing its inhibition by 
tumour suppressor pRb and associated histone deacetylases (Pelletier et al., 2000).  
SL-1 
SL-1 is essential to initiate the formation of the pre-initiation complex. It is known 
that ‘basal’ levels of rDNA transcription in vitro can be supported by the presence of 
only SL1 and Pol I (Russell and Zomerdijk, 2005). During mitosis, Cdk1/cyclin B 
phosphorylates TAFI110, a subunit of SL1/TIF-IB, on threonine 852, thus impairing 
the interaction of SL1/TIF-IB with UBF and silencing Pol I transcription (Heix et al., 
1998). In a reconstituted in vitro system, p300/CBP-associated factor PCAF, a 
histone acetyltransferase, acetylates SL1/TIF-IB subunit TAFI68 and promotes its 
DNA binding activity. In contrast, the histone deacetylase, mSir2a, deacetylates 
TAFI68 and represses rDNA transcription (Muth et al., 2001). These suggest, in 
response to external signals, revisable acetylation on SL1 could be another effective 




Transcription initiation factor TIF-IA, the mammalian homolog of yeast Rrn3, is a 
crucial member of the RNA polymerase I transcription machinery. Of all Pol I 
complex factors, TIF-IA is the critical component for responding to environmental 
cues and cellular stress. TIF-IA interacts with Pol I β, coordinating the interaction of 
Pol I and SL-1/TIF-IB, which is necessary for recruiting Pol I to the rDNA promoter 
and to assemble the transcription initiation complex (Yuan et al., 2002).  
Since TIF-IA plays a crucial role in regulating growth-dependent rDNA transcription, 
disruption of TIF-IA always induces impairment of rRNA synthesis and generally 
leads to abnormal cell growth and apoptosis. Yuan X et.al inactivated the TIF-IA 
gene by Cre-mediated homologous recombination in mice. TIF-IA-/- embryos 
exhibited retardation of growth and development and died before or at embryonic 
day 9.5. They also discovered using induced deletion of TIF-IA in MEFs, that 
disrupting nucleoli, caused cell cycle arrest and high rates of apoptosis, as well as 
activation and stabilization of p53. These TIF-IA depletion effects were abrogated by 
knocking down p53 (Yuan et al., 2005). In another set of data where TIF-IA was 
specifically knocked out in the nervous system, TIF-IA-deficient mice displayed 
upregulated p53 levels in neural progenitors and hippocampal neurons and 
demonstrated neurodegeneration and dies shortly after birth (Kiryk et al., 2013; 
Kreiner et al., 2013; Parlato et al., 2008). These findings indicate that it is possible to 
induce cell suicide or tissue damage by ablation of TIF-IA. 
TIF-IA is targeted by multiple protein kinases in response to environmental signals, 
which regulates the formation of the transcription initiation complex and accordingly, 
modulates cell growth and proliferation (Table 1.1). Following oxidative or ribotoxic 
stress, JNK2 was shown to phosphorylate TIF-IA at Thr200. This effect causes TIF-
IA nucleolus to nucleoplasm translocation and results in inhibition of rRNA 
synthesis (Mayer et al., 2005). mTOR regulates two phosphorylation sites on TIF-IA, 
serine 44 and serine 199, under certain nutrient related stresses. Interestingly, mTOR 
mediated phosphorylation at these two sites has opposite effects. Inhibition of mTOR 
activity causes TIF-IA to translocate to the cytoplasm, impairs formation of the 
rDNA transcription initiation complex and suppresses rRNA synthesis (Mayer et al., 
2004). AMP-activated protein kinase (AMPK) regulates TIF-IA under energy 
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depletion stress. In this case, AMPK phosphorylates serine 635 of TIF-IA leading to 
impairment of the interaction between TIF-IA and SL1 and down-regulation of Pol I 
transcription activity (Hoppe et al., 2009).  
In addition to stress-related regulation, TIF-IA activity is regulated by growth factors 
(Table 1.1). These factors increase rRNA synthesis through activating mitogen-
activated protein kinase (MAPK) phosphorylation of TIF-IA. Serine 633 and 649 on 
TIF-IA are targeted by ERK and RSK to transfer growth signals to rDNA 
transcription initiation and ribosomal subunit biogenesis (Zhao et al., 2003). 
Phosphorylation of serine 170/172 at TIF-IA by Casein Kinase 2 (CK2) is required 
for efficient rDNA transcription cycling. This phosphorylation triggers the switch 
from rDNA transcription initiation to elongation phase by disassociating TIF-IA 
from Pol I. FCP1 dephosphorylates these two sites and re-tethers TIF-IA to the Pol I 
polymerase to switch a new round rDNA transcription initiation (Bierhoff et al., 
2008).  
Besides phosphorylation, a few researches have shown basal TIF-IA is regulated by 
ubiquitination dependent degradation. Fatyol and Grummt demonstrated that TIF-IA 
associates with proteasomal ATPases and demonstrated that this may contribute to 
TIF-IA’s functional ubiqutination-degradation (Fatyol and Grummt, 2008). 
Meanwhile, Le Xuan Truong Nguyen and Beverly found that the E3 ligase MDM2 
co-localizes with TIF-IA in the nucleus and increases its ubiquitination and 
degradation (Nguyen le and Mitchell, 2013). However, the regulation of TIF-IA 
protein levels following cellular stress has never been reported. 
Given that TIF-IA coordinates multiple extracellular signals to link rRNA synthesis 
with stress response and cell growth, it represents a promising molecular target for 




1.2 The plurifunctional nucleolus   
A bold but prescient statement came out at the same time as the ribosome 
biosynthesis function of nucleolus unravelled. In a summary report of the historic 
Montevideo conference on the nucleolus in 1965, C.H.Waddington, an embryologist 
from Edinburgh, said: ‘‘The nucleolus probably should not be considered a relatively 
simple organelle with a single function, comparable to a machine tool turning out a 
particular part of an automobile. It is not just ‘the organelle where the cell 
manufactures ribosomes’. It is rather a structure through which materials of several 
different kinds are flowing, comparable more to a whole production line than to a 
single machine tool.’’(Pederson, 2011)  
It was shortly after this statement that experimental data suggested the nucleolus has 
functions in addition to ribosome biogenesis. In the late 1960s and early 1970s, the 
Harris lab deduced that nucleoli participate in the biogenesis of certain messenger 
RNA. By fusing chicken erythrocytes containing a condensed inactive nucleus with 
transcriptionally active HeLa cells, they found that, despite the presence of HeLa cell 
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ribosomes in the cytoplasm, the new synthesized chicken specific proteins only 
became detectable in the heterokaryons after the inactive erythrocyte nucleus had 
undergone chromatin decondensation and nucleoli had been formed (Pederson, 2011).  
Despite Harris’s effort to promulgate the additional functions of nucleolus beyond 
assembly of ribosomes, the diversity of nucleolar functions was only really realised 
by the world in the early 1990s, when Thoru Pederson’s lab discovered its role in the 
biosynthesis of the signal recognition particle (SRP). The SRP is a ribonucleoprotein 
complex that can bind to the signal sequence of nascent polypeptides to halt 
translation elongation. Subsequently, it is involved in the process of transporting new 
synthesized peptides to recognition components on the endoplasmic reticulum (ER) 
for secretory or membrane translocation (Jacobson and Pederson, 1998). The mature 
SRP is abundant in the cytoplasm. Therefore, Thoru Pederson lab supposed SRP 
RNA would not localize in nucleoli and would be a suitable negative control for a 
study to define nucleolar targeting RNAs. To their surprise, following the 
microinjection into the nucleus, the fluorescently labelled SRP RNA demonstrated a 
rapid but transient translocation into the nucleolus, before moving out of nucleolus to 
its conventional cytoplasmic location (Jacobson and Pederson, 1998). This finding, 
together with a number of other discoveries showing certain mRNAs were generated 
in the nucleolus rather than the cytoplasm, led Thoru Pederson to propose the 
‘plurifunctional nucleolus’ hypothesis (Pederson, 1998). Further studies built on this 
discovery by demonstrating the distribution of SRP RNA within the nucleolus was 
distinct from the known stations of ribosome biogenesis, and revealing the nucleolus 
is indeed a site of SRP assembly (Sommerville et al., 2005). These discoveries 
therefore suggested there might be subnucleolar regions specialized for other 
function beside ribosome biogenesis. 
The idea of the ‘plurifunctional nucleolus’ was significantly enhanced by work from 
the Lamond lab defining the nucleolar proteome. They first combined nucleoli 
purification and mass spectrometry (MS) to identify a group of nucleolar proteins, 
including some proteins without previously known nucleolar functions, and some 
proteins were encoded by uncharacterized genes at that time (Andersen et al., 2002). 
This proteomic data revealed more complicated nucleolar functionality than 
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previously thought. In addition, using the well-established technique of large-scale 
biochemical isolation of nucleoli combined with stable isotope labelling with amino 
acids in cell culture (SILAC)-based quantitative proteomics, they were able to 
demonstrate that human nucleoli contain over 4500 proteins, and the majority of 
which (70%) have functions outside of ribosome biogenesis (Ahmad et al., 2009). 
This further indicated a multifaceted role for the nucleolus as central hub to link 
ribosomal subunit biosynthesis with other cellular functions. Since these initial 
experiments, a wealth of information has been deduced regarding the nucleolar 
proteome from a number of different species and in response to different stimuli 
(Boisvert et al., 2012; Boisvert et al., 2010; Moore et al., 2011). Interestingly, a study 
from the lab comparing the human and yeast nucleolar proteomes found that ~90% 
of the nucleolus-associated yeast proteins have a human homologue (Andersen et al., 
2005) indicating high conservation of the nucleolar proteome through evolution.  
From proteomic studies, there are also some interesting findings been revealed, like 
the existence of a large pool of unassembled ribosomal proteins and ubiquitination 
and proteasome degradation of ribosomal proteins, which are beyond the 
conventional notion of ribosome biosynthesis in the nucleolus and reveal more 
surprises regarding nucleolar function (Pederson, 2011). 
Moreover, proteomic data have implied the nucleolus is involved in the regulation of 
cellular functions that determine the cell fate (Figure 1.4). This have also been 
evidenced by a growing body of experimental studies, reinforcing the multifunctional 




1.2.1 Nucleolus and cell cycle progression 
One particular area regulated by nucleoli is the cell cycle. Firstly, the cell cycle itself 
influences nucleolar function. For example, factors in the Pol I transcription complex 
are modulated by different cyclin-dependent-kinases to dynamically activate or de-
activate rDNA transcription and then subsequently assemble or dissasemble nucleoli. 
Secondly, as cells need nucleoli to produce sufficient ribosomes for protein-synthesis, 
cell growth and division is tightly linked with the nucleolus. It is no doubt that cells 
with impaired nucleoli and limited ribosome production will be disfavoured by 
natural selection and destined to die. It has been well established that perturbation of 
ribosome synthesis can cause cell cycle arrest through deprivation of newly 
synthesised ribosomes (Tsai and Pederson, 2014). However, beyond this obligatory 
relationship, nucleolus has also been shown playing roles in coordinating cell-cycle-
control in ways that unrelated to its ribosome production function. This was first 
mentioned by the Thoru Pederson lab, as they selectively inhibited rDNA 
transcription using low dose of actinomycin D, which had minor effect on cells’ 
ribosome store, had caused cell cycle arrest (Pederson and Powell, 2015). Then a 
nucleolar surveillance system centred around the p53 pathway has been proposed in 
the regulation of cell cycle progression after nucleolar disruption (Tsai and Pederson, 
2014).   
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Probably, the most intensively studied mechanism linking nucleoli to cell cycle 
progression is activation of p53. p53 also participates in other downstream effects of 
nucleolar perturbation. How p53 contributes to the ‘plurifunctional nucleolus’ will be 
discussed in full below. 
The nucleolus may also regulate the cell cycle by sequestering specific cell cycle 
proteins. One example is, in yeast, a protein phosphatase named cdc14 is sequestered 
in the nucleolus by the anchoring protein Net1 during interphase. Upon entry into 
anaphase, Net1 is phosphorylated, which releases activated cdc14, allowing it to 
dephosphorylate the mitotic cyclin degradation activator—Cdh1, thus promoting exit 
from mitosis. Nucleolus can also regulate cell cycle by merely sequestering factors 
required for cell cycle in this subcompartment without any post-translational 
modification process. One example is the nucleolar sequestration of telomerase. In 
primary human cells, the telomerase remains in the nucleolus until the beginning of 
telomeres replication at the late stage of S phase. This regulated sequestration-release 
has been suggested to play a crucial role in ensuring the appropriate timing of 
telomeres replication, as this sequestration is disrupted and telomerase mobilizes 
from nucleolus to nucleoplasm either in transformed cells or in cells underwent DNA 
damage (Wong et al., 2002). 
1.2.2 Nucleolus and cell apoptosis, cellular senescence, stem 
cell biology and viral replication  
Beyond cell cycle and cell growth control, studies have broadened the role of 
nucleoli to other fields like cell apoptosis, cellular senescence, stem cell biology and 
viral replication.  
A number of evidences have revealed a role of the nucleolus in regulating 
programmed cell death. RelA is a transcription factor of the NF-κB signalling 
pathway, which binds to targeted gene promoter and drives gene expression in the 
nucleoplasm. In colorectal cancer cells, proapoptotic stimuli (such as aspirin 
treatment, UV-C exposure and serum deprivation) caused cell apoptosis through 
sequestration of transcription factor NF-κB RelA in the nucleolus and inhibiting NF-
κB-driven pro-survival effects (Stark and Dunlop, 2005). Furthermore, in a parallel 
17	
	
way, nucleolar sequestration of RelA triggered translocation of nucleolar protein 
nucleophosmin (NPM) from nucleolus to cytoplasm, where it facilitated BAX 
mitochondrial accumulation and then cell apoptosis (Khandelwal et al., 2011). A 
recent study further supported the link between the nucleolus and BAX-mediated 
apoptosis. Peter Pan (PPAN), a protein mainly localized in the nucleolus and 
mitochondria, was released from nucleolus and accumulated in mitochondira under 
nucleolar stress, where it increased BAX-mediated mitochondrial outer membrane 
permeabilization and promoted cell apoptotic activity (Pfister et al., 2015). 
There are few but provocative evidences link nucleolus to cellular senescence, the 
majority of which are focus on the human-aging-linked Werner Syndrome (WS), 
although the mechanism of this connection have been poorly investigated (Pederson, 
2011). Briefly, the lack of an active Werner syndrome protein (WRN) would lead to 
WS, studies shown the human WRN displayed a nucleolar location, and identified 
amino acids 949-1092 are responsible for it (Marciniak et al., 1998; von Kobbe and 
Bohr, 2002).  
The possible connection between the nucleolus and stem cell biology began to 
receive attention when, in a nuclear cloning experiment, the donor nucleolus was 
found experienced immediate reversible disassembly after a somatic nucleus 
injecting to the egg cytoplasm. It also found two Xenopus germ cell RNA-binding 
proteins FRGY2a and FRGY2b were responsible for this intriguing behaviour 
(Gonda et al., 2003). There were more links arose, that Martindill and his colleagues 
found phosphorylation status of nucleolar protein Hand 1 in trophoblast stem cell 
plays as a molecular switch from cell proliferation and renew to commitment giant-
cell differentiation (Martindill et al., 2007).  
There is evidence to suggest that RNA viruses interact with nucleoli to facilitate 
virus replication by consuming materials in the nucleolus (Hiscox, 2007). Studies 
also demonstrate nucleolar trafficking of regulatory factors is indispensable for HIV 
replication (Michienzi et al., 2006; Michienzi et al., 2002), Although the mechanism 
linking nucleoli and viral replication still unclear, it dose provoke an interesting 
question that why certain viruses specifically choose the nucleolus rather than other 
nuclear regions as a site of assembly (Pederson, 2010).  
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1.3 Nucleolus in disease and cancer 
Given that ribosomal biogenesis is a tightly controlled process that plays a critical 
role in the maintenance of cellular homeostasis, metabolism, proliferation and 
growth, it is not surprising that disruption of it leads to pathophysiological disorders. 
Indeed, dysregulation of ribosomal proteins and Pol I transcription are linked with a 
broad range of human diseases.  
Ribosomopathies are a heterogeneous class of diseases caused by genetic mutations 
and loss of functions in the molecular constituents of the ribosome. Examples of 
ribosomopathies include Diamond-blackfan anemia and 5q- syndrome. Other 
disorders intimately associated with rDNA transcription and processing include 
Treacher Collins Syndrome, Werner Syndromes, Shwachman–Diamond Syndrome 
and Cartilage Hair Hypoplasia (Narla and Ebert, 2010). It is still unclear how such 
mutations in ribosomal proteins result in rare congenital syndromes. However, there 
is increasing evidence to show nucleolar stress and activation of the HDM2-p53 
surveillance pathway are critical for the pathological effects of these mutations (Ellis, 
2014; Hannan et al., 2013; Nakhoul et al., 2014; Narla and Ebert, 2010).  
In addition, gene mutations on factors associated with rDNA transcription could lead 
diseases by directly affecting Pol I transcription process. For example, Treacher 
Collins Syndrome (TCS) is a ribosomopathy that primarily results from a mutation in 
one copy of TCOF1 gene. TCOF1 encodes a phosphoprotein called treacle, which 
localizes to the DFC of the nucleolus and associates with pre-rRNP complex. Treacle 
regulates Pol I transcription by directly interacting with rDNA chromatin, the Pol I 
enzyme and UBF. It was shown that TCOF1 gene knock out in mouse embryos 
caused similar growth retardation and craniofacial abnormalities as human TCS 
(Valdez et al., 2004). Filamin A is a well-characterised F-actin binding protein acting 
as a signalling scaffold to regulate cell shape and mobility. Filamin A is encoded 
from the FLAN gene, mutation of which has been linked to a number of human 
genetic disorders with skeletal, craniofacial or cardiovascular defects (Hannan et al., 
2013). One study has demonstrated Filamin A localizes to nucleolus and associates 
with the Pol I enzyme and the Pol I complex component, TIF-IA (Rrn3 in mouse). 
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This interaction prevents Pol I binding the rDNA promoter and thus, inhibits rDNA 
transcription (Deng et al., 2012).  
In addition to ribosomopathies, a wide range of growth dependent and developmental 
diseases are associated with dysfuntion of Pol I transcription, directly or through 
dysregulated upstream signalling networks. For example, diseases like muscle 
hypertrophy and atrophy originate from the imbalance between protein synthesis and 
degradation at the cellular level. A wide range of studies have demonstrated that a 
central mechanism for the development of these diseases is the dysregulation of 
growth related signalling pathways, such as PI3K/AKT/mTOR and RAS/RAF/ERK, 
and the subsequent modifications of key modulators of Pol I transcription (Hannan et 
al., 2013). Nucleolar stress is also associated with the pathogenesis of neurological 
diseases, for example, Parkinson's disease and Huntington's diseases (HD) (Lee et al., 
2014; Parlato and Liss, 2014). In respect to the molecular mechanisms, studies have 
shown dysfunction of crucial Pol I factors can lead to neurological disorders. For 
example, post-translational modifications on UBF, such as acetylation and 
methylation, have been shown to play a central role in the development and 
progression of HD (Lee et al., 2014); Neuronal degeneration is promoted in TIF-IA 
gene knock-out mice or in neurons with perturbed TIF-IA(Parlato et al., 2008; Rieker 
et al., 2011). 
1.3.1 Nucleolus and cancer 
Impairment of nucleolar functions is also an indicator of cancer development and 
emerging as a promising therapeutic target for cancer treatment. Firstly, increased 
Pol I transcription leads to enlargement of nucleoli. Indeed, abnormal nucleolar size 
has been used by pathologists as an indicator of tumour proliferation as much as a 
century ago, well before the primary function of nucleoli was established. Secondly, 
tumour cells need hyper-activated Pol I transcriptional activity to meet the high 
protein needs required for uncontrolled proliferation. Generally, tumour cells 
abnormally promote Pol I transcription by means of hyper-activate oncogenes, 
inactivate tumor suppressors and up-regulate protein kinase. For example, oncogene 
c-Myc enhances the association of SL1/TIF-IB to rDNA promoter or directly up-
regulates expression of UBF (Schlosser et al., 2003), and a murine model of 
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spontaneous lymphoma overexpressing MYC in B lymphocyte (Eµ-Myc) displayed 
highly expression of TIF-IA and UBF compared to normal B lymphocytes (Bywater 
et al., 2012). This indicates the increased Pol I transcription is an early event in 
carcinogenesis. Therefore, suppression of hyperactivated rRNA production is a good 
approach to restrain the uncontrolled cell proliferation of tumour cells. 
1.3.2 Targeting Pol I factors for disease therapy 
Targeting the nucleolus and ribosome biogenesis for disease therapy remains 
controversial. As ribosome biogenesis is essential to maintain proliferation of normal 
cells, it is technically difficult to design drugs that can act specifically on diseased 
cells with impaired nucleoli and ribosome biosynthesis (Quin et al., 2014). However, 
as ribosome biosynthesis is regulated by numerous processes, many clinically 
approved drugs have been shown to alter their activities, at least in part, through 
affecting Pol I transcription. A screen of current commonly used chemotherapeutic 
agents found that the majority of these drugs (21 out of 36) could affect ribosome 
biogenesis, although at different levels and stages (Burger et al., 2010). Actinomycin 
D and doxorubicin intercalate with rDNA to inhibit Pol I transcription. 5-fluorouracil 
affects the late rRNA processing through incorporating into the 47s pre-rRNA. 
Cisplatin crosslinks rDNA and inhibits Pol I transcription by possessing a high 
affinity with UBF thus hijacking it away from the place of action, this is extremely 
interesting as there is a strong inverse correlation between UBF expression level and 
Cisplatin sensitivity in patients (Huang et al., 2002); Notably, a most recent study 
found the platinum analogs of cisplatin, carboplatin and oxaliplatin, result in cell 
death through inducing ribosome biogenesis stress. Oxaliplatin, which is frequently 
applied in colorectal cancer treatment, enhance the nucleolar foci formation in a 
similar way as actinomycin D. In addition, the study also demonstrated the nucleolar 
stress response pathway ‘RPL11-MDM2-P53’ was essential for oxaliplatin 
cytotoxicity (Bruno et al., 2017).  
Although many commercialized therapeutics act indirectly on rRNA biogenesis, a 
number of small molecule inhibitors have emerged that specifically target Pol I 
transcription. CX-3543 (also called quarfloxin) was the first of these. CX-3543 
disrupts the nucleolin protein/G-quadruplex DNA complex in rDNA, a critical 
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interaction for Pol I transcription that is particularly amplified in cancer cells. By 
acting in this way, the small molecule inhibits Pol I transcription and induces tumour 
cells apoptosis (Drygin et al., 2009). CX-3543 had been carried through to phase II 
clinical trial on patients with carcinoid and neuroendocrine tumours, based on the 
potential clinical benefits from the scientific and clinical findings of a phase I trial in 
2009 (Drygin et al., 2010).  
More recently, two novel Pol I transcription inhibitors, CX5461 and BMH-21, were 
developed to selectively target tumours cells while spare normal cells. CX5461 
potently and selectively inhibits Pol I transcription by preventing SL1/TIF-IB bind to 
the rDNA promoter and impairing the initiation stage of rDNA transcription. The 
downstream consequences of CX5461 treatment are cell senescence and autophagy 
(Drygin et al., 2011). Further investigation into the tumour specific activity of 
CX5461 suggested heamatologic malignancies are more sensitive to CX-5461 than 
solid tumours. This is an intriguing finding and led to questions about the molecular 
mechanism underlying this selectivity. The same group also found CX-5461 has very 
limited toxicity on normal B cells (Bywater et al., 2012). One hypothesis is that a 
p53 dependent pathway is central for predicting sensitivity to CX-5461 (Drygin et al., 
2014). This hypothesis came from evidence demonstrating CX-5461-induced 
apoptosis in lymphoma cells is dependent on activation of a functional p53 pathway, 
while in normal B cells p53 stays inactivate in response to CX-5461 treatment 
(Bywater et al., 2012). In addition, sensitivity to CX-5461 in solid tumours is 
variable and p53-independent (Drygin et al., 2011). This hypothesis could be 
supported by a more recent study showing there is a direct relationship between the 
amount of stabilized p53, cellular ribosome biosynthesis rate and ribosome inhibition 
outcome (Scala et al., 2016). Interestingly, CX-5461 induced p53-dependent 
apoptosis is rapid but does not interfere with further ribosome production or protein 
translation, and this can even be achieved by transient treatment of the agent (Negi 
and Brown, 2015). Given the significant cancer preventative effect of CX-5461, it is 
now tested in clinical trial for patients with advanced haematological malignancies 
(Hannan et al., 2013).  
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BMH-21 is another small molecule that represses Pol I transcription and that has 
anti-tumor activity. It acts by a combination of specifically binding to GC rich 
regions on the rDNA promoter and mediating proteasome-dependent degradation of 
Pol I enzyme subunit RPA194 (Peltonen et al., 2014). One study demonstrated 
BMH-21 exerts anticancer activity without triggering DNA damage responses, which 
make it a promising therapeutic agent with a low cost of normal tissue toxicity (Colis 




1.4 Nucleolus under stress 
Given the energy required in the generation of ribosomes, it is not surprising that 
there is a close link between ribosome biogenesis and cellular homeostasis. Indeed, 
any environmental or internal stress that threatens homeostasis inhibits ribosome 
biogenesis and causes stress response on nucleolus.   
In stressed cells, changes in ribosome subunit production are always accompanied by 
distinct changes in the nucleolar architecture (Boulon et al., 2010). For example, 
DNA damage triggered by UV irradiation or DNA damaging drugs causes nucleolar 
segregation, which is segregation of the DFC and FC to the periphery of the 
nucleolus forming ‘nucleolar caps’ (Al-Baker et al., 2004; Rubbi and Milner, 2003); 
Inhibition of RNA Pol I machinery by Actinomycin D induces rapid shrinkage of 
nucleoli, formation of ‘nucleolar caps’ and repositioning of nucleolar and Cajal 
Bodie’ proteins (Shav-Tal et al., 2005). In contrast, Inhibition of RNA Pol II by DRB 
induces unravelling and fragmentation of nucleoli (Rubbi and Milner, 2003); Viral 
infection can also cause modulation of nucleolar shape (Hiscox, 2007). 
The nucleolar proteome also changes dynamically under stress conditions. It has 
been interestingly found that, under metabolic stresses like transcription inhibition 
and proteasome inhibition, and DNA damage inducing stresses like UV-C and 
ionizing radiation, nucleolar-associated proteins dynamically translocate between 
different cell compartments based on mass-spectrometry (MS)-based SILAC 
quantitative proteomics (Andersen et al., 2005; Boisvert et al., 2010; Moore et al., 
2011). These discoveries reinforced the notion that nucleolus is a dynamic 
compartment. That is, in response to stress, nucleolus can act as a specific place 
where proteins can be temporarily sequestered to or excluded from, in order to 
participate certain signal transduction processes in their proper location, or just 
simply stabilize or destabilize them by separating them from their interacting 
partners. This notion further makes it interesting to understand nucleolar proteins 
associated signaling pathways under stress conditions. 
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1.4.1 p53-dependent pathways 
Although it is well established that nucleolar architecture and the nucleolar proteome 
are altered in response to stress, and that nucleoli coordinate stress response, the 
molecular mechanisms by which nucleoli sense stress and regulate the downstream 
consequences remain poorly understood.  
The most studied downstream effector of nucleolar stress response is p53 (Figure 
1.5). p53 protein, encoded from TP53 gene, is well known as a tumor suppressor as it 
activates genes transcription or coordinates signalling pathways that results in 
inhibiting cell cycle progression, promoting apoptosis and autophagy. TP53 gene is 
frequently mutated and recognized as a common feature of human cancers (Bouaoun 
et al., 2016). The functional properties of TP53 gene mutations have been 
extensively investigated, establishing the essential role of p53 in cancer biology 
(Muller and Vousden, 2013).  
Under unstressed condition, the level of active p53 is kept low due to MDM2 
(murine/or HDM2 in human)-mediated p53 ubiqutinylation followed by nuclear 
export and degradation. MDM2 protein contains a N-terminus p53 binding domain, a 
C-terminus RING finger domain with E3 ubiquitin ligase activity and a central acidic 
domain which is likely to fold to make N-terminus bound p53 adjacent to carboxy 
RING finger for ubiquitin-mediated proteasomal degradation (James et al., 2014). 
One hypothesis is reducing the folding flexibility of MDM2’s central acidic domain 
would prevent the ubiquitination and degradation of MDM2 bound p53, and it has 
been revealed that most of the stimuli or stress which cause activation of p53 
pathway targeted this domain to block the activity of MDM2 (James et al., 2014). 
p53 becomes activated by a set of protein kinases in response to a variety of stress, 
including but not limited to DNA damage, oxidative stress and aberrant oncogene 
expression. Interestingly, these stresses also cause nucleolar disruptions, implies that 
a common denominatior of stresses that stabilise p53 is disruption of nucleoli (Rubbi 
and Milner, 2003). The link between nucleolar disruption and stabilization of p53 
was first evidenced by Rubbi and Milner. They demonstrated that micropore 
irradiation-induced DNA damage was unable to stabilize p53 unless the nucleolar 
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disruption was concurrently occurred. In addition, directly impaired nucleolar 
function by blocking the upstream binding factor (UBF) stabilizes p53 without 
causing DNA damage (Rubbi and Milner, 2003). A later study strongly supported 
this model by finding TIF-IA knock-out, which lead to nucleolar disruption, also 
induced cell death and upregulation of p53 levels in MEFs (Yuan et al., 2005).  
Since then a huge amount of literature has described the molecular pathways by 
which disruption of the nucleolus stabilises p53. Upon nucleolar stress, the defects in 
ribosome biosynthesis are always coupled with aberrant redistribution of ribosomal 
proteins (RPs). Several ribosomal proteins (e.g RPL11, RPL5, RPL23, RPS3, and 
RPS7) have been shown to bind MDM2, thus stabilising p53 (James et al., 2014). 
RPL11, RPL5 and 5s rRNA can also form a trimeric complex to bind MDM2 and 
block the uquitin-mediated p53 degradation (Donati et al., 2013; Sloan et al., 2013). 
Based on this and many coherent studies, Deisenroth et.al proposed a ‘RP-MDM2-
p53 ribosome biogenesis surveillance pathway’. They suggested that in response to 
unfavourable stress conditions, disruption in rRNA synthesis/processing, or RPs 
imbalances, would allow a subset of RPs to bind to MDM2, thus inhibiting its 
interaction with p53, evoking cell arrest or apoptosis (Deisenroth and Zhang, 2010). 
In this way, nucleolar stress response also acts as a surveillance mechanism that 
inspects the quantitiy and quality of ribosomes. This surveillance pathway has also 
been shown in response to oncogenic stress specifically induced by oncogene c-Myc. 
Study found MDM2 carrying a cysteine-to-phenylalanine mutation in the acidic 
domain has impaired binding ability to RPL5 and RPL11. Mice harboured this 
mutation lost the p53 protective action in response to ribosome biosynthesis 
perturbation and accelerated c-Myc-induced lymphomagenesis (Macias et al., 2010).  
Interestingly, in a reverse way, p53 was also shown necessary for the initial release 
of ribosomal proteins from nucleolus under DNA damage stress. In a quantitative 
proteomic study using unbiased MS-based SILAC, FM. Boisvert and A.I. Lamond 
found in p53-wild type cells, nucleolus exhibited specific segregation and ribosomal 
proteins like RPL11 exported from nucleolus following etoposide treatment. In 
comparison, p53-knockout cells showed less extent of nucleolar segregation and had 
less effect on ribosomal proteins nucleolar localization under the same condition. 
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This study indicates a feedback regulation between p53 and ribosomal proteins under 
stress condition (Boisvert and Lamond, 2010).  
 
Another nucleolar factor known to regulate MDM2 activity and p53 stabilization in 
response to stress is p14ARF. p14ARF (p19ARF in mice) is one of the alternate 
reading frame protein products of the ARF-INK4a locus. It functions as a tumour 
suppressor mainly through its ability to bind with MDM2 thus activating p53. In 
addition, p14ARF can directly modulate rRNA biogenesis through interfering with 
other nucleolar factors, such as UBF (Ayrault et al., 2006), or binding to 5.8S rRNA 
(Sugimoto et al., 2003).  
In non-stressed cells, p14ARF is maintained at low levels in the nucleolus. Following 
oncogenic stress, such as Myc and Ras overexpression, p14ARF is upregulated and 
released from nucleoli. This allows it to bind to the central acidic region of MDM2, 
which prevents degradation of p53 and thus, controlling cell growth through cell 
cycle arrest or inducing apoptosis (James et al., 2014). The central importance of the 
p14ARF-MDM2-p53 pathway is highlighted by the finding that tumours often 
display mutated or silenced p14ARF (Sherr, 1998). Activity and stabilization of 
p14ARF is mainly regulated by its interaction with nucleophosmin (NPM), another 
nucleolar stress regulator. Studies have demonstrated NPM interacts with p14ARF to 
prevent ubiquitin-mediated degradation of p14ARF (Chen et al., 2010). NPM is also 
up-regulated by oncogenic stress therefore stabilizing p14ARF and promoting the 
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interaction between p14ARF and MDM2 and activating p53. However, there is a 
negative feedback loop in this pathway, as evidenced by overexpression of p14ARF 
promotes the ubiquitination and degradation of NPM, which subsequently disrupts 
ribosomal biosynthesis (Itahana et al., 2003).  
1.4.2 p53-independent pathways 
However, given the following three facts: 1. Nucleoli in yeast response to stress as 
human cells but there is no characterized human p53 or MDM2 homologues in yeast; 
2. More than 50% of known cancer cells have non-functional p53; 3. The huge 
changes in the nucleolar proteome in response to stress, it is likely that other p53-
independent signalling pathways are affected and involved in the downstream 
consequences of nucleolar stress (James et al., 2014). Clarifying these pathways 
would benefit for targeting p53-deficient cancers. However, current knowledge 
regards this are extremely deficient.  
In recent years, there are emerging evidence have demonstrated nucleolar stress 
directly triggers additional signaling bypassing p53 pathway, and results in 
regulation of cell cycle process, cell growth and cell death. These downstream 
effectors of nucleolar stress include factors, such as E2F1, c-Myc and NF-κB, which 
have been known to be critical in controlling diverse cell functions.   
E2F1 (E2F transcription factor 1) is a crucial transcription factor that controls 
expression of genes favoring cell cycle progression and cell proliferation, and is 
highly expressed in many types of cancer. Its transcriptional activity is negatively 
controlled by interacting with retinoblastoma protein pRB and is modulated by the 
upstream cyclin-dependent kinase, such as cyclin D1/CDK4. In another circumstance, 
it also plays an important role in mediating both p53 dependent and independent 
apoptosis mainly through up-regulating various pro-apoptotic genes. Notably, it has 
been shown down-regulation of E2F1 links ribosome biogenesis perturbation and 
cell cycle arrest in cells with inactivated p53. Donati et.al discerned the E2F1 
involved nucleolar stress response pathway, that upon rDNA suppression by 
selectively depletion of a subunit of Pol I POLRIA, the release of ribosomal protein 
RPL11 antagonizes the interaction between E2F1 and MDM2 and leads to 
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destabilisation of E2F1, resulting in G1 cell cycle arrest (Donati et al., 2011). This 
finding indicates a potential role of E2F1 as a downstream effector of nucleolar stress. 
c-Myc is a strong proto-oncogene that is mutated, deregulated and constitutively 
overexpressed in many cancers. Transcription factor c-Myc has been demonstrated 
critical in controlling cell proliferation and cell differentiation through facilitating 
expression of a large cohort of factors, including those involved in crucial steps of 
rRNA synthesis and ribosome production. Studies have implied c-Myc could 
potentially be a downstream effector of nucleolar stress based on the finding that 
ribosomal proteins, particularly RPL11, negatively regulate the transcriptional 
activity of c-Myc. This has been supported by the finding revealed ribosomal stress 
stimuli, like low dose actinomycin D and 5-fluorouracil, enhanced the association 
between RPL11 and the 3’-untranslatied region (3’-UTR) of c-Myc mRNA thus 
down-regulating the expression of c-Myc (Challagundla et al., 2011). 
Most recently, another p53-independent nucleolar stress response pathway has been 
defined and involves Peter Pan (PPAN). PPAN is known to be involved in mRNA 
splicing and ribosomal maturation. The endogenous PPAN is mainly localized in 
nucleoli and mitochondria. Upon nucleolar stress stimuli, such as staurosporine and 
actinomycin D, PPAN released from nucleoli to cytoplasm where it was cleaved and 
degraded in a caspases-dependent pathway. The cytoplasmic translocation and loss 
of PPAN under stress condition subsequently caused destabilization of nucleolar 
factor UBF and NPM, and increased BAX-mediated mitochondrial outer membrane 
permeabilization thus triggering cell apoptosis. They also shown this novel nucleolar 
stress response pathway is through a p53-independenet fashion (Pfister et al., 2015). 
This study indicates a role of PPAN as a novel nucleolar stress effector, which links 
UBF, NPM and mitochondrial-mediated cell apoptotic pathway.  
1.5 NF-kappaB  
Similar to the p53 pathway, NF-κB plays a critical role in maintaining cellular 
homeostasis in response to stress, is dysregulated in cancer and controls cell 
proliferation and apoptosis. Emerging data also shows NF-κB as a candidate effector 
of nucleolar stress response. Studies from the Perkins’ lab revealed the NF-κB 
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pathway is suppressed by the nucleolar protein p14ARF through impairing the 
transcription activation domain of RelA in response to oncogenic activation (Rocha 
et al., 2003) (Rocha et al., 2005). There are also other proteins that are known to be 
involved in the NF-κB response to stress reside within nucleoli, such as CK2 and 
Eukaryotic translation initiation factor 2α (EIF2α) (Jiang et al., 2003; Kato et al., 
2003). In addition, there is a growing body of literature indicates most of the stresses 
that disrupt the nucleolus can activate the NF-κB signalling pathway. In this section I 
will introduce the NF-κB signalling pathway, mainly focussing on modulation of this 
pathway in cancer and under stress condition.  
The NF-κB transcription factor is a ubiquitously expressed family of proteins that 
play a critical role in multiple physiological processes including immune and 
inflammatory response, cell growth and proliferation, cell differentiation, apoptosis 
and stress response. In mammalian cells, the NF-κB transcription factor family 
consists of five members: NF-κB 1(p105/p50), NF-κB 2(p100/p52), RelA (p65), 
RelB and c-Rel. Among them, NF-κB1 and NF-κB2 are initially transcribed as 
precursor forms p105 and p100, which, in the process of activation, are cleaved to 
form the mature proteins p52 and p50 (Hayden and Ghosh, 2012). All NF-κB family 
members share a N-terminal Rel homology domain (RHD), which supports their 
function of subunit dimerization and DNA binding. A nuclear localization sequence 
(NLS) resides within the RHD domain that facilitates their nuclear translocation. In 
resting state, the NLS on NF-κB family proteins is bound by the multiple ankyrin 
repeat domains (ANK) on a group of NF-κB inhibitor, IκB family (IκBα, IκBβ, IκBε, 
IκBγ, Bcl-3, IκBNS, p100 and p105). This binding enables IκB family halt the 
function of NLS and contribute to the sequestration of NF-κB proteins in the 
cytoplasmic of unstimulated cells.  
NF-κB family proteins form homodimer or heterodimer which bind to κB consensus 
sequences on the promoters and enhancers of target genes. This can both positively 
and negatively regulate gene transcription dependent on the types of dimers (Chen et 
al., 1998). Only RelA, RelB and c-Rel contain a C-terminal transactivation domain 
(TAD), which confers their ability to initiate transcription. p52 and p50 lack this 
domain and so, p52 or p50 homodimers always act as transcription suppressors, 
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competing with TAD-containing heterodimers for binding to κB sites (Hayden and 
Ghosh, 2012). Once in the nucleus, the strength and kinetics of NF-κB driven 
transcription is influenced by a number of factors including binding of co-activators 
and repressors (e.g P300/CBP, p53 HDACs) and post-translational modifications 
(PTMs) of NF-κB proteins (Hayden and Ghosh, 2012).  
NF-κB is the most central factor that regulates both innate and adaptive immune 
response, in the past 30 years, huge amount of works has been done to elucidate the 
role of NF-κB as a master regulator in inflammatory and immune response and 
results in a well-defined and complex signalling pathways network. 
Dependent on the stimulus, NF-κB signalling can be activated by the “canonical” or 
“non-canonical” pathways (Gerondakis et al., 2014). The two pathways differ in the 
upstream activation cascades and the NF-κB family members involved as well as the 
eventual outcome on gene expression and biological functions (Figure 1.6). The NF-
κB canonical pathway, or classical pathway, represents the general scheme of NF-κB 
pathway regulation and is very well established. Upon exposure of cells to stimuli 
such as cytokines, cellular stress or infection, triggered signals culminate in the 
phosphorylation and activation of the IκB kinase (IKK) complex, which is composed 
of the two kinase subunits IKKα and IKKβ, and one regulatory protein NEMO (or 
IKKγ) (Hinz and Scheidereit, 2014). Activated IKKs, especially IKKβ, 
phosphorylates IκBα on serines 32 and 36 and targets IκBα for ubiquitination and 
degradation by proteasome, allowing dimers (mainly RelA/p50) to translocate to the 
nucleus, bind to the specific κB motif and regulate gene expression. The non-
canonical NF-κB pathway is induced by specific stimuli, such as CD40 ligand, B-
Cell activation factor (BAFF), receptor activator of nuclear factor κB ligand 
(RANKL) or lymphotoxin-β. It is dependent on NF-κB-inducing kinase (NIK)-
induced phosphorylation of IKKα and subsequently phosphorylation and cleavage of 
p100, which leads to formation and nuclear translocation of a RelB/p52 complex 
(Sun, 2011). As almost all research to date suggest stresses, chemopreventative and 
chemotherapeutic agents regulate the canonical pathway, only this will be further 




1.5.1 NF-κB in cancer 
NF-κB is crucial for human health and aberrant regulation of nuclear NF-κB activity 
is always associated with development of disorders, (e.g inflammatory bowel disease, 
autoimmune disorders, and cancer (DiDonato et al., 2012)). The first line of evidence 
suggesting an association between NF-κB and cancer came from studies that show 
the genes encoding NF-κB transcription factor family members, IκB and IKK 
proteins are mutated, deleted or chromosomally translocated in lymphoid 
malignancies (Xia et al., 2014).  
Although in some specific cases NF-κB seems to be anti-tumourigenic, such as in 
Ras-induced invasive growth of epidermal tumours and in carcinogen-induced 
hepatocellular carcinomas, the constitutive activation of NF-κB is prevalent in most 
major types of cancers and is believed to be an important driver of tumorigenesis 
(Ben-Neriah and Karin, 2011). Multiple mechanisms have been proposed to explain 
how NF-κB is constitutively activated in tumours and how this activation contributes 
to carcinogenesis (Figure 1.7). 
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It has been proposed that NF-κB constitutive active in tumours may be the result of 
two events: gene mutations that affect pathway components and/or increased 
inflammatory cytokines in the tumour microenvironment which chronically activate 
NF-κB (Ben-Neriah and Karin, 2011). Gene mutations that activate NF-κB signalling 
were first evidenced in MALT lymphomas (a group of tumours involving the 
mucosa-associated lymphoid tissue). It was found that rearrangement of Bcl-10 and 
MALT1, which were common mutations in MALT lymphomas, lead to assembly of 
a protein complex that activated IKKs and NF-κB (Uren et al., 2000). Another 
mutation on Toll-like receptor (TLR) adaptor, MYD88, has also been found to 
activate NF-κB and contribute to diffuse large B cell lymphoma. The L265P 
mutation in the MYD88 Toll/IL-1 receptor (TIR) domain promoted lymphoma cell 
survival by spontaneously assembling a protein complex containing MYD88 
associated kinase, IRAK1 and IRAK4, enhancing IRAK4 kinase activity and 
phosphorylation of IRAK1, which in turn activated NF-κB (Ngo et al., 2011).  
Constitutive activation of NF-κB in tumour cells can also arise from exposure to 
inflammatory cytokines in the tumour microenvironment. Chronic inflammation can 
promote cancer in multiple ways, such as prolonged activation of pro-proliferative 
pathways and generation of DNA damage that leads to oncogenic mutations 
(Grivennikov et al., 2010). As a central mediator of inflammatory response, NF-κB 
also acts as a master regulator of the cross-talk between chronic inflammation and 
carcinogenesis. This have been proven in inflammation-linked cancer models like 
colitis-associated colon cancer (CAC). A study in a mouse CAC model found that 
IKKβ in intestinal epithelial cells was activated and contributed to increased tumour 
incidence by inducting anti-apoptotic gene expression (Bcl-xL) and repressing pro-
apoptotic gene expression (Bax and Bak). In contrast, conditional deletion of IKKβ 
in intestinal epithelial cells attenuated colitis-associated tumour incidence (Greten et 
al., 2004). In the same CAC model, conditional ablation of IKKβ in myeloid cells 
also decreased colitis-associated tumour incidence. Rather than affecting cell 
apoptosis, perturbation of IKKβ inhibited NF-κB mediated transcriptional activation 
of tumour-promoting paracrine inflammatory factors thus halting cell growth (Greten 
et al., 2004). These studies demonstrate that in inflammation associated cancer, 
activation of the NF-κB pathway can convey a pro-tumorigenesis effect both by 
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directly perturbing apoptotic-related gene expression in tumours cells and by 
indirectly affecting myeloid cells and hence, the production of tumour-promoting 
inflammatory factors. In agree with the findings in CAC model, additional studies in 
hepatitis-associated liver cancer, gastric cancer and lung cancer model also 
demonstrated that activation of NF-κB mediated inflammatory response is crucial for 
carcinomas.  
Beside stimulation by inflammatory factors in the microenvironment, NF-κB in 
tumour cells can be triggered by the DNA damage/genomic instability associated 
with prolonged exposure to inflammatory cytokines. For example, ROS induced 
DNA damage, which will be discussed in the NF-κB under stress section (1.5.2).  
Once activated, NF-κB can promote cancer initiation and development through 
multiple mechanisms including stimulation of cell proliferation/inhibition of 
apoptosis, regulation of tumour angiogenesis, promotion of tumour metastasis, 
facilitation of escape from immunosurveillance and remodelling of tumour 
metabolism (Perkins, 2012; Xia et al., 2014) (Figure 1.7). Importantly, it should be 
noted that all of these mechanisms modulated by NF-κB have been identified as 




Among them, NF-κB had been well known to regulate cell proliferation and 
apoptosis mainly through its role as a transcription factor. As early as 18 years ago, 
study had demonstrated NF-κB contributes to cell growth and proliferation by 
regulating transcription of the cell-cycle regulator, cyclin D1 (Hinz et al., 1999). 
Studies in the past years have extensively expaned this finding both in vitro and in 
vivo, and have revealed and established a growing list of cell proliferation/apoptosis-
related genes that are actived by NF-κB, including genes with pro-growth (GM-CSF, 
M-CSF and VEGF-C) and anti-apoptotic functions (X-linked inhibitor of apoptosis 
(XIAP), Inhibitors of Apoptosis (IAPs), Fas ligand and BCL2 family proteins) 
(website resource: http://www.bu.edu/NF-κB/gene-resources/target-genes/, 
maintained by Thomas Gilmore’s laboratory). Similarly, in the list of known NF-κB 
transcriptional targets, numerous other genes have been recognized to regulate a 
wide spectrum of cellular functions that would contribute to cancer development. 
This includes, but not limited to, agenogenic molecules (Vascular Endothelial 
Growth Factor (VEGF), IL-8 and Matrix metalloproteinases (MMPs)), and cell 
adhesion molecules, chemokines and transcription factors that involved in tumour 
metastasis (chemokines receptor CXCR4, Twist 1 and Snail).  
Besides modulating hallmarks of cancer for cancer promotion and progrsssion, a 
recent study demonstrated the role of NF-κB in cancer stem cells, which shed a new 
insight of NF-κB contribution to tumourigenesis. Using an inducible intestinal 
epithelial cell (IEC)-restricted β-catenin constitutive activation mice model that 
recapitulate most of the events during the colon cancer initiation, Schwitalla S et.al 
found NF-κB activity was significately elevated in Wnt signalling activated IEC cells 
and proliferative crypt stem cells (cancer stem cells). Notably, they demonstrated 
NF-κB activation promotes colorectal tumourigenesis through dedifferentiating 
intestinal cells and endowing them with cancer-stem-cell-like properties by direct 
targeting Wnt signalling and modulating Wnt-dependent stem cell gene expression 
(Schwitalla et al., 2013).   
1.5.1.1 Crosstalk between NF-κB and p53 in cancer 
Upon activation, NF-κB consistently inter-talks with other transcription factors to 
coordinate gene expressions and regulate tumourigenesis. One of the well-
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established coordinator of NF-κB in this regulation is p53. NF-κB effects on cancer 
cell growth are strongly dependent on the cellular status of p53 and there are multiple 
areas of crosstalk between the two pathways.  
Firstly, an early study had shown that NF-κB and p53 inhibit each other’s gene 
transcriptional activities. They revealed that interactions with transcriptional 
coactivator proteins p300 and CREB-binding protein (CBP) are essential for the 
activity of both NF-κB and p53. However, the limitation of p300/CBP cellular pools 
led to a competition between the two transcriptiona factors for this functional binding 
(Webster and Perkins, 1999).  
We now clearly know that, the relation between NF-κB and p53 is intricate and 
shows variability dependent on different cellular conditions. Although there are some 
studies showing NF-κB activation is correlated with p53-meidated tumour cell 
apoptosis, the majorty of studies in the crosstalk between these two vital 
transcriptional factors have pointed that NF-κB functions in cancer development are 
always antagonized by wild-type p53. For example, Perkins et.al found that 
regulation of mitochondrial respiration by NF-κB is dependent on the status of p53. 
They demonstrated that p53 inhibits translocation of RelA to mitochondria by 
blocking an essential interaction between RelA and mitochondrial heat shock protein 
HSP, mortalin. Upon deletion of p53, RelA was transported into the mitochondria 
where it directly repressed mitochondrial gene expression (Johnson et al., 2011). 
Considering that reprogramm of tumour cell metabolism is emerging as another 
hallmark of cancer and mitochondrial respiration is a critical metabolic event that is 
required to maintain cellular homeostasis, this finding implied a strong dependence 
of NF-κB on p53 status in regulating tumour metabolism and energy production.  
In addition, many studies have shown that loss of p53 or p53 mutant upregulates the 
activity of IKKα/β and NF-κB transcription activity. Especially, in p53 deficient or 
p53 mutant condition, activated NF-κB is likely to play more important role in 
tumour development. For example, activation of NF-κB is evidenced essential in 
maintaining tumour metabolism in p53-null tumour model. Oncogenic Ras-induced 
transformation of p53-null MEFs and consequent increase in aerobic glycolysis were 
abrogated when p65 was simultaneously deleted (Kawauchi et al., 2008).  
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Interestingly, using a mouse model of lung adenocarcinoma that harbours conditional 
loss-of-function p53, Meylan et.al revealed tumours from this type of mice have 
elevated NF-κB activity compared to tumours from mice with wide-type p53. 
Whereas, restoring p53 in the model mice abolished increased NF-κB activity. 
Moreover, they evidenced inhibition of NF-κB in vivo by infecting mice with 
letivirus that constitutively express IκB-SR (dominant-negative form of IκBa) has 
almost completely blocked the initiation and development of lung tumours. 
Therefore, this study further addressed the importance of the p53 status in NF-κB 
activation-mediated cancer development (Meylan et al., 2009). Furthermore, 
common mutant p53 (mutp53) isoforms in pancreatic cancer cells or colorectal 
cancer cells prolonged low dose TNF-α-induced NF-κB activation and subsequently 
IL-8 elevation, indicating a role of mutp53 in promoting chronic inflammation 
response. This was further supported by in vivo experiments, that mice harbouring 
germline mutp53 were highly susceptible to inflammation inducing agent dextran 
sodium sulfate (DSS)-induced chronic inflammation, tissue damage and colon 
carcinoma. Notably, the accumulation of mutp53 in the inflamed colon or carcinoma 
was concomitant with the activation of NF-κB (Cooks et al., 2013).  
Furthermore, NF-κB pathway components that contribute to tumourigenesis, such as 
IKKβ, can also target the p53 pathway. It has been shown that p53 contains a 
consensus motif which is harboured by most of the IKKβ substrates, like IκBα. Upon 
doxorubicin treatment, IKKβ regulates p53 stability through phosphorylating p53 at 
serine 362 and serine 366, thus leading it binds to E3 ligase β-TrCP–Skp1-Cullin-F-
box protein (SCF) complex and degraded by ubiquitination-dependent proteasome 
degradation. Besides, p53 degradation under this pathway is independent of MDM2 
acitity. Notably, this regulation only happens under DNA damage stress, but not 
under TNF-α stimulus, suggesting this particular IKKβ-mediated p53 modification is 
a specific stress response, or a result of DNA damage-induced chronic inflammation 
environment (Xia et al., 2009).  
Given the importance of p53 in cancer development and ubiquitous of the inter-talks 
between p53 and NF-κB pathway, clarifying the p53 status is necessary when 
investigating the contribution of NF-κB in particular cancers. 
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1.5.2 NF-κB and stress 
In addition to its role in immune function and cancer development, NF-κB is a 
critical regulator of stress response. The NF-κB pathway is activated by a wide 
variety of extracellular stresses such as nutrient stress, DNA damaging agents, 
chemotherapeutic/preventative agents and oxidative stress.  Intracellular stress, 
including ER protein overload, are also know to stimulate the pathway. However, 
compared to the well-established role of NF-κB in immune response and cancer 
development, the role of NF-κB signalling in stress response, especially the 
molecular basis underlying stress stimulation of NF-κB, remains poorly understood. 
One question that needs to be answered is how such a diverse range of stresses and 
agents can activate NF-κB.  
Oxidative stress is defined as an increase of the intracellular concentration of 
reactive oxygen species (ROS) such as H2O2, superoxide (O2−), or hydroxyl radical 
(·OH). Oxidative stress was shown to activate NF-κB pathway and was once 
proposed as a common messager converging stresses on NF-κB activation based on a 
set of findings (Schmidt et al., 1995). Firstly, it was shown that micromolar 
concentrations of H2O2 activate the NF-κB pathway in T cell and HeLa cells. Most 
importantly, this activation was blocked by using specific antioxidant compounds 
such as N-acetyl-L-cysteine (NAC) and pyrrolidine dithiocarbamate (PDTC), and by 
overexpressing antioxidative enzymes that decreased the level of intracellular ROS 
(Meyer et al., 1993; Schreck et al., 1991). Secondly, several studies demonstrated 
that ROS is necessary for NF-κB activation induced by many other agents including 
TNFα, okadaic acid, cycloheximide, double-stranded RNA, calcium ionophore, 
active phorbol ester, interleukin-1, lipopolysaccharide, lectin, and CD28 surface 
receptor.  
ROS regulates the NF-κB pathway through directly modulating NF-κB proteins or 
pathways upstream of NF-κB. For example, Jamaluddin et.al found ROS enabled 
TNFα-induced IL-8 transcription through inducing phosphorylation of RelA on 
serine 276 by cAMP dependent protein kinase A (PKAc), thus promoting the binding 
between RelA and CBP/300 to enhance gene expression (Jamaluddin et al., 2007). 
Takada et.al demonstrated that rather than induce the typical TNF-α-induced S32/36 
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IκBα phosphorylation and degradation, H2O2 induces NF-κB activation and nuclear 
translocation through Syk-mediated phosphorylation of IκBα on tyrosine 42 without 
degradation of this protein. This suggested a distinct IκBα modification and NF-κB 
activation mechanism under ROS stress condition. However, they failed to explain 
how Syk-mediated NF-κB nuclear translocation could happen without IκBα 
degradation in this situation (Takada et al., 2003). These evidences show a complex 
regulation of NF-κB by oxidative stress. However, the mechanisms by which ROS 
regulates NF-κB remain controversial. 
Although ROS induced NF-κB activation was proposed as a common model of 
stress-stimulation of NF-κB, emerging studies have provided evidence against this 
notion. One example is stress inducers that cause DNA-damage activate NF-κB 
without producing ROS. Compared with ROS-related stimulation of NF-κB, the 
primary pathways by which DNA damage activates NF-κB are clearer. DNA damage 
response (DDR) in mammalian cells is well established and mediated by a family of 
phosphatidylinositol 3-kinase like proteins—ATM, ATR and DNA-PK (McCool and 
Miyamoto, 2012). DNA damage can be induced by various simuli, including UV 
light exposure, ionizing radiation and agents like camptothecin and bleomycin. Stein 
et.al was the first to demonstrate DNA damage, caused by UV exposure, activated 
the cytoplasmic NF-κB pathway (Stein et al., 1989). Although there are still many 
unknowns regarding the molecular mechanisms involved in DNA damage-induced 
NF-κB activation, in the past 30 years a clear ATM-NEMO-TAK1-IKK axis has 
been identified. That is, upon sensing DNA damage or double strand breaks (DSB), 
DSB-responsive ATM kinase modulates nuclear NEMO by different means of post-
translational modifications, including SUMOylation, phosphorylation and 
monoubiquitination. It is followed by the activation of growth factor bactivated 
kinase-1 (TAK1) in the cytoplasm, which subsequently phosphorylates and activates 
IKKs (McCool and Miyamoto, 2012).  
In addition, DNA damage also regulates NF-κB in other atypical pathways. For 
example, Kato et.al proposed an IKKs-independent NF-κB activation pathway in 
response to UV-C stress. They found UV-C exposure in HeLa cells induced 
phosphorylation and degradation of IκBα, which is dependent on p38 MAPK 
39	
	
mediated CK2 activation. In addition, activation of this pathway resulted in a 
protective effect of cells against low dose UV-C. Notably, in this regulation, stress-
activated CK2 phosphorylated IκBα at a cluster of C-terminal sites, but not the N-
terminal sites which targeted by IKKs, indicating a stress specific regulation pattern 
(Kato et al., 2003).  
An overwhelming number of studies indicate that chemotherapeutic and 
chemopreventative agents act on cancer cells, either positively or negatively, by 
activating the NF-κB pathway. For example, NF-κB activation was found to 
contribute to doxorubicin induced neuroblastoma cell death (Bian et al., 2001). In 
human non-small cell lung carcinoma cells, etoposides were shown to activate NF-
κB before the induction of apoptosis (Tabata et al., 2001). Since many 
chemotherapeutic agents deliver their cytotoxicity by exerting oxidative stress or 
DNA damage, the mechanisms underlying NF-κB activation by these agents may be 
shared with those induced by ROS and DNA-damage. Another group of agents that 
act through the NF-κB pathway are nonsteroidal anti-inflammatory drugs (NSAIDs), 
including aspirin. These agents primarily provide analgesic, antipyretic and anti-
inflammatory effects. However, it has been shown that long-term administration of 
this group of drugs has favourable effects on reduction of cancer incidence and 
prevention of tumor progression in many solid tumor entities like colorectal cancer 
(Rothwell et al., 2011). This suggests targeting NF-κB activation under low-grade 
inflammation context could be a potential strategy for cancer prevention and therapy. 
The effects of NSAIDs on the NF-κB pathway will be discussed in full in next 
section of this chapter (see section 1.6.2.2).  
Studies as far have shown a complex regulation of NF-κB under different stress 
conditions. However, the mechanisms by which stress regulates NF-κB still remain 
controversial and unclear, while many of the different outcomes on regulation of NF-
κB observed between studies are probably due to the cell-specific response and 
different experiment settings. It will be with great interests to investigate whether 
there is a common denominator that could sense a range of stress signals and 
culminate in activation of NF-κB pathway, like stress-induced stabilization of p53 
through nucleolar stress-mediated regulation on MDM2. 
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1.5.3 NF-κB as a therapeutic target 
Given the importance of NF-κB in multiple pathologies, including cancer initiation 
and progression, chemical compounds that specifically inhibit this pathway have 
been extensively explored. However, unfortunately, hundreds of compounds, most of 
which were efficient in laboratory studies, have not shown significant efficiency in 
clinical trials for cancer therapy (Ben-Neriah and Karin, 2011; Xia et al., 2014). 
Since NF-κB signalling is critical for innate and adaptive immune response, 
immunosuppression is a major toxicity. In clinical trilas the inhibitors have shown 
low efficiency and tumours have been found to aquire resistance. One possible 
direction to improve the efficiency is choosing the appropriate timing of compounds 
treatment. That is, applying NF-κB inhibitors may be more desirable at the chronic 
inflammatory stage when immune factors mainly contribute to tumourigenesis, rather 
than at the later tumour phases when immune cells primarily target and eliminate 
transformed cells (Hoesel and Schmid, 2013).  
Another promising direction for improved NF-κB inhibitors efficacy would be the 
combination NF-κB inhibition with other cancer therapies (Xia et al., 2014). This 
strategy is mainly based on the fact that NF-κB pathway is activated under numerous 
cellular stresses, which can be induced by many kinds of anti-cancer therapies such 
as radiotherapy and chemotherapies as discussed above. From this aspect, NF-κB 
inhibition and anti-oncogenic therapies could have some synergetic anti-tumour 
effects. For example, Wang et.al demonstrated inhibition of NF-κB via the 
adenoviral-mediated delivery of super-repressor form of IκBα into tumour cells 
enhanced the sensitivity of chemoresistant cells to chemotherapeutic compound 
CPT-11 (Wang et al., 1999). Similarly, Bortezomib, a proteasome inhibitor which 
blocks degradation of IκBα, overcame chemoresistance in colorectal tumour cells 
when combined with CPT-11 (Cusack et al., 2001). However, the efficacy of this 
strategy has not been completely verified in vivo and in clinical patients.  
Stress stimulation of NF-κB is a potential mechanism of the acquisition of resistance 
to chemo- or radio-therapies induced apoptosis. Therefore, NF-κB activation could 
be at least a potent biomarker for optimized chemo- or radio-therapies. Some in vitro 
study has shed light on this possibility, such as a more recent study evidenced NF-κB 
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activation-mediated mesenchymal differentiation and enrichment of CD44 
subpopulations enhanced the radiotherapy resistance in glioblastoma. For my 
knowledge, there are some ongoing clinical trials investigating the relationship 
between NF-κB activation and cancer-therapy outcomes. For examples, the trial 
works on NF-κB activation in response to treatment with external beam radiotherapy 
in adenocarcinoma of the rectum (NCT00280761), and the trial studies the 
significance of NF-κB as a biomarker to predict the benefits of the postoperative 
adjuvant chemotherapy in stage II/III gastric cancer patients (NCT01905969) (Xia et 
al., 2014). It will be with great interest to see the outcomes of these clinical trials.  
1.6 Anti-tumour effects of aspirin 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that provide 
analgesic, antipyretic and anti-inflammatory effects, which include some well-known 
agents like aspirin, ibuprofen and naproxen. Mechanistically, these drugs are grouped 
together as their ability to inhibit the prostaglandin H (PGH) synthase--
cyclooxygenase (COX) pathway thus blocking the COX-catalysed metabolism of 
arachidonic acid and down-regulating the level of prostanoids. Prostanoids are a 
group of biologically active signalling lipids including prostaglandin D2 (PGD2), 
prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and 
thromboxane A (TXA2), which have profound effects in inflammatory response and 
vasoconstriction (Thun et al., 2012).  
Among NSAIDs, aspirin differs from others in the way of inhibiting COX. COX has 
two identified isozymes, COX-1 and COX-2, which are derived from different genes. 
Both of them are expressed in most of tissues and are induced during inflammation 
response. COX-1 is the only COX isozyme expresses in platelet and plays essential 
role in platelet aggregation, while COX-2 is the primarily source of PGI2 in vascular 
endothelium. Inhibition of COX by other NSAIDs is reversible, as they compete with 
arachidonic acid for binding to COX thus interfering the catalyse efficiency. In 
contrast, aspirin inhibits the activity of COX through acetylates serine 529 on COX-1 
and serine 516 on COX-2 which makes this inhibition irreversible (Thun et al., 2012). 
Given the fact that platelets, unlike nucleated cells, can’t synthesize COX isozymes, 
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this property gives aspirin special advantage in blocking platelets function thus 
preventing thrombosis or other related disorders (Thun et al., 2012).  
1.6.1 Anti-tumour effects of aspirin 
There is a considerable body of evidence supporting that long-term regular low-dose 
aspirin is effective in prevention and treatment of cancers, especially colorectal 
cancer (CRC) (Figure 1.8). The first epidemiological evidence about aspirin and 
other NSAIDs reduce cancer incidence in human beings arose about 28 years ago 
from a case-control study of 715 colorectal cancer cases compared to 727 age/sex-
matched controls. In this study, which aimed to find link between CRC risks and 
various clinical conditions, they evidenced aspirin use significantly reduces 
colorectal cancer risks (Relative Risk [RR]=0.57, 95 % CI= 0.41-0.79, p<0.001), and 
there was a statistically borderline reduction in the incidences by taking NSAIDs 
(RR=0.77, 95 % CI= 0.60-1.01, p=0.06) (Kune et al., 1988). Subsequently, couples 
of placebo-controlled randomized trials (RCTs) in patients with previous CRC have 
implicated regular low-dose aspirin can effectively prevent occurrence of adenomas 
(RR=0.83, 95% CI = 0.72-0.96) and advanced-lesion occurrence (RR=0.72, 95% CI 
= 0.57-0.90) (Cole et al., 2009). CAPP2 study, a randomized trial aimed to 
investigate aspirin’s effect on patients with high risk of hereditary colorectal cancer 
known as Lynch Syndrome, have indicated a relative high does (600mg daily) of 
aspirin taken for a mean of 25 months induce about 40% reduction of CRC incidence 
after a mean of 55·7 months follow up (Burn et al., 2011). More solid evidence of the 
aspirin benefits cancer incidences and mortality were provided by Rothwell and 
colleagues from a number of meta-analysis results of randomized trails (RCTs) 
designed originally to evaluate aspirin on vascular protection. Among these data, 
they demonstrated long-term allocation to daily low dose aspirin (up to 6 years) 
significantly reduced cancer death regarding all solid cancers types (Hazard Ratio 
[HR]=0·80, 95% CI= 0·72–0·88, p<0·0001) (Rothwell et al., 2011), and reduced 
CRC incidence (HR=0.76, 95% CI=0.60-0.96, p=0.02) and mortality (HR=0.65, 95% 
CI=0.48-0.88, p=0.005) after 20-year follow up period (Rothwell et al., 2010). 
Aspirin also induced about 40% reduction on the risks of cancer metastasis 
(HR=0.64, 95% CI=0.48-0.84, p=0.001) (Rothwell et al., 2012). Results from RCTs 
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are also supported by substantial observational studies. In 2006, a review of ~100 
cohort and case–control studies up to 2005 demonstrated about 30% reduction on 
CRC risks with aspirin allocation (RR=0.71, 95% CI= 0.67–0.75) (Bosetti et al., 
2006). Most importantly, a systematic comparison study suggests there is a strong 
agreement between results carried out by RCTs and case-control studies (Algra and 
Rothwell, 2012). Furthermore, more recent systematic reviews and meta-analyses on 
previously published studies also gave a more comprehensive review of all up to date 
RCTs and observational studies, and build up the notion that aspirin can substantially 
reduce cancer incidence and mortality, prevent cancer metastasis and spread (Chubak 
et al., 2015; Elwood et al., 2016). Besides colorectal cancer, several trials also 
suggested aspirin use might protect against other type of cancers, but these results 
remain provocative rather than decisive due to the limited number of trials and 




Despite the substantial evidence convincingly show daily aspirin use reduces cancer 
risks, aspirin has not been widely considered by clinical guidelines as a 
chemopreventative agents. This is largely due to the following reasons:  
1). Not all studies have shown the positive correlation between aspirin allocation and 
cancer prevention. Among them, two large randomized controlled trials from the 
Physicians’ Health Study (PHS) and Women’s Health Study (WHS) both failed to 
demonstrate aspirin’s effect on cancer prevention. They found, following 5 years or 
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10 years alternate daily low dose aspirin treatment, there were no significant 
reduction in colorectal cancer incidence immediately at the end of randomized 
treatment or after a 12-year follow-up respectively (Cook et al., 2005; Sturmer et al., 
1998).  
2). Long-term use of aspirin brings major risks on intracranial haemorrhage, 
gastrointestinal bleeding and other kind of gastrointestinal complications (Thun et al., 
2012). The most-important risk of long-term aspirin use is bleeding, mainly due to 
the inhibition of TXA2 synthesis dysfunction platelets’ activation and aggregation. In 
addition, result from the inhibition of PGE2 synthesis, which has protective effects in 
the gastrointestinal tract, aspirin use increases the risks of gastrointestinal irritation. 
Many epidemiological studies have indicated the side effects associated with long-
term use of aspirin thus provoking a question whether aspirin’s cancer prevention 
benefits outweigh the harm associated with the long-term use of this agent (Thorat 
and Cuzick, 2015). Given this unclear balance, the U.S Preventative Service Task 
Force has advised against routine use of aspirin for primary chemoprevention of 
colorectal cancer in individuals at average risks (Chubak et al., 2015).  
3). Optimised dose and treatment duration of aspirin on cancer prevention are still 
not available. Given the side effects of high-dose aspirin, daily low-dose aspirin use 
(75mg-300mg per day) was widely suggested and studied for the cancer prevention 
outcome. However, there are conflicts between studies. For example, there was a 
study shown dose more than 75mg cannot clearly increase aspirin’s benefits 
(Rothwell et al., 2010), while another study evidenced a daily aspirin consumption at 
600mg largely reduced the incidence of colorectal cancer in persons with Lynch 
Syndrome (Burn et al., 2011). For how long people need to take aspirin in order to 
efficiently prevent cancer is not conclusive yet, but it seems clear that aspirin has a 
delayed anti-tumorigenesis effect. As noted above, a ~30% reduction on colon cancer 
incidence, ~40% reduction on colon cancer mortality and ~40% reduction on the risk 
of metastasis was observed after a 20-year follow up study (Rothwell et al., 2010; 
Rothwell et al., 2012). And in particular, although the initial analysis of WHS data 
failed to demonstrate the positive role of aspirin on cancer prevention, a second 
analysis after 10-20 years did observed a significant reduction in mortality rate after 
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aspirin allocation (Rothwell et al., 2011). Moreover, studies also suggest a daily 
continuously uptake of aspirin benefits better than an alternate use (Thun et al., 2012).  
4). The population groups that would benefit from aspirin most are unclear. Studies 
have suggested aspirin’s cancer prevention benefit are unrelated to sex and smoking, 
but may maximally benefit older people at age >65 years (Rothwell et al., 2011). To 
further ensure a precise personalised assessment on the advantage and disadvantage 
of aspirin treatment, there are emerging studies on molecular and genetic level to 
investigate clues that would affect the outcome of aspirin (Coyle et al., 2016)(Drew 
et al., 2016). In particular, the status of PIK3CA gene has been linked to aspirin’s 
clinical outcome. PIK3CA gene encodes PI3K, which is down regulated by aspirin 
and then inhibiting the activity of COX-2. A study in patients with diagnosed 
colorectal cancer has found, in patients carry mutant PIK3CA, aspirin treatment 
delivered a favourable outcome on cancer-specific survival (HR=0.18, 95% CI=0.06-
0.61), while aspirin treatment was not associate with cancer-specific survival among 
patients with wide-type PIK3CA (HR=0.96, 95% CI=0.69-1.32) (Liao et al., 2012). 
The similar effect that genotypic differs clinical outcome of aspirin on colorectal 
cancer was also found on the genetic status of BRAF, gene encodes RAF kinases 
which promote COX-2 activity. As report by the same group, people with mutant 
BRAF were less sensitive to aspirin regarding colorectal cancer incidence (HR=1.03, 
95% CI=0.76-1.38) compared to BRAF wide-type population (Nishihara et al., 2013). 
In addition, the T allele of the single nucleotide polymorphism (SNP) rs6983267 on 
chromosome 8q24 in individuals, along with the postivie nuclear expression of β-
catenin, are also associated with positive effects of aspirin in lowering colorectal 
cancer risk (Odd ratio (OR)= 0.83; 95% CI = 0.74 to 0.94) (Nan et al., 2013). 
Furthermore, the overexpression of PTGS2 gene, which encodes COX-2, was 
associated with favourable aspirin outcome in reducing colorectal cancer incidence 
(Positive PTGS2 (RR= 0.64; 95% CI=0.52-0.78) compared to negative PTGS2 
expression (RR= 0.96; 95% CI=0.73-1.26)) (Chan et al., 2007) (Figure 1.8).  
5). Molecular mechanisms underlying the anti-tumorigenesis of aspirin are not 
completely understood. Given the promise of aspirin on cancer prevention and the 
disadvantages of it due to potential side effects, it is extremely necessary to deeply 
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understand the molecular mechanisms by how aspirin exert its anti-tumour effects in 
order to identify novel molecular targets of this agent and develop other drugs or 
combination strategy to build on the cancer prevention benefits.  
1.6.2 Mechanism of anti-tumour action of aspirin 
Although the molecular mechanisms of aspirin and other NSAIDs induced inhibition 
of platelets activity and inflammation reaction have been clearly established as 
described above, how they confer their anti-tumour action are still largely unknown. 
Currently, there are mainly two proposes to explain the chemoprevention action of 
these agents, dependent on whether inhibition on COX activity is required. 
1.6.2.1 COX dependent pathways 
Direct inhibition of COX activity has been pointed as the main mechanism by which 
aspirin and other NSAIDs use to prevent cancer development. This hypothesis has 
been supported by several epidemiologic and experimental studies.  
Firstly, COX-2 level are increased in many solid tumour types, especially colorectal 
cancer. There was evidence that colorectal cancer patients with elevated COX-2 
expression were associated with bigger tumours size, higher rate of metastasis and 
reduced survival. Therefore, COX-2 could be used a prognostic indicator of 
colorectal cancer (Soumaoro et al., 2004). Considering that colorectal cancer 
response best to low-dose of aspirin in cancer prevention, this study suggested the 
possibility that aspirin could target COX-2 expression for chemotherapeutic purpose. 
A robust support for this possibility comes from an epidemiologic study evidenced 
the cancer prevention outcome of aspirin use is strongly related to the COX-2 
expression level. In this study, they applied immunohistochemistry assay in a cohort 
of colorectal cancer patients, and demonstrated aspirin use reduced colorectal cancer 
incidence in patients with overexpressed COX-2 (RR= 0.64; 95% CI=0.52-0.78) but 
not in patients with low expression or absence of COX-2 (RR= 0.96; 95% CI=0.73-
1.26) (Chan et al., 2007). This has been supported by more recent case-control 
studies, which show the risk of colorectal cancer in response to aspirin are also 
associated with overexpression of other COX-2 pathway related metabolites, such as 
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hydroxyprostaglandin dehydrogenase 15-(NAD) (15-PGDH, HPGD) (Fink et al., 
2014) and PGE-M (Bezawada et al., 2014).  
Mechanistically, aspirin with low-dose and high-dose have been suggested to affect 
different steps of colon tumorigenesis through selectively inhibiting COX activity. In 
early stage of intestinal carcinogenesis, activated platelets-induced upregulation of 
COX-2 in stromal cells and intestinal epithelial cells promotes the transformation 
from normal mucosa to adenoma. Low dose aspirin may counteract the early events 
of neoplasia through a mechanism, by which inhibition of COX-1 in platelets and 
then subsequently suppress the induction of COX-2 in stromal cells and intestinal 
epithelial cells (Thun et al., 2012). This hypothesis is compatible with the findings 
from several RTC trials which prove low-dose aspirin can effectively prevent 
occurrence of adenomas (Cole et al., 2009), and using coxibs, a class of traditional 
NSAIDs selectively inhibit COX-2, generates the similar effects on prevention of 
adenomatous polyps (Arber et al., 2006). Experimental studies in mouse model of 
colorectal cancer further supports this hypothesis. For example, deletion of COX-2 
gene or applying COX-2 inhibitor dramatically decrease the number and size of the 
intestinal polyp in Apc delta716 knockout mice (Oshima et al., 1996); Homologous 
deletion either COX-1 and COX-2 gene reduced about 80% of the polyp formation in 
Apc(Min/+) mice (Chulada et al., 2000). Different from low-dose aspirin, aspirin 
used in anti-inflammatory high dose could inhibit COX-2 activity directly. Therefore, 
high-dose aspirin could target intestinal adenomas directly, which already have high 
levels of COX-2 expressed, thus inhibit the progression from adenomas to advanced 
lesions or metastasis (Dovizio et al., 2012).   
However, given the fact that aspirin has a short half-life (15-20 minutes due to 
metabolism by liver and plasma esterases) and platelets in the portal circulation 
experience highest concentration of aspirin, the low-dose (75-300mg once daily) 
aspirin is considered only sufficient to irreversibly and selectively inhibits COX-1 in 
platelets and prevent thrombotic events, while just having minor effects on COX in 
nucleated cells (Thun et al., 2012). Besides, although high dose aspirin does achieve 
appropriate concentration to simultaneously inhibit COX-1 and COX-2, study has 
evidenced high doses don’t further reduce the cancer incidence and mortality 
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compared with low dose (Rothwell et al., 2010). Therefore, it is likely that other 
signalling pathways besides COX are effected by aspirin treatment and conduct the 
anti-tumour effects of the agent.  
1.6.2.2 COX independent pathways 
Despite the importance of COX activity in colon tumorigenesis and the accumulated 
evidence of inhibition of COX is responsible for aspirin and other NSAIDs’ 
antineoplastic action, there are large amount of evidence have suggested a COX-
independent way of this effect. The direct evidences of NSAIDs may act through 
COX-independent mechanism for their chemoprevention role come from a couple of 
studies, which demonstrated NSAIDs were effective in suppressing cell 
transformation and inducing cell apoptosis in COX null cells (Hanif et al., 1996; 
Zhang et al., 1999).  
Through modulation on inflammatory and immune responses 
Aspirin’s anti-inflammatory properties and the well-established connection between 
chronic inflammation disease and colorectal tumorigenesis have strongly suggested a 
causal link between aspirin’s chemopreventative effects and modulation on host 
immune response (Drew et al., 2016; Terzic et al., 2010). There are numbers of 
epidemiological studies have examined the association between CRC risk, cancer 
prevention outcome by aspirin and immune markers. For example, a case-control 
study in 32,826 women found the high plasma levels of the soluble tumour necrosis 
factor receptor 2 (sTNFR-2) was correlated to higher risk of CRC. The use of aspirin 
associated with lower risk of CRC among women with high baseline of sTNFR-2 
(RR=0.39; 95% CI=0.18-0.86), but not among women with low baseline of sTNFR-2 
(RR=0.86; 95% CI=0.41-1.79) (Chan et al., 2011). Similarly, the high levels of 
another inflammatory marker, macrophage inhibitory cytokine-1 (MIC-1 or GDF15), 
in plasma was linked to colorectal carcinogenesis as well. In an exploratory analysis 
of a cohort study, the same group also found high baseline of plasma MIC-1 was 
associated with reduced risk of COX-2-positive CRC upon regular use of aspirin (RR 
= 0.60; 95% CI=0.41-0.88) (Mehta et al., 2014).  
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A very recent Genome-Wide Association Study (GWAS) further implicated the role 
of aspirin in modulating immune response. In this genome-wide analysis of gene x 
environment interactions, two SNPs were identified showing genome-wide 
significant interactions with aspirin use. One of them, the SNP rs16973225 is located 
at chromosome 15q25.2 near the IL-16 gene, which encodes IL‑16, a pleiotropic 
cytokine functions as a chemoattractant for T-cells and involves in T-cells activation. 
The case-only analysis in the study indicated regular use of aspirin was associated 
with a lower CRC risk among individuals with rs16973225-AA genotype (OR = 0.66; 
95% CI=0.62–0.71; P = 1.9 × 10−30) but not among individuals with rs16973225-AC 
or CC genotypes (OR = 0.97; 95% CI 0.78–1.20) (Nan et al., 2015).  
Taken these evidence into account, and together with a very early finding that aspirin 
induced antigen presentation proteins HLA-DR expression in colon cancer cells 
(Arvind et al., 1996), aspirin may modulate inflammatory or immune response and 
increase the immune surveillance for its cancer prevention purpose.  
Through modulation on cellular signalling pathways 
Studies up to date have indicated aspirin and other NSAIDs could alter numbers of 
cellular signalling pathways which are critical or associated with carcinogenesis 





APC gene mutation has been well-known as a key factor drives initiation of 
colorectal cancer or adenomatous polyp formation. Familial adenomatous polyposis 
(FAP) is caused by germ-line APC mutations; by the age of 40 years old, the risk of 
colorectal cancer is almost 100% in APC gene mutation carriers (Markowitz and 
Bertagnolli, 2009). In most cases, a direct result of APC gene mutation is the 
dysregulation and activation of Wnt/β-catenin pathway. APC gene encodes APC 
protein, a tumour suppressor that negatively regulates Wnt/β-catenin signalling 
pathway. APC protein is a part of β-catenin ‘destruction complex’, which controls 
the cellular level of β-catenin by driving ubiquitination-dependent proteolysis of it. 
Loss of APC protein will cause abnormal high level of cytoplasmic β-catenin whose 
nuclear translocation activates the transcription of proliferative genes.  
Given the importance of APC gene mutation and activation of Wnt/β-catenin 
pathway in colorectal cancer development, the interplay between aspirin and Wnt/β-
catenin has been investigated to illuminate the anti-cancer mechanisms of aspirin 
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(Gala and Chan, 2015). Phosphorylation of β-catenin is crucial for its degradation. 
Bos CL et.al found millimolar level of aspirin in vitro inhibits the activity of Wnt 
pathway, evidenced by observations showing increased phosphorylation of serine 
41/threonine 45 on β-catenin, enhanced ubiquitination-dependent degradation of β-
catenin, reduced nuclear translocation of β-catenin and reduced gene expression of 
Wnt target genes. They also demonstrated aspirin-induced phosphorylation of β-
catenin is a consequence of upstream inhibition on protein phosphatase 2A (PP2A) 
enzymatic activity by the reagent (Bos et al., 2006). In addition, aspirin can also 
target the downstream effectors of Wnt/β-catenin pathway, like Peroxisome 
proliferator–activated receptor-δ (PPAR-δ). PPAR-δ is highly expressed in colorectal 
cancer and this gene is a direct transcriptional target of Wnt/β-catenin signalling, 
therefore PPAR-δ is suppressed by functional APC. Activation of PPAR-δ associates 
with increased number and size of intestinal polyps in Apc(Min/+) mice (Gupta et al., 
2004). Study found in Apc(Min/+) mice, traditional aspirin covalently attached with 
a NO releasing moiety (NO-ASA) efficiently dismisses intestinal tumorigenesis 
through its inhibitory effect on PPAR-δ expression (Ouyang et al., 2006). 
Considering that APC gene mutation and activation of Wnt/β-catenin pathway is 
crucial in the early stages of colorectal carcinogenesis, these studies would suggest 
the inhibitory effects of aspirin on adenoma formation (evidenced in the 
epidemiologic studies) are possibly in part through its regulation on Wnt/β-catenin 
pathway.  
Notably, recent case-control studies have found the single nucleotide polymorphism 
(SNP) rs6983267 on chromosome 8q24, which is a CRC susceptibility locus, is 
associated with an advantage effect of aspirin in preventing colorectal cancer (OR= 
0.83; 95% CI = 0.74 to 0.94) (Nan et al., 2013). The T allele of the rs6983267 
impairs the binding of transcription factor 7 like-2 (TCF7L2) to β-catenin, thereby 
decreasing the expression of MYC oncogenes. Moreover, among the population that 
carries T allele of the rs6983267, the cancer preventative effects of aspirin are only 
limited to individuals with positive β-catenin expression. This study provides 
evidence for tailored aspirin treatment dependent on the status of rs6983267 and 




Mitogen-activated protein kinase (MAPK) pathways are widely expressed signalling 
cascades involved in converting a diverse array of external stimuli (such as mitogens, 
stress factors and cytokines) to cellular responses that effect cell proliferation, 
differentiation, survival and apoptosis (Cargnello and Roux, 2011). MAPK pathways 
can be characterized into several subgroups, which conventionally comprise the 
extracellular signal-regulated kinases 1/2 (ERK1/2), Jun N-terminal kinases/stress 
activated protein kinases (JNKs/SAPKs), p38 kinase and ERK5. MAPK pathways 
share the same typically three-tiered activation process, as the MAP3Ks activated by 
phosphorylation or binding to a small GTP-binding protein upon the stimuli, 
activated MAP3Ks activate MAP2Ks by phosphorylation which sequentially 
stimulate MAPKs through dual phosphorylation on threonine and tyrosine residues 
(Cargnello and Roux, 2011).  
Aberrantly activated MAPK pathways is an essential feature for many types of 
malignancies, and there are a growing number of MAPK specific inhibitors have 
been approved for cancer treatment. Genomic profiling also revealed that the 
mutations on MAPK pathway components, such as BRAF gene encoding RAF kinase 
which is an important regulator of MAPK pathway, are common in human tumours 
(Burotto et al., 2014). Interestingly, there was an analysis on a RCT of colorectal 
cancer patients, which shown patients with wide-type BRAF gene convert more 
reduction on cancer incidence after aspirin allocation (HR=0.73; 95% CI=0.64-0.83) 
than their BRAF mutant counterparts (HR=1.03, 95% CI=0.76-1.38) (Nishihara et al., 
2013). This finding strongly suggested the possibility that aspirin could achieve 
chemotherapeutic purpose through modulating MAPK pathways. Indeed, there are 
numbers of in vitro studies have indicated that aspirin regulates MAPK pathways, for 
example modulating phosphorylation of ERK. In one study, aspirin induced 
phosphorylation of ERK was linked with the inhibition of melanogenesis in 
melanoma cells, and specific ERK phosphorylation inhibitor abrogated the anti-
melanogenic effect of aspirin (Nishio et al., 2016).  
In addition to ERK, aspirin also regulates p38 MARK activity. Evidenced by the 
hosting lab, aspirin activates the p38 MAPK pathway, which followed by 
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degradation of cyclin D1 degradation and NF-κB nucleolar translocation, is 
responsible for aspirin caused colorectal cancer apoptosis. To support this, chemical 
inhibitor of p38 MAPK has been shown abolished aspirin’s effect on downstream 
NF-κB and cell apoptosis (Thoms et al., 2007b). Similarly, aspirin treatment in 
human vascular smooth muscle cells also increases the phosphorylation of p38 
MAPK (Redondo et al., 2010). This set of data provides strong evidence that 
aspirin’s modulation on MAPK pathways is a potential mechanism underlying the 
pro-apoptotic effects of this agent.  
AMPK and mTOR 
The 5'-adenosine monophosphate-activated protein kinase (AMPK) and mammalian 
target of rapamycin (mTOR) pathways are two critical sensors involved in the 
fundamental regulation of cellular energy balance. They are regulated by various 
energetic factors, such as growth factors and amino acids, and accordingly 
converting these signals to control cellular metabolism and homeostasis. Defect on 
any of them will lead to metabolic disorders including obesity, type 2 diabetes and 
cancer. AMPK activity is mainly regulated by its conformational change upon 
binding to AMP or ADP that promotes phosphorylation and inhibits 
dephosphorylation at threonine 172. Therefore, AMPK can sense cellular energy 
change by monitoring ATP to AMP or ADP ratio (Inoki et al., 2012). There have 
been some direct evidence show aspirin activates AMPK. Hawley et.al demonstrated 
that salicylate, products from hydrolysis of aspirin in vivo, directly binds to and 
allosterically activates AMPK through inhibiting the dephosphorylation on threonine 
172. They also indicated, this regulation is central for aspirin enhanced fat utilization 
and reduced circulating lipids in fat-feed mice (Hawley et al., 2012). This is in 
agreement with the finding that aspirin promotes hepatocellular lipid metabolism by 
upregulating the phosphorylation of AMPK (He et al., 2015).  
mTOR pathway has close inter-connection between AMPK pathway in response to 
energetic factors. mTOR, as a serine/threonine kinase, is also a downstream targets 
of AMPK (Inoki et al., 2012). Beside, mTOR always couples with PI3K/Akt 
pathway in regulating ribosomal biogenesis and cancer development (Porta et al., 
55	
	
2014). Interestingly, a recent study demonstrated mice carrying PIK3CAH1047R gene 
mutation, which express constitutively active PI3K, develop human-like invasive 
adenocarcinomas in a Wnt-independent way. These PI3K mutation-initiated tumours 
are sensitive to PI3K/mTOR inhibition suggesting the dependence on the 
PI3K/mTOR pathway (Yueh et al., 2016). This study, together with a previous 
randomized controlled trial shown colorectal cancer patients with PIK3CA gene 
mutation are more sensitive to aspirin’s pro-survival effects (Liao et al., 2012), 
strongly indicate PI3K/mTOR pathway is a potential target for aspirin. Indeed, study 
from Din et.al in colorectal cancer demonstrated aspirin both activates AMPK 
through increase AMP: ATP ratio and direct binding and reducing mTOR activity 
through inhibiting the mTOR downstream effectors--S6K1 and 4E-BP1. They also 
demonstrated this pathway is partially involved in aspirin-induced autophagy in 
colorectal cancer (Din et al., 2012). But not all research has supported this notion that 
activation of AMPK/mTOR contributes to aspirin’s anti-tumour effects. Recently, 
Gao et.al found activation of AMPK-mTORC2-Akt-ERK1/2 axis and induction of 
MCL-1 expression compromises aspirin’s pro-apoptotic effects, whereas 
combination treatment of aspirin and sorafenib (a kinase inhibitor block aspirin-
induced MCL-1 upregulation) are more efficient in preventing hepatocellular 
carcinoma and colorectal adenomas(Gao et al., 2016).  
NF-kappaB 
As described in section 1.5 of this chapter, NF-κB signalling pathway is well known 
as its critical and pleiotropic role in various cell functions, especially inflammatory 
response and cancer development. Other than COX pathway, the role of NF-κB 
pathway in anti-tumour activity of aspirin has been most heavily investigated in the 
past 20 years.  
There is a set of early studies have demonstrated that aspirin inhibits the activation of 
NF-κB pathway. The very first report described aspirin affects NF-κB transduction 
was in a study that investigated the anti-inflammatory nature of aspirin. Kopp et.al 
evidenced that in vitro anti-inflammatory doses of aspirin as well as sodium 
salicylate (up to 10mM) prevented the degradation of IκBα and nuclear translocation 
of NF-κB, and therefore inhibited the NF-κB dependent gene transcription in human 
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B cell and T cell lines under LPS- and phorbol 12-myristate 13-acetate (PMA) 
treatment (Kopp and Ghosh, 1994). A later study built on this concept by evidencing 
sodium salicylate inhibited TNFα-induced IκBα phosphorylation in endothelial cell 
line, resulted in the inactivated NF-κB pathway, reduced endothelial-leukocyte 
adhesion molecule expression and inhibition of transendothelial migration of 
neutrophils. They also noticed this inhibition was not due to the inhibition of COX 
pathway (Pierce et al., 1996). A subsequent study had gone deeper into the 
mechanism of this inhibition, established that aspirin and sodium salicylate 
specifically inhibited IKKβ activity through binding to IKKβ and competing with 
ATP for binding this kinase, thereby preventing IKKβ dependent phosphorylation of 
IκBα and activation of NF-κB pathway under TNFα treatment (Yin et al., 1998). 
Aspirin had also been reported inhibited degradation of IκBα through interfering 
with the proteasome function (Dikshit et al., 2006).  
However, in contrast to these findings based on anti-inflammatory effect of aspirin, 
recent studies (including a body of studies in the hosting laboratory) about this 
agent’s pro-apoptotic mechanism have suggested aspirin activates the NF-κB 
pathway. The hosting laboratory was the first to analyse aspirin and other NSAIDs’ 
effects on NF-κB pathway and the association between these effects and cell death of 
colorectal cancer. In the absence of additional stimuli, they observed aspirin induced 
proteasomal-dependent degradation of IκBα and nuclear translocation of NF-κB in a 
time- and concentration-dependent manner. This activation was also evidenced 
associated with colorectal cancer cell apoptosis by applying a super-repressor form 
of IκBα which was resistant to stimuli-induced phosphorylation and degradation. 
They found cells constitutively expressed this super repressor IκBα were resistant to 
aspirin-induced NF-κΒ activation and most importantly apoptosis (Stark et al., 2001). 
Similar activation of NF-κΒ pathway was later observed by the same group in vivo in 
two mouse models of human colorectal cancer, in which they also demonstrated that 
even low-dose aspirin (40 mg/kg) could achieve the concentration of salicylate levels 
in xenografted tumours to activate NF-κB pathway and induce apoptosis of 
neoplastic epithelial cells (Stark et al., 2007).  
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Further studies from the host laboratory also elucidated the detailed molecular 
pathways underlying aspirin-induced NF-κΒ activation and revealed a novel 
mechanism explaining aspirin’s pro-apoptotic action. They found, under the pro-
apoptotic stimuli like aspirin, UV-C and serum starvation, NF-κΒ/RelA translocates 
to nucleus but is sequestered in nucleolus thus inhibiting NF-κB-driven 
transcriptional activity and inducing apoptosis. To the contrary, in response to stimuli 
like TNFα or TRAIL, RelA only accumulated in nucleoplasm and promoted NF-κB-
driven transcriptional activity. They also identified the nucleolar localisation signal 
(NoLS) on RelA and deletion of which was evidenced inhibited aspirin induced 
RelA nucleolar sequestration and cell apoptosis (Stark and Dunlop, 2005). 
Subsequently, they examined and identified COMMD1, the component of the RelA 
ubiquitin ligase complex upregulated by aspirin, was a critical factor regulating 
ubiquitination and nucleolar translocation of RelA (O'Hara et al., 2014; Thoms et al., 
2010). In addition, they draw the upstream pathway of this signal transduction 
network by revealing p38 MAPK-Cyclin D1/CDK4 axis and c-Src tyrosine kinase 
pathway act upstream and mediate aspirin-activated NF-κΒ (Brady et al., 2011; 
Thoms et al., 2007b). It is need to be addressed here that, although the mutation of 
tumour suppressor p53 has been widely studied and linked with colorectal 
tumorigenesis, the hosting laboratory has demonstrated aspirin-induced modulation 
on NF-κB and colorectal cancer cell apoptosis were irrespective to the p53 gene 
status (Din et al., 2004). 
In addition to aspirin, the host laboratory also demonstrated that other NSAIDs 
(including sulindac, sulindac sulfone and indomethacin) stimulates NF-κB in 
colorectal cancers and suggested NF-κB as a common signalling target responsible 
for the chemoprevention effects of NSAIDs (Loveridge et al., 2008). This was 
supported by another study that demonstrated NSAID diclofenac promoted IκBα 
degradation and the nuclear levels of NF-κΒ. In this instance, they also postulated a 
crosstalk between NF-κΒ and Wnt/β-catenin pathway, as activation of NF-κΒ 
suppressed β-catenin driven transcription which is important in the early 
transformation of colorectal cancer (Cho et al., 2005).  
Significance of aspirin’s effect on NF-κΒ 
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Although it was contentious about the unique role of NF-κΒ in aspirin-mediated anti-
inflammatory and anti-tumour response (as evidence shown aspirin and sodium 
salicylate non-specifically affected various cellular kinase activity (Frantz and 
O'Neill, 1995)), these body of researches did demonstrated NF-κB pathway was a 
molecular target of aspirin in a pharmacologically relative dose level. Ιt is even 
promising about aspirin’s potential modulation on NF-κΒ when we consider the 
pivotal role of NF-κB pathway in mediating inflammatory response and cancer 
development, and the significance that even a partial change of this pathway can 
have substantial effects on downstream cellular events. 
In addition, what makes the investigations of aspirin’s effect on NF-κΒ more 
interesting is, the host laboratory has indicated a cell-type specificity of aspirin-
induced NF-κB activation (Stark et al., 2001) (Din et al., 2004). They observed that 
aspirin specifically stimulated NF-κB and induced apoptosis in all colorectal cancer 
cells rather than in normal intestinal mucosa (Stark et al., 2007) or in other non-
gastrointestinal origins (Stark et al., 2001) (Din et al., 2004). They further underlined 
that aspirin stimulated NF-κB is a general effect in colorectal cancer, which is 
unrelated to COX-2 expression levels and gene mutation status of APC, p53 or DNA 
mismatch repair (MMR) genes (Din et al., 2004). This finding, paralleled with the 
observations from abundant epidemiological studies that aspirin protects colorectal 
cancer to a greater degree than noncolonic cancers, strongly suggests activation of 
NF-κΒ as a central molecular rationale for the particular chemoprevention effect of 
aspirin against colorectal cancer.  
In order to improve the benefits of aspirin in colorectal cancer prevention and 
develop tailored assessment on the advantage and disadvantage of aspirin treatment 
in individuals, recent case-control studies along with genomic analysis have 
identified several genetic markers that may confer the differential benefits from 
regular aspirin use (Figure 1.8). Notably, most of these identified markers have 
known associations with the NF-κΒ pathway. For example, TNFR2 and IL-16 are 
factors that are involved in immune response and regulating the NF-κΒ pathway. 
PI3K and MAPK pathways have well-establised inter-talks with the NF-κΒ pathway. 
It would be interesting to explore whether these genetic alterations are associated 
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with activation of the NF-κΒ pathway in these studies, and whether the activation of 
NF-κΒ is directly related to the outcome of aspirin treatment in colorectal cancer 
prevention.  
Through modulation on cellular organelles 
Intense researches on the molecular basis of aspirin and other NSAIDs’ 
antineoplastic effects have clearly shown that multiple pathways are involved in 
these effects, but they display cell-type specificity and not all the pathways are 
shared by all the members of NSAIDs. Compared with signal transduction pathways, 
the formation and function of cellular organelles are more conserved across all 
tissues and cell-type thus could be potential targets of aspirin and other NSAIDs for 
delivering anti-tumour effects. In this part, I will mainly describe the evidence and 
the promising facts of mitochondria and nucleolus in the chemoprevention effects of 
aspirin.  
Mitochondria  
Mitochondria are the most recognized power plants in eukaryotic cells, and are now 
well established as a central controller of the mitochondrial apoptotic pathway (or 
intrinsic apoptotic pathway). In this intrinsic signalling pathway, the mitochondrial 
membrane permeability change will lead to the release of numbers of pro-apoptotic 
factors, such as cytochrome c, into cytosol where they activate the caspase cascade 
and promote apoptosis process (Suzuki et al., 2010). There is a large of body of 
evidence showing aspirin and other NSAIDs cause cell apoptosis through affecting 
mitochondrial functions. 
Bellosillo et.al found aspirin induced a decrease in cell viability and cytotoxic 
through activation of caspase dependent pathway in B-cell chronic lymphocytic 
leukemia cells derived from patients (Bellosillo et al., 1998), and they later 
demonstrated this activation is a result of aspirin-induced mitochondrial membrane 
permeability change and release of cytochrome c (Pique et al., 2000). Meantime, in 
agreement with this finding, Zimmermann et.al evidenced aspirin induced cytosol to 
mitochondria translocation of BAX in HeLa cells, which then promoted cytochrome 
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c release from mitochondria and bind with pro-apoptotic factor Apaf-1 to activate 
downstream caspase cascade and induce cell apoptosis (Zimmermann et al., 2000). 
Notably, all of these studies have found caspase inhibitor, Z-VAD-FMK, blocked 
aspirin-induced cell apoptosis then strongly suggested the involvement of the 
caspase-dependent apoptosis pathway in the pro-apoptotic effect of this agent. 
Subsequently, Dikshit et.al demonstrated aspirin mediated changes in the 
mitochondrial membrane permeability, release of cytochrome c from mitochondria, 
and activation of caspase-9 and caspase-3 in mouse Neuro 2a cells and HeLa cells. 
Besides, an alternative aspirin-induced proteasomal malfunction mechanism was 
postulated in this study, as aspirin treatment decreased proteasome activity and 
increased the accumulation of ubiquitylated proteins in the cells, which paralleled 
with its effect on cell death (Dikshit et al., 2006). Study from the host laboratory 
shed light on a potential crosstalk between NF-κB pathway and mitochondrial 
apoptotic pathway in response to aspirin stress. They revealed a novel molecular path 
that nucleolar translocation of RelA promoted nucleolus to cytoplasm translocation 
of nucleolar protein nucleophosmin (NPM), which caused apoptosis by mediating the 
mitochondrial accumulation of BAX and was independent of NF-κB driven 
transcription (Khandelwal et al., 2011). 
Mitochondria plays important role in regulating and maintaining cellular Ca2+ 
concentration. Imbalanced intracellular Ca2+ concentration has been associated with 
cell apoptosis (Suzuki et al., 2010). Núñez et.al proposed another mechanism 
facilitating aspirin mediated cell apoptosis through mitochondria. They found 
salicylic acid inhibited mitochondrial Ca2+ uptake by interrupting a Ca2+ influx 
pathway, Store-operated Ca2+ entry (SOCE), which correlated with impairment of 
cell growth and induction of cell death in Jurkat and human colon cancer cells 
(Nunez et al., 2006).  
Nucleolus 
The nucleolus has been comprehensively discussed in section 1.1 to 1.4 of this 
chapter. Considering its central role in sensing cellular stress and converting various 
signals into cellular function response, nucleoli could be an area of interest in the 
anti-tumour activity of aspirin. Indeed, work carried out in the past decade in the host 
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laboratory has clearly identified the nucleolus as a convergent point in aspirin-
mediated NF-κB pathway modulation, with NF-κB/RelA sequestered in the 
nucleolus upon stimulation with aspirin, UV-C and serum starvation (Brady et al., 
2011; Stark and Dunlop, 2005; Stark et al., 2007; Thoms et al., 2007b; Thoms et al., 
2010).  
In the course of these studies, the host laboratory surprisingly found that aspirin and 
other stresses that cause nucleolar accumulation of RelA, induce a distinct nucleolar 
stress. That is, increased nucleolar size decreased nucleolar number and repression of 
rDNA transcription (unpublished) (Figure 1.10 A-C). These modifications on 
nucleolar morphology are also observed in response to stresses like UV-C exposure 
and serum starvation. Furthermore, it was found that they preceded stimulation of the 
NF-κB pathway, as evidenced by degradation of IκBα and nuclear/nucleolar 
translocation of RelA (unpublished) (Figure 1.10 D and E).  
These gave an exciting possibility that nucleolar stress may act upstream of NF-κB in 
response to aspirin. However, the molecular basis of aspirin’s effect on nucleolus and 
whether aspirin-induced nucleolar stress is responsible for subsequent NF-κB 
activation and cell death are completely unknown. Although a diversity of cellular 
stresses converge on the NF-κB pathway, no common model has been found to 
mediate this activation. Interestingly, previous literature reviewed in the host lab 
revealed almost all the stresses that stimulate the NF-κB pathway also cause 
nucleolar disruption, although with different effects on the organelle (Table 3.1). 
Together with the preliminary data from the host laboratory, these data suggest that it 
would be really interesting to explore whether the nucleolus is a common sensor 




Taken together, these preliminary data lead us to some very interesting scientific 
questions regarding the role of the nucleolus in the effects of stresses (such as the 
chemopreventative/therapeutic agent aspirin) on the NF-κB pathway and apoptosis. 
Given the crucial role of the nucleolus in multiple cell functions, further investigation 
into the effects of aspirin and other stress inducers on this organelle, and how these 
effects induce functional consequences, is desirable. This would not only provide 
further knowledge about the nature of nucleolus in regulating cell growth and cell 
death, but also may help us reveal additional molecular targets for targeting its 




1.7 Project Aims 
This project used biomedical approches and mainly in vitro tumour cell line study to 
identify a novel nucleolar stress response pathway that culminates in the activation of 
NF-κB pathway and with a view to investigate the significance of this pathway in the 
anti-tumour effects of aspirin. The ultimate aim of this project is to identify potential 
molecular targets for novel anti-cancer agents and improving the chemoprevention 
efficiency of aspirin. 
Aims of the project are: 
1. To examine whether modulation of NF-κB pathway is a downstream 
consequence of nucleolar stress;  
2. To elucidate the molecular basis that links stress stimuli, nucleolar response 
and stimulation of NF-κB pathway;  
3. To test the significance of this nucleolar stress response pathway in pro-









2.1 Mammalian Cell culture and manipulation  
2.1.1 Cell lines and maintenance 
Different colorectal cancer cell lines were applied. SW480 cells, a Dukes' type B 
colorectal adenocarcinoma (ATCC® CCL-228™) and RKO cells (ATCC® CRL-
2577™) were obtained from the American Type Culture Collection (ATCC). HRT18 
parental cells and the counterparts IκBα mutant cells--IκBSR1 and SR28 clones (that 
are resistant to aspirin-induced nuclear and nucleolar translocation of RelA) were 
developed and characterised previously (Stark et al., 2001). The HCT116 wide-type 
and the p53 null derivative of HCT116 (HCT116 p53-/-) were gifts from Professor B 
Vogelstein (John Hopkins University School of Medicine, USA) and has previously 
been described (Din et al., 2004).   
HeLa, Human Cervical cancer cells (ATCC® CCL-2™) and U2OS, Human Bone 
Osteosarcoma Epithelial Cells (ATCC® HTB-96™) are available from the American 
Type Culture Collection (ATCC). 
Cells were grown in Leibovitz’s L-15 medium (Gibco) (SW480 cells), RPMI1640 
medium (Gibco) (HRT18 cells, HCT116 cells), Dulbecco's Modified Eagle Medium 
(DMEM medium) (Gibco) (RKO cells, HeLa cells, U2OS cells) respectively. 
Medium were supplemented with 10 % fetal calf serum (FCS) and 1 % penicillin and 
streptomycin solution (10% FCS, p/s+ medium). Cells were cultured in T25 flask 
(25cm2) or T75 flask (75cm2) container (CellStar® Cell Culture Flasks) in 37°C 5% 
CO2 incubator (Hera Cell 240, Heraeus, Germany). 
Cells were passaged in the laminar flow cabinet (Heraeus, Germany). Cells were 
washed by 1 x phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM 
anhydrous; Na2HPO4, pH 7.4) followed by incubated with 1:1 tyrpsin:versene (T:V) 
at 37 °C for 10 minutes. Cells were maintented and passaged in a 1: 5- 1:20 dilution 
dependent on the further requirements.  
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2.1.2 Treatment procedure 
Cells were counted by Coulter Counter (Z Series, Beckman Coulter, High Wycombe, 
UK). Since cell confluence in in vitro tissue culture system is a criterion that could 
potentially affect cell cycle progression and influence on Pol I transcription and 
differ the drug treatment outcome (Hannan et al., 2000), cells were seeded in an 
initially intensity of 3 x 104, 5 x 104 or 1 x 105 per cm2 in 6 wells plate for the 
appropriate assays. 24 hours after seeding (cells with 50-80% cell confluent), cells 
were washed with 1 x PBS and changed medium to low serum medium (0.5% FCS 
medium supplemented with 1 % penicillin and streptomycin solution) prior to 
continuously exposure to specific drugs and indicated time duration. Immediately 
after treatment, cells were washed with 1 x PBS again at 4 °C to remove floating 
dead cells and debris, followed by harvesting or fixation for the appropriate assays.  
2.1.3 Drugs 
Aspirin was prepared as described in (Stark et al., 2001). Briefly, stock solution of 
aspirin (ASA; 0.5 M, pH 7.0; Sigma Aldrich, Gillingham, UK) was prepared by 
solubilising in distilled water (dH2O), with 5 M NaOH used to adjust the pH 
appropriately. 
The CDK4 inhibitors (2-bromo-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H)-dione) (CDK4i, Calbiochem) was prepared by solubilising in 
dimethyl sulfoxide (DMSO, Sigma) to stock concentration 2mM. Stored in -20°C in 
darkness. Palbociclib (PD-0332991) (Selleckchem, Cat. No. S1116), another CDK4 
inhibitor, was prepared by solubilising in DMSO to stock concentration 1mM. Stored 
in -20°C protected from light. 
MG132: MG132 (Z-Leu-Leu-Leu-al) (Sigma Aldrich, C2211-5MG) was prepared by 
solubilising in DMSO to stock concentration 50mM. Stored in -20°C.  
BMH-21 (12H-Benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide, N-
[2(dimethylamino)ethyl]-12-oxo) (Kindly supplied by Prof. Marikki Laiho from 
Johns Hopkins University School of Medicine, USA) 
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CX-5461: CX5461 (Selleckchem, Cat.No.S2684) was prepared by solubilising in 
DMSO to 1mM stock concentration. Stored in -20°C. 
Nutlin-3 (Kindly supplied by Prof. Kathryn Ball from Edinburgh Cancer Research 
Centre, UK) 
Calyculin A (Cell Signaling Technology), Cycloxexamide (Sigma), Lactincystin 
(Calbiochem), Ceramide isoforms (Sigma), Bafilomycin (Sigma), Quinacrine 
(Sigma), TNFa (R&D Systems) and Actinomycin D (Sigma) were all prepared as per 
manufacturer’s instructions. 
2.1.4 RNA interfere 
One day prior to siRNA transfection, cells were seeded in a 6-wells plate in an initial 
intensity of 3 x 104 per cm2. Cells were then transfected with specific siRNA using 
Lipofectamine 2000 (Invitrogen) following the optimised manufacturer’s instructions 
below. (Quantities indicated below are for transfection in a well of a 6-wells plate). 
For every transfection, 125 pM of siRNA designed against specific genes or 
scrambled siRNA were added to 312.5ul optimem (optimem reduced serum media 
(Invitrogen)). 6.25ul lipofectamine 2000 were gently mixed with 305.25ul optimem 
before leaving it static for 5 minutes in room temperature. The siRNA: optimem 
solution and lipofectamine 2000: optimem solution were then mixed 1:1 and 
incubated for 30 minutes in room temperature. In the meantime of incubation, cells 
were washed by 1 x PBS once and supplied with 1.875ml fresh medium without 
penicillin and streptomycin solution (10% FCS, p/s- medium). After 30 minutes’ 
incubation, 625ul of lipofectamine 2000: siRNA mixture were added into each well 
and returned to 37 °C incubator. To enhance the gene knockdown efficiency, a 
second siRNA transfection was performed one day after following the same process 
as described above. Cells then grew in 37 °C incubator for another day before 





Table 2.1 siRNA species used for transfection 
Name Sequence (5’-3’) Manufacturer 
TIF-IA CUAUGUAGAUGGUAAGGUU Sigma Aldrich 
UBF CCAAGAUUCUGUCCAAGAA Eurofins MWG 
Operon 
p14ARF  AAGACCAGGUCAUGAUGAUGG Eurofins MWG 
Operon 
CDK4 #1 AAGGCCCGUGAUCCCCACAGU Eurofins MWG 
Operon 
CDK4 #2 AAGCCGACCAGUUGGGCAAAA Eurofins MWG 
Operon 
Scrambled control AGGUAGUGUAAUCGCCUUG Eurofins MWG 
Operon 
 
2.1.5 Plasmids transfection 
One day prior to plasmids transfection, cells were seeded in a 6-wells plate in an 
initial intensity of 5 x 104 per cm2. Cells were then transfected with indicated 
plasmids using Lipofectin (Invitrogen) following the optimised manufacturer’s 
instructions below. (Quantities indicated are for transfection in a well of a 6-wells 
plate). For each transfection, 3ug of appropriate plasmids were mixed with 100ul 
optimem. 10ul of lipofectin were added to a separate 100ul optimem in the meantime. 
Plasmids: optimem and lipofectin: optimem solutions were incubated for 45 minutes 
in room temperature separately before mixing them 1:1 for another 15 minutes in 
room temperature. In the meantime, cells were washed by 1 x PBS twice and applied 
with 800ul optimem which was enough to cover whole well. Then 200ul plasmids: 
lipofectin mixture were added to each well and returned to 37 °C incubator. 6 hours 
after transfection, plasmids: lipofectin transfection mixture were removed and 
replaced by fresh 10%FCS p/s+ medium. Cells were then incubated in 37 °C for a 




Table 2.2 Plasmids used for transfection 
Plasmids Constructed by /Manufacturer 
pEGFP-C1 Commercially available from Clonetech 
pEGFP-C1-hTIF-IA Kindly provided by I. Grummt (German 
Cancer Research Centre) 
pEGFP-C1- hTIF-IA-94-204aa Dr. Pierre Morin  
pEGFP-C1- hTIF-IA-94-302aa Dr. Pierre Morin 
pEGFP-C1- hTIF-IA-94-403aa Dr. Pierre Morin 
pEGFP-C1- hTIF-IA-Δ1-94aa Dr. Pierre Morin 
pEGFP-C1- hTIF-IA-S170A or S170E Jingyu Chen 
pEGFP-C1- hTIF-IA-S172A or S172E Jingyu Chen 
pEGFP-C1- hTIF-IA-S170/172A or 
S170/172E 
Jingyu Chen 
pEGFP-C1- hTIF-IA-S199A or S199E Jingyu Chen 
pEGFP-C1- hTIF-IA-T200A or T200E Jingyu Chen 
pEGFP-C1- hTIF-IA-S44A or S44D Jingyu Chen 
Flag-UBF wild type Kindly provided by R. Voit (German 
Cancer Research Centre) 
Flag-UBF S484A Kindly provided by R. Voit (German 
Cancer Research Centre) 
3 x κB ConA Luciferase Plamsid Kindly provided by R.Hay (University of 
Dundee) 
ΔκB ConA Luciferase Plasmid Kindly provided by R.Hay (University of 
Dundee) 
pCMV-β Commercially available from Promega 
Flag-p14ARF Kindly provided by A. Lamond 
(University of Dundee) 
pcDNA3-IκBα s32/36 Kindly provided by R.Hay (University of 
Dundee) 
 
2.2 Bacterial cell culture 
2.2.1 Site-specific mutagenesis  
The TIF-IA site mutant pEGFP fusion plasmids were generated based on the pEGFP-
C1-hTIF-IA plasmid (kindly supplied by Professor. Ingrid Grummt from German 
Cancer Research Centre). Pairs of complimentary oligonucleotides containing the 




QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies) was used and 
the manufacturer’s instructions were followed. Briefly, prepared the sample reaction 
(5ul of 10 x reaction buffer, 1ul of dNTP mix, 1ul (20uM) of oligonucleotide forward 
primer, 1ul (20uM) of oligonucleotide reverse primer, 1.25ul of PfuUltra HF DNA 
polymerase, 0.5ul (50 ng) of pEGFP-C1-hTIF-IA plasmids, 40.25ul ddH2O to a final 
volume of 50ul) (pUC18 plasmids supplied in this kit was used as control plasmids 
of transformation), cycled the reaction using the parameters (95°C 30s, [95°C 30s, 
55°C 1mins, 68°C 8mins][18 cycles], 68°C 10mins, 4°C 30mins) in PCR machine 
(PTC-225 Peltier Thermal Cycler, MJ Research). Then add 1ul of the Dpn I 
restriction enzyme directly to each reaction and incubate at 37°C for 1 hour to digest 
the nonmutated parental dsDNA plasmids. Transfer 10ul of DpnI digested reaction 
solution into 50ul thawed XL-1 blue supercompetent cells (supplied in this kit). Put 
the reaction on ice for 30 minutes before heat pulse the reaction at 42°C for 45 
seconds then place for 2 minutes on ice. Add 0.5ml pre-warmed Mg+ Lysogeny broth 
(LB) medium and incubate at 37°C for 1 hours with continuous shaking at 225rpm. 
Then gently span down bacteria with 3000rpm for 5 minutes, removed supernatant to 
200ul and gently re-suspended bacteria pellets to spread on agar LB plates containing 
50ng/ml kanamycin. Put the transformation plate at 37°C for more than 16 hours. 
Single colonies grew on the plate would be picked for further characterised (IGMM 
technical service for DNA sequencing) and application.  
2.2.2 Plasmids transformation in DH5α E.coli 
In order to produce sufficient plasmids stock for further application, chemically 
competent Subcloning Efficiency DH5α Escherichia coli (Invitrogen) were 
transformed by intaking exogenous plasmids following manufacturer’s instructions. 
That is, 10ng of dsDNA plasmids were added into 50ul of commercial DH5α cells. 
Put cells and plasmids mixture on ice for 30 minutes before heat pulse the reaction at 
42°C for 20 seconds. Cells were returned to ice for 2 minutes before adding 900ul 
pre-warmed LB medium to recover the cells in 37°C for 1 hours with continuous 
shaking at 225rpm. 100ul-200ul of the culture was then evenly spread onto agar LB 
plates containing appropriate antibiotics (100ng/ml ampicillin or 50ng/ml 
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kanamycin). To allow the single colony formation, leave the plate in 37°C incubator 
for more than 16 hours.  
2.2.3 Growth of transformed E.coli 
Single colony was picked by using a p10 tip and directly put into a tube containing 
3ml LB medium with appropriate antibiotics (100ng/ml ampicillin or 50ng/ml 
kanamycin). The mini-culture was put into a 37°C incubator for 8 hours with 
continuous and vigorous shaking (250rpm). For expanded plasmids production, 
500ul of the incubated mini-culture was inoculated into 200-500ml LB medium 
containing appropriate antibiotics (maxi-culture), which was subsequently incubated 
at 37°C overnight with continuous and vigorous shaking at 250rpm.  
2.2.4 Preparation of plasmids (Maxi-prep) 
Plasmids were prepared from overnight-incubated maxi-culture by using Plasmids 
Maxi Kit (Qiagen, 12163), the manufacturer’s instructions were followed.  
2.2.5 Storage of transformed E.coli and plasmids.  
For long-time storage, transformed E.coli culture were 1:1 mixed with sterilized 50% 
glycerol solution, this mixture was then kept in -80°C. Plasmids were directly stored 
in -80°C condition for years.  
 
2.3 Preparation and handling of nucleic acid 
2.3.1 RNA extraction 
Total RNA was extracted from cells using RNeasy mini kit (Qiagen, 74104) 
following the manufacturer’s instructions. Briefly, Up to 1 x 107 cells were disrupted 
and homogenized in Buffer RLT. One volume of ethanol was added to the lysate, 
which creates conditions that promote selective binding of RNA to the RNeasy 
membrane in the spin column. All the samples were then transferred to the RNeasy 
Mini spin column. Multiple spins were then applied for washing away contaminants 
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(by buffer RW1 and RPE), and purified total RNA is eluted in RNase-free wate. 
Quantify and quality of RNA were measured on Nano-drop (Thermo Scientific). 
2.3.2 Dnase I treatment and cDNA synthesis 
To purify extracted RNA, Dnase I (RQ1 RNase-free DNase, Promega, M610A) was 
applied to eliminate genomic DNA as follow. Prepared the sample reaction (1ul 
Dnase I, 1ul 10 x 1ul 10 x Reaction/Dnase buffer (Promega, M198A), 1ug RNA in 
total volume of 7 ul H2O), place in the reaction in water bath at 37°C for 45 minutes 
before adding 1ul RQ1 Dnase stop solution (Promega, M119A) and transferring all 
the volume above to a new PCR tube. Place it in PCR machine (PTC-225 Peltier 
Thermal Cycler, MJ Research) for another 10 minutes at 65°C. In order to synthesis 
complimentary DNA (cDNA), added the following ‘reverse transcriptase mixture’ 
directly into the reaction above (4ul 5 x M-MLV RT reaction buffer (Promega, 
M531A), 2ul Random primer (Promega, C118A), 2ul dNTP (10mM) (Roche, 
11483188001), 1ul M-MLV Reverse Transcriptase (Promega, M170B), 1ul 
RNasin®Plus RNase Inhibitor (Promega, N261B)), gently and thoroughly mixed and 
returned the tube into PCR machine, set up cycling parameter as follow: 42°C 1 hour, 
95°C 5 minutes, 4°C 30 minutes. Synthesized cDNA was stored at -20°C for further 
PCR measurement.  
2.3.3 PCR 
Normal PCR was performed following the standard PCR process. Prepared and well 
mixed reaction (5ul 10 x buffer, 1ul 10mM dNTP, 1.7ul 50mM MgCl2, 1ul 20uM 
primer forward, 1ul 20uM primer reverse, 0.4ul Plantium Taq polymerase 
(Invitrogen), 1ul DNA template, 38.9ul ddH2O) was placed in PCR machine (PTC-
225 Peltier Thermal Cycler, MJ Research) to process the following cycles: 94°C 5 
minutes, [94°C 1 minute, 58°C 1 minute, 72°C 30 seconds][25-32 cycles, dependent 




2.3.4 Quantitative real-time polymerase chain reaction (qRT-
PCR) 
Taqman gene expression system (Thermo Fisher Scientific) or SYBR green based 
system were used to set up quantitative real-time polymerase chain reaction (qRT-
PCR). 
2.3.4.1 Quantitative real-time polymerase chain reaction (qRT-PCR) 
with Taqman gene expression system 
Taqman gene expression system (Thermo Fisher Scientific) contains a pair of 
unlabelled traditional oligonucleotide primers targeting a protein-coding transcripts 
and an oligonucleotide probe, which binds to a specific region that lies within the 
amplicon, with a fluorophore (FAM™ or VIC® dye) covalently attached to the 5’ 
end and a minor groove binder (MGB) and nonfluorescent quencher (NFQ) on the 3’ 
end. The fluorescence emitted by the fluorophore on the probe is quenched by the 
quencher based on FRET (Fluorescence Resonance Energy Transfer) principal when 
they are in proximity. During amplification, as the primers being extended, the 5´–3´ 
exonuclease activity of Taq polymerase degrades the probe and removes the 
fluorophore reporter from the probe. The break of the proximity between reporter 
and quencher allows the fluorescence of fluorophore become detectable. Therefore, 
the intensity of detected fluorescence is proportional to the amount of DNA template 
amplifications.  
qRT-PCR was set up in 384 wells plate (Thermo Scientific). Each qRT-PCR reaction 
contains the following components: 5ul Taqman Gene Expression Master Mix 
(Applied Biosystems, 4369016), 0.5ul primers + probe, 2.5ul Rnase/Dnase-free 
ddH2O (Gibco, 1097-035), 2ul cDNA template. Plate was then placed in the 
lightcycler HT7900 (Life Technologies) and cycled the reaction using the parameters 





Table 2.3 Primers and probes used in Taqman gene expression assay 
Gene 
Name 













p14ARF N/A N/A Life Technologies 
(Order No. 
HS99999189_m1) 
GAPDH N/A N/A Life Technologies 
(Cat# 4352934E) 
IκBα N/A N/A Life Technologies 
(Order No. 
Hs00355671_g1) 
Bcl-xL N/A N/A Life Technologies 
(Order No. 
Hs00236329_m1) 
Bax N/A N/A Life Technologies 
(Order No. 
Hs00180269_m1) 
XIAP N/A N/A Life Technologies 
(Order No. 
Hs00745222_s1) 




2.3.4.2 Quantitative real-time polymerase chain reaction (qRT-PCR) 
with SYBR green.  
SYBR green is a fluorescent DNA binding dye which preferentially binds double–
stranded DNA by intercalating between base pairs, and fluoresces only when bound 
to DNA. Therefore, the amount of the SYBR green emitted fluorescence and the 
amplified double-stranded DNA in the sample is in a direct proportion.  
qRT-PCR was set up in 384 wells plate with each reaction contains the following 
components: 5ul 2 x SYBR Green Mix (Qiagen), 0.175ul 20uM forward primer 
(Sigma), 0.175ul 20uM reverse primer (Sigma), 3.65ul Rnase/Dnase-free ddH2O, 1ul 
(50ng) cDNA template. Plate was then placed in in the lightcycler HT7900 (Life 
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Technologies) and cycled the reaction using the parameters (95°C 10 minutes, [95°C 
10 seconds, 60°C 30 seconds][45cycles]). 
Primers used for SYBR green based qRT-PCR (IL-6, IL-8, IL-11, IL-32) were kindly 
supplied by Dr. Simon Wilkinson lab (Edinburgh Cancer Research Centre, UK).  
2.3.4.3 Data analysis 
Data analysis were based on Ct value. ddCt algorithm was applied for quantifying 
relative changes in gene expression compared to control samples (siControl or non-
treated control) (Chang et al., 2009). Absolute quantification using the standard 
curve method was also utilised in some experiments, for example examining the 
difference of specific gene expression levels in individual cell types (Pfaffl, 2001). 
Mean values (added up all values and then divided by the number of repeats) are 
represented in graphs where there are more than one values. Standard deviations (SD) 
are also calculated for samples where there are more than one values.  
2.3.5 Storage of RNA and cDNA 
Samples of RNA were stored in -80°C, cDNA were stored in -20°C.  
2.4 Preparation and handling of protein 
2.4.1 Soluble protein extraction from whole cells 
In order to prepare protein samples for further analysis, whole cell lysis buffer (10 x 
Whole Cell Lysis Buffer, Cell Signalling Technology) was applied following the 
manufacturer’s instructions. 1 x Whole Cell Lysis Buffer was prepared in advance by 
mixing the following components: 100ul 10 x Whole Cell Lysis Buffer, 10ul 100 
mg/ml Pefabloc SC (Roche, 11429876001), 40ul 25 x Complete Protease Inhibitors 
Cocktail (Roche, 11873580001), 1ul 1mM Pepstatin A, 2ul 500mM Na3VO4, 10ul 
100mM NaF, 1ml ddH2O. Add 100ul 10 x phosSTOP (Roche) if phosphorylated 
proteins need to be analysed. Cells, which were treated as indicated in a well of 6-
wells plate, were washed by 2ml pre-cold 1 x PBS twice before removing the cell 
culture medium. Then add another 1ml pre-cold 1 x PBS to each well and cells 
detached from well using disposable cell scraper (Greiner Bio-One, 541070) and 
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decanted into a 15 ml Falcon tube. Pelleting cells by centrifuging at 500G for 10 
minutes in 4°C. 40-80ul 1 x Whole Cell Lysis Buffer was applied to re-suspend cell 
pellets and transferred into a new micro-centrifuge tube. Incubate the tube on ice for 
30 minutes with vigorous vortex every 10 minutes. Then centrifuge at 12000 rpm for 
6 minutes to pellet insoluble fragments, collected supernatant as the soluble protein 
extraction stock. This soluble protein extraction from whole cells was stored in -
20°C for further analysis.  
2.4.2 Cytoplasmic extraction 
For specified experiments, in which cytoplasmic proteins and nuclear proteins need 
to be extracted separated, the following procedure was followed. Cells with specified 
treatment in 6-wells plate (with 100% confluent) were washed by pre-cold 1 x PBS 
twice before removing cell culture medium. Cells were then detached by using 
disposable cell scraper in 1ml 1 x PBS and decanted into a micro-centrifuge tube. 
Spin down the cell pellets for 10 min at 500G in 4°C. Then discarded supernatant 
and re-suspended each pellet from a well in 30 ul Cytoplasmic Extraction Buffer 
with NP40 (CEB buffer + NP40) (0.1% NP40, 10mM HEPES PH 7.4, 60mM KCl, 
1mM DTT, 1x Complete Protease Inhibitors Cocktail (Roche), 1mg/ml Pefabloc SC 
(Roche), 1uM Pepstatin A, 1mM EDTA, add ddH2O to final volume 1ml)(Add 1 x 
phosSTOP if phosphorylated proteins need to be analysed). Vigorous vortex the tube 
for 5 seconds before leaving on ice for 3 minutes. Tubes were then centrifuged at 
1200 G for 5 minutes in 4°C. The clear supernatant here contains the crude cytosolic 
and loosely-associated membrane proteins and the pellet here contains nuclei and 
remaining cell debris. Decanted the supernatant to a new micro-centrifuge tube and 
re-spin it for 20 min at 7000G to pellet and separate any contaminating nuclei, 
collected supernatant here as cytoplasmic extract stock (CYT) and stored in -80°C. 
To dissolve the nuclear proteins, washed the pellet once in CEB buffer without NP40 
and re-collected the pellets by spinning at 1200G for 5 minutes in 4°C. Then re-
suspended the pellet in 50 ul Nuclear Resuspension Buffer (NRB) (20mM Tris-HCl 
PH8, 1mM MgCl2, 600mM KCl, 1mM DTT, 25% Glycerol, 1x Complete Protease 
Inhibitors Cocktail (Roche), 1mg/ml Pefabloc SC (Roche), 1uM Pepstatin A, 1mM 
EDTA, add ddH2O to final volume 1ml)(Add 1 x phosSTOP if phosphorylated 
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proteins need to be analysed). Vigorous vortex the tube for 5 seconds before 
alternately freezing and thawing the tube 3 times in dry ice or -80°C freezer. To 
collect the nuclear extract (NUC), centrifuge the tube for 20 min at 7000G in 4°C. 
Nuclear extracts were stored in -80°C.  
In order to prevent gelling of NUC fractions when SDS-PAGE samples were 
prepared, added 1 ul RQ1 DNase (1unit) (Promega) per sample when the samples 
were in preparation for loading. 
2.4.3 Insoluble proteins 
Some of the proteins in cells were becoming aggresome and not soluble with the 
method mentioned in 2.4.1. The protocol here purifing aggresomes to get detergent 
insoluble proteins is adapted from an established method (Song et al., 2008). Cells 
were cultured in 10mm cell culture dishes and treated as specified as mentioned in 
2.1.2. Removed the medium and washed cells after treatment with 10ml chilled PBS 
(+200mM iodoacetamide) twice. Then, added 1ml Disruption Buffer (DB buffer: 
20mM Tris/HCl, PH 7.5, 2mM EDTA, 150mM NaCl, 1.2% Sodium deoxycholate, 
1.2% Triton X-100, 200mM iodoacetamide (184.96g/mol), 1 x Protease Inhibitors 
Cocktail (Roche), 1mg/ml Pefabloc SC (Roche), 1uM Pepstatin A, 1mM Na3VO4, 
1mM NaF) into dish, detached cells and transfer them into a 1.5ml microcentrifuge 
tube. Sonicated the sample in a sonicater with parameter setting: high power, 7*7s 
pulses with 15s break between) in chilled metal block. Centrifuged at 13000rpm for 
15 minutes in 4°C. Pellets were then washed twice by 200ul DB buffer before 
centrifuged again used the same centrifuge condition. Removed supernatant and 
followed by suspending pellets in 25ul SDS loading buffer (1ml glycerol, 500ul b-
Mercaptoethanol, 2ml 10% SDS, 1.25ml 1M Tris-HCl PH6.8, 3ml 0.05% 
Bromophenol Blue). Incubated sample in 95°C for 5mins and forwarded to western 
blot analysis. 
2.4.4 Protein quantification by Bradford assay 
Prepare 1 x Bradford Assay Reagent by diluting 5x stock (Bio-Rad, Hemel 
Hempstead, UK) with ddH2O. Diluted reagent was filtered using Stericup/Steritop 
device (Millipore, Consett, UK) prior to use. Bovine serum albumin (BSA) was 
78	
	
made up to 1mg/ml in ddH2O in advance for generating a standard curve. This assay 
was performed in a flat bottom 96 wells plate. A layout of 1mg/ml BSA loading for 
standard curve is shown below:  
 1 2 3 4 5 6etc 
A 0 0 0    
B 0 0.2ul 0.2ul    
C 0 0.5ul 0.5ul    
D 0 0.8ul 0.8ul    
E 0 1.0ul 1.0ul    
F 0 1.5ul 1.5ul    
G 0 2.0ul 2.0ul    
H 0 0 0    
 
Samples (1ul) were placed anywhere else on the plate in triplicate. Then added 200 
µl 1 x Bradford Assay Reagent into all wells. Place the plate on a plate shaker for 
several seconds before incubating in room temperature for 10 minutes. Place the 
plate onto a Labsystems Multiskan MS Plate Reader, absorbance at 620 nm was 
measured and the concentration of protein samples (ug/ul) were calculated and 
output by extrapolation from the standard curve.  
2.4.5 SDS-PAGE (SDS Polyacrylamide Gel Electrophoresis) 
Mini-PROTEAN ® Electrophoresis System (Bio-rad) was used for separation of 
protein samples by denaturing SDS-PAGE. Freshly-made gels were poured into a 
glass-plate-formed groove in advance which contain an upper layer of stacking gel 
on the top of a lower layer of resolving gel (see below for the formation of stacking 
gel and resolving gel). Combs (1.0mm or 1.5mm with 10 or 15 wells could be chosen 
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for appropriate experiments) (Bio-rad) were used to build separated lanes for loading 
samples.  
Sample preparation and electrophoresis 
Protein samples were prepared and denatured by adding 3ul SDS loading buffer (1ml 
glycerol, 500ul b-Mercaptoethanol, 2ml 10% SDS, 1.25ml 1M Tris-HCl PH6.8, 3ml 
0.05% Bromophenol Blue) into 22ul (5-30ug) cell lysate. Samples were incubated at 
95-100°C for 5 minutes in a heating block before loading. Each well of 1.0mm 10-
wells comb could be loaded maximum 25ul of samples. PageRuler Plus Prestained 
protein ladder (Thermo Scientific) was loaded in a lane beside samples to identify 
proteins of interest by molecular weight.  Electrophoresis carried out in a Mini-
PROTEAN Tetra Cell filled with 1 x Running buffer (10 x Running buffer: 30g Tris-
base, 144g Glycine, 100ml 10% SDS, add  ddH2O to 1L total volume) at 100V-150V 
for 1.5-2 hours until the blue bromophenol dye reached the bottom of the glass plates. 
Formation of Resolving gel (volume specified are for 2 gels)  
GEL % 8.0 10.0 12.0 12.5 
ddH2O (ml) 5.406 4.806 4.206 4.056 
4 x Resolving Buffer 
(ml)  
4.000 4.000 4.000 4.000 
40% acrylamide (ml) 2.400 3.000 3.600 3.750 
10% APS (ml) 0.182 0.182 0.182 0.182 
TEMED (ml)  0.012 0.012 0.012 0.012 
TOTAL (ml) 12 12 12 12 
1. 4x resolving buffer: 18.17g Tris-base, 4ml 10% SDS, add ddH2O to 
100ml total volume. 
2. 40% (w/v) acrylamide: Acrylamide Bis-Acrylamide stock solution 
(Severn Biotech Ltd. Cat No. 20-2400-05) 
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3. 10% APS (Ammonium Persulfate):  1g ammonium persulfate in 10ml 
ddH2O  
4. TEMED (N,N,N’,N’-Tetramethylethylenediamine) (Sigma-Aldrich, 
T9281) 
Formation of Stacking gel (volume specified are for 2 gels)  
ddH2O (ml) 3.243 
4 x Stacking Buffer (ml) 1.332 
40% acrylamide (ml) 0.654 
10% APS (µl) 84 
TEMED (µl) 5 
1. 4x stacking buffer: 6.07g Tris-base, 4ml 10% SDS, add ddH2O to 
100ml total volume.   
2. TEMED (N,N,N’,N’-Tetramethylethylenediamine) (Sigma-Aldrich, 
T9281) 
2.4.6 Western blot analysis 
Western blot was performed by a standard process. Briefly, after SDS-PAGE, 
proteins were transferred onto PVDF transfer membrane (Thermo Scientific, Prod 
88518) by using Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-rad) filled up 
with 1 x wet transfer buffer (100ml 10 x Wet Transfer (30g Tris-base, 144g Glycine 
in 1L ddH2O) + 100ml Methanol + 800ml ddH2O) at 100V for 60-90 minutes. 
Transferred membrane was blocked in a solution with 5% no-fat dried milk in PBST 
(0.1 % TWEEN® 20 (Sigma) in PBS) at 4°C overnight. Then incubate the blocked 
membrane with primary antibody (Details of antibodies been used and dilution rate 
applied are summarized below) with appropriate dilution in 5% no-fat dried milk in 
PBST for 1 hour at room temperature. Washed away non-specific binding for 30 
minutes (3 x 10 minutes) by using PBST. Membrane was subsequently incubated 
with secondary antibody conjugated to horseradish peroxidase diluted in 5% no-fat 
dried milk in PBST for 45 minutes at room temperature. 3 x 10 minutes PBST 
washing were then followed before using a 1:1 mixture of ECL reagents (Santa Cruz 
Biotechnology) to detect bounded antibody. Western blot bands on the membrane 
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were output by either using Fuji medical X-RAY films (Super Rx-N, Cat. No. 47410 
19289), which was exposed and developed by a SRX-101A X-ray film processor 
(Konica Minolta), or directly detected and pictured by camera of Image Quant 
LAS4000 (GE Healthcare Life Sciences) (Method: Chemiluminescence; Digitization: 
Epi-illumination).  
Table 2.4 Antibodies used for western blot 




Anti-TIF-IA Rabbit 1:2000  1 hour at RT2 BioAssayTech, 
B8433 
Anit- Rrn3 Mouse 1:500 1 hour at RT Santa Cruz 
Biotechnology, 
sc-390464 
Anti- GFP Rabbit 1:1000 1 hour at RT Santa Cruz 
Biotechnology, 
sc-8433 
Anti- UBF  Mouse 1:500 1 hour at RT Santa Cruz 
Biotechnology, 
sc-13125 
Anti-p53 Mouse  1:2000 1 hour at RT Oncogene, 
OP43 









Anti-RPA194 Mouse  1:500 1 hour at RT Santa Cruz 
Biotechnology, 
sc-48385 
Anti- CDK4 Mouse 1:250 1 hour at RT BD, 559677 





Anti-Capsesin Mouse 1:1000 Overnight at 
4°C 
Gift from Prof 
Kathryn Ball 
(ECRC) 
























2.4.7 Co-Immunoprecipitation (Co-IP) 
In order to examine protein-protein interaction, Co-immunoprecipitation was 
performed as followed. Magnetic beads (Dynabeads®, Novex) were used in this 
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protocol. Colorectal cancer cells were seeded into T75 (75cm2) flask and followed by 
specified treatment. Cells were normally >90% confluent in a T75 flask when Co-
immunoprecipitation carried out. Removed medium and washed cells with pre-cold 1 
x PBS before adding 1.5ml NP40 cell lysis buffer (50 mM Tris, pH 7.5, 250 mM 
NaCl, 5 mM EDTA, 1% Nonidet P40 (NP40), 1 x Protease Inhibitors Cocktail 
(Roche), 1 x phosSTOP (Roche), 1mg/ml Pefabloc SC (Roche), 1uM Pepstatin A, 
1mM Na3VO4, 1mM NaF) directly into the flask. Incubated cells with NP40 cell 
lysis buffer on ice for 5 minutes followed by detaching cells using disposable cell 
scraper and decanting to a 1.5ml microcentrifuge tube. Incubated tube on a roller 
(Scientific Laboratory Supplies) in 4°C for 30 minutes to gently and thoroughly 
solve the cells. Harvested the supernatant containing the soluble proteins by 
centrifuging at 13000rpm for 5 minutes in 4°C. The supernatant was then incubated 
with 10ul Dynabeads® on a roller in 4°C for 1 hour to pre-clear the factors that can 
non-specifically band to the beads. Placed the tube on a magnet rack (DynaMag™-2 
Magnet, Thermo Fisher Scientific, 12321D) to separate the beads from the solution 
and kept the supernatant. Performed Bradford Assay as stated in 2.4.4 and diluted 
protein concentration to 1 or 2mg/ml with NP40 cell lysis buffer. Kept 25ul samples 
here as Input control. Added 2ug specified antibody into 500ul samples solution (0.5 
or 1mg proteins), returned sample tube to the roller in 4°C for incubating overnight. 
Then added 50ul Dynabeads® into the sample tube which contained antigen-
antibody complex, return tube to the roller in 4°C to incubate for 4 hours to allow 
Dynabeads® bind to antigen-antibody complex. Placed the tube on the magnet rack 
and removed supernatant before washing the Dynabeads®-antibody-antigen complex 
three times using pre-cold 1 x PBS,  separated on the magnet rack between each 
wash, removed supernatant and resuspended by gentle pipetting. To elute the target 
antigen, 30ul elution buffer (20ul 1 x PBS + 10ul SDS loading buffer (1ml glycerol, 
500ul b-Mercaptoethanol, 2ml 10% SDS, 1.25ml 1M Tris-HCl PH6.8, 3ml 0.05% 
Bromophenol Blue) was added and thoroughly mixed by vortex followed by 
incubation in 90°C for 8 minutes. Put tube on the magnetic rack again to collect 




Table 2.5 Antibodies used for Co-IP 
Antibody Host Species Manufacturer Info. 
Anti-Rrn3 (TIF-IA)  Mouse  Santa Cruz Biotechnology, 
sc-390464 





Cells were grown in wells of 6-wells plate with sterilised coverslips placed in and 
were treated as specified. Briefly washed cells with pre-cold 1 x PBS and added 3 ml 
Methanol: Acetone (1:1) to fix cells in -20°C for 30 minutes. Then removed 
methanol-acetone and gently washed with 1 x PBS for 3 times for 30 minutes on a 
shaker at room temperature before adding 2 ml 10% donkey serum (Sigma; diluted in 
PBS) to each well and incubated for 30 minutes at room temperature to block non-
specific binding. Cells were then incubated with 200ul of the primary antibody with 
1:200 diluted in 10 % donkey serum in room temperature for 1 hour. Post primary 
antibody incubation, cells were washed by PBST (0.1 % Tween-20 in 1 x PBS) 3 
times for 30 minutes. Incubated cells for 30 minutes at room temperature in darkness 
then in the presence of 200ul secondary antibody 1:200 diluted in 1.5 % donkey 
serum, which followed by another 3 x 10 minutes washes in the dark by PBST. 
Coverslips were then mounted in Vectashield containing 1ug/ml DAPI (Vector 
Laboratories, Inc., H-1200), which stain DNA, by placing cells facing down onto on 
the slides after carefully cleaning the back of the coverslip. Left 15 minutes to set 





Table 2.6 Antibodies used for immunocytochemistry 
Antibody Host Species Dilution rate Manufacturer Info. 
Anti-TIF-IA Rabbit 1:200 BioAssayTech, 
B8433 
Anti-RelA (C20) Rabbit 1:200 Santa Cruz, SC-372 
Anti-Fibrillarin Mouse 1:200 Cytoskeleton, 
AFB01 
 
2.5.2 Fluorescence microscope 
Images were captured using a Coolsnap HQ CCD camera (Photometrics Ltd, Tuscon, 
AZ, USA) Zeiss Axioplan II fluorescent microscope, 63 × Plan Neofluor objective, a 
100 W Hg source (Carl Zeiss, Welwyn Garden City, UK) and Chroma 83 000 triple 
band pass filter set (Chroma Technology, Bellows Falls, UT, USA). Image capture 
was performed using scripts written for IPLab Spectrum 3.6 or iVision 3.6 in house. 
For each experiment, a constant exposure time was used and at least 10 distinct fields 
were observed and recorded for each sample. 
2.6 Others 
2.6.1 NF-κB and gene reporter assay 
NF-κB reporter assay and gene (IκBα, Bcl-xl) reporter assay were performed to 
examine the activation of NF-κB pathway. Cells were grown in wells of 6-wells plate 
and co-transfected with specified reporter plasmids and PCMV-β- galactosidase 
following the transfection process referred in 2.1.5. Treatment may followed in some 
experiments when stated. Medium was then removed and washed cells with pre-cold 
1 x PBS. Directly added 250ul 1 x Cell Culture Lysis Buffer (Promega, E153A) into 
the well and placed the plate on a room temperature shaker to solve the cells for 20 
minutes. After incubation, completely detached cells by using disposable cell scraper 
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and decanted all 250ul 1 x cell lysis buffer plus cells into a 1.5ml microcentrifuge 
tube. Vigorously mixed it by vortex for 15 seconds. Centrifuged at 13000 rpm for 1 
minute at room temperature to collect supernatant in a fresh tube for analysis. The 
expression of reporter-driven luciferase was detected by using Luciferase Assay 
System (Promega, E1500) in the luminometer (Lumat LB 9507 Luminometer, 
Berthold Technologies). Relative Luciferase Unit (RLU) were output as the 
indication of luciferase intensity of the sample. 20ul of sample were needed in a 5ml 
Sarstedt PS tubes (SARSTEDT, 55.1579, Germany) for each measurement. Each 
sample was measured twice. PCMV-driven expression of β-galactosidase was used 
as control for transfection and can be detected by using β-Galactosidase Enzyme 
Assay System (Promega, E2000). β-galactosidase was performed in a 96-wells plate. 
In each well, thoroughly mixed 50ul sample with 50ul 2x Assay Buffer (Promega, 
E203A). Each sample was measured three times. Incubated plate at room 
temperature until the colour of sample solution began to turn pale yellow. Read the 
plate on a plate reader (Labsystems Multiskan MS, LabX) which output the 
absorbance at 420nm as relative β-galactosidase intensity. The absolute number of 
the relative β-galactosidase intensity should below 0.8-1.0 when the sample and 2 x 
assay buffer reaction came to saturation and the absorbance at 420nm became non-
linear.  
Data analysis: Analysed relative luciferase activity in Microsoft Excel. Divide the 
results from the luciferase assay by the results from the galactosidase assay to 
normalize reporter activity by transfection efficiency. Mean values (added up all 
values and then divided by the number of repeats) are represented in graphs where 
there are more than one values. Standard deviations (SD) are also calculated for 
samples where there are more than one values. 
2.6.2 Apoptosis assay 
Apoptosis Detection Kit (Calbiochem) was used to detect apoptotic cells by staining 
cell apoptosis marker, cell surface phosphatidylserine. Manufacturer’s instructions 
were followed and optimized as following. Cells were cultured in T25 flasks and 
transfected or treated as indicated. Post treatment, medium with floating cells were 
decanted into a 15 ml Falcon tube at 4°C in order to collect any detectable apoptotic 
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cells. Washed the attached cells twice with pre-cold 1 x PBS in prior to incubate with 
1:1 tyrpsin:versene (T:V) at 37 °C for 5 minutes or until cells detached. 3ml of pre-
cold 1 x PBS was then added and moderately pipetted to mix and single the cells 
before decanting to the 15ml Falcon tube containing floating cells. Counted cells in 
the Coulter Counter as described above. Collected cell pellets by centrifuging at 
2000rpm for 5 minutes and re-suspended at a concentration of 1x106 cells/ ml with 
appropriate volume of pre-cold 1 x PBS.  1ml of cells (1x106 cells) were transferred 
to a microcentrifuge tube and pelleted at 2500 rpm for 3 minutes in 4°C. Re-
suspended pellets in 1 x binding buffer (dilute from 5 x binding buffer supplied in the 
kit) before incubating with 2ul Annexin-V-FITC in darkness at room temperature for 
30 minutes and pelleted again with centrifugation at 1000G for 5 minutes. Aliquoted 
cells into a microcentrifuge tube and incubated as above without adding Annexi-V-
FITC to act as a negative control and help analysis parameter setting. Re-suspended 
pellets in 600ul 1 x binding buffer and placed samples on ice for further analysis.  
Detect apoptotic cells by fluorescent microscope 
5ul of Vectashield containing 1ug/ml DAPI and 5ul of cells suspension were mixed 
on a glass slide and mounted with coverslip. Fluorescence microscope (as described 
in 2.5.2) was applied to count cells with DAPI staining (nuclear) and FITC staining 
(cell surface phosphatidylserine, looks like a ring under microscope). The percentage 
of cells undergoing apoptosis was calculated by subtracting FITC-positive cells 
(apoptotic cells) with DAPI positive cells (total cell number).  A minimum of 200 
cells were measured per sample. 
Detect apoptotic cells by Fluorescence Activated Cell Sorting (FACS) 
10ul Propidium Iodide were added into cell suspension in darkness in prior to FACS 
measurement. BD FACSAriaII SORP (Beckton Dickinson, Oxford, UK) flow 
cytometer were used. 488 nm laser were used to measure DAPI (685/35 nm bandpass 
filter) and FITC fluorescence (525/50 nm bandpass filter). The percentage of cells 
undergoing apoptosis was output. A minimum of 10,000 cells were measured per 




2.6.3 UV-C exposure  
UV-C exposure was performed in Hoefer UVC 500 Crosslinker (Hoefer, Inc, USA). 
Cells were seeded in 6-wells plate (1 x 105/cm2) and grown for 24 hours. Collected 
medium into 50 ml Falcon tube and placed in 37°C water bath. Washed cells with 
pre-warmed 1 x PBS once and put another 1ml pre-warmed 1 x PBS in wells to 
avoid cells dried out. Took of the plate cover and horizontally placed plate into 
Hoefer UV 500 Crosslinker, and set up intensity of UV-C (254nm) to 40j/m2. Kept 
control ‘mock’ plate in room temperature without exposing to UV-C. Post UV-C 
exposure, immediately replaced PBS with the pre-warmed collected-medium in 50ml 
Falcon tube before returning plates into 37°C incubator. Detached and harvested 
cells into a 15ml Falcon tube after 1 x PBS washing at the indicated time point. Cell 
pellets were then processed to ‘Soluble protein extraction from whole cells’ and 




Chapter 3: Results—Nucleolar stress activates 





















Although the primary function of nucleolus is ribosome biogenesis, many proteomic 
and functional studies in the last decade have revealed that the organelle is 
multifunctional and provides a critical link between stress signalling, ribosome 
subunit biosynthesis and multiple cellular functions like cell cycle progression and 
cell proliferation (Boulon et al., 2010). 
The most established downstream effector of nucleolar stress is p53 (see section 
1.4.1). However, there is increasing evidence to show that nucleolar stress can 
modulate cell phenotype in a p53 independent manner. For example, recent studies 
have identified transcription factor E2F1 as regulator of nucleolar stress-mediated 
cell cycle arrest (Donati et al., 2011); Peter Pan, which mainly localizes in nucleoli 
and functions in ribosome maturation, links a nucleolar stress response pathway to 
cell apoptosis (Pfister et al., 2015). Besides, quantitative proteomic analysis of 
nucleoli in mammalian cells have revealed hundreds of proteins with p53 
independent functions shuttle from nucleoli in response to stresses such as UV light, 
ionizing radiation and DNA damage (Boisvert et al., 2010; Moore et al., 2011). As 
mentioned in section 1.3, ribosome biogenesis is hyperactivated in the majority of 
tumours and thus, the organelle is emerging as a promising therapeutic target. Since 
more than 50% of cancers have non-functional p53, clarifying these p53-independent 
pathways would allow targeting of nucleoli in p53-deficient cancers and reveal 
additional molecular targets for cancer therapies that exploit nucleolar stress 
response pathways (James et al., 2014).  
Like p53, the NF-κB pathway is a critical regulator of cell stress (see section 1.5.2) 
and multiple lines of evidence suggest that, also like p53, NF-κB may act as a 
downstream effector of nucleolar stress reponse. Firstly, NF-κB is a pleiotropic 
transcription factor and involved in multiple cellular functions. It regulates the 
expression of a wide range of genes which are involved in all downstream 
consequences of nucleolar stress such as cell cycle, apoptosis and senescence.  
Secondly, multiple nucleolar proteins and known pathways which are involved in 
nucleolar stress response are also known in coordinating with or regulating NF-κB 
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signalling. One of the examples is the protein kinase casein kinase 2 (CK2), a 
component of Pol I transcription machinery. In this instance, CK2 was shown 
required for C-terminal phosphorylation of IκBα under UV light stress (Kato et al., 
2003). On the other hand, proteins in NF-κB pathway are also evidenced have 
nucleolar localization or nucleolar function. Such as nucleolar translocation of RelA 
in response to aspirin or other NSAIDs (Thoms et al., 2007a), and NIK is shuttling 
between cytoplasm, nucleoplasm and nucleolus and differentially regulates NF-κB 
pathway (Birbach et al., 2004). In addition, signalling pathways like p53/MDM2, 
p14ARF, AMPK and p38 MAPK, which are engaged in nucleolar stress response 
(James et al., 2014), are also known having intriguing inter-connections between NF-
κB signalling in multiple situations (Boulon et al., 2010). 
Thirdly, the nucleolus and NF-κB are both emerging as critical stress sensors. From 
literature reviews, it is very striking and interesting to find an extensive overlap 
between stress inducers that disrupt nucleoli and stimulate NF-κB (Table 3.1). For 
example, genotoxic stress that causes DNA damage (such as UV light, ionizing 
radiation, camptothecin), which were shown have exclusive impact on nucleolar 
proteome and function (Boisvert et al., 2010; Moore et al., 2011), also have long-
known effects on NF-κB activation (Leung and Lamond, 2003). Similarly, energy 
homeostasis status changes induced by oxidative stress/hypoxia, nutrient stresse and 
oncogenic stress also have simultaneous effects on nucleolar disruption and NF-κB 
regulation. Most importantly, many chemotherapeutic agents have effects on both the 
NF-κB pathway and nucleoli, suggesting the exciting possibility that they may be 
linked.  
From the above aspects, the host laboratory had tried to move forward by identifying 
the molecular network that links modulation of NF-κB and changes in nucleoli in 
response to aspirin treatment (see Figure 1.10 for preliminary data), which could 
shed lights on understanding the anti-tumour effect of this agent and identify further 
targets. Based on these data, I set out to investigate the relationship between 
nucleolar stress and activation of the NF-κB pathway. Firstly, I examined whether 
direct disruption of Pol I transcription machinery, could induce activation of NF-κB 





3.2.1 Pol I complex disruption induces NF-κB-driven 
transcription 
Previous studies from the host laboratory suggested that nucleolar stress may act as a 
common stress sensor which converges on NF-κB signalling. However, this 
hypothesis was incompletely tested and the potential mechanism that links nucleolar 
stress to NF-κB signalling is unknown. Therefore, I firstly set out to test whether 
nucleolar disruption has direct effects on NF-κB activation.  
Firstly, I mimicked nucleolar stress in SW480 colon cancer cells using RNA 
interference against TIF-IA and UBF, two critical components of the Pol I 
transcription machinery that coordinate rDNA transcription (Drygin et al., 2010). I 
found that in SW480 cells, knocking down TIF-IA and UBF both efficiently 
mimicked nucleolar stress as evidenced by the repression of rDNA transcription 
(Figure 3.1 A). To test the effects of disrupting Pol I on NF-κB activity, NF-κB 
reporter assays were performed on cells depleted for TIF-IA and UBF. NF-κB 
reporter constructs in which the luciferase gene is driven by 3x enhancer κB binding 
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sites, or equivalent plasmids with the κB sites deleted were utilised. TNFα, a strong 
stimulant of the NF-κB canonical pathway, was used as a positive control (Figure 3.1 
B). I found that knocking down TIF-IA and UBF enhanced NF-κB-driven 
transcription. This was specific as it was not observed when κB binding sites were 
deleted (Figure 3.1 C and D). This is in agreement with the preliminary data from 
others in the lab which demonstrated that knocking down Pol I factors induces the 
degradation of IκBα protein and the phosphorylation of RelA on serine 536, direct 





Data above indicated that disruption of the Pol I complex activates the NF-κB 
pathway. To confirm that knockdown of Pol I factors stimulated cytoplasmic to 
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nuclear translocation of NF-κB, (rather than affecting DNA bound NF-κB), I used 
HRT18 cells which the group previously engineered to constitutively express a 
superrepressor form of IκB (IκBSR) (HRT18-IκBSR). This IκB is mutated at the 
critical serine phosphorylation sites (S32/S36) and is resistant to TNFα-induced 
phosphorylation and degradation (Stark et al., 2001; Zwacka et al., 2000). Firstly, I 
confirmed the expression of IκBSR in HRT18 cells efficiently inhibited TNFα-
induced NF-κB-driven transcription activity (about 2-fold decrease compared to 
HRT18 parental cells) (Figure 3.2 A). Similar to SW480 cells, I found that knocking 
down UBF and TIF-IA significantly enhanced NF-κB activity in HRT18 parental 
cells. However, this increase was blocked in HRT18-IκBSR cells (Figure 3.2 B and 
C).  
These results demonstrated that mimicking nucleolar stress by depleting crucial Pol I 
factors stimulates NF-κB transcriptional activity. They also suggest that cytoplasmic 




3.2.2 Nucleolar disruption modulates NF-κB-controlled gene 
expression 
Activation of NF-κB will generally lead to increased expression of NF-κB target 
genes. Therefore, I further determined whether nucleolar disruption activates NF-κB 
activity by testing effects on the expression of NF-κB target genes. The most 
recognised and classic target of NF-κB is its inhibitor, IκBα. The Bcl-2 family are 
also direct transcriptional targets of NF-κB. Western blot analysis indicated that 
knocking down TIF-IA and UBF in SW480 cells increased cellular levels of Bcl-xL 
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and IκBα (Figure 3.3 A). Reporter assays, in which the luciferase gene is driven by 
the full length IκB promotor (kindly supplied by Neil Perkins in the Newcastle 
University), also indicated that nucleolar disruption significantly increased 
transcription of this protein. I also indicated this was dependent on NF-κB as the 
effects were lost when a promotor in which the κB sites were deleted was used. 
(Figure 3.3 B). Furhtermore, qRT-PCR also suggested depleting TIF-IA or UBF 
increased IκBα gene transcription. These data indicates nucleolar disruption 
modulates the NF-κB activity and has downstream effects on NF-κB targets (Figure 




The NF-κB pathway is crucial in both inflammatory response and cancer and 
regulates hundreds of genes involved in these functions. Therefore, I next used qRT-
PCR to examine more generally the effects of disrupting the Pol I complex on NF-
κB-controlled gene expression. Taqman or SYBR green gene expression assays were 
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used. I chose several NF-κB target genes to test including Bcl-xL, BAX and XIAP, 
which regulate apoptosis (Figure 3.4 A) and IL-6, IL-8 and IL-11 which control 
inflammatory response (Figure 3.4 B)). It was thought this assay could reveal the 
cellular functions nucleolar stress directly affects through the NF-κB pathway. 
Interestingly, I found that most of the NF-κB target genes I tested were significantly 
repressed following nucleolar disruption (Figure 3.4). They also appeared to fall into 
two groups. Those that were repressed by both TIF-IA and UBF knockdown (BAX, 
IL-6, IL-8), and those that were only repressed upon depletion of TIF-IA (Bcl-xL and 
XIAP) (Figure 3.4). This result suggested nucleolar stress down-regulates genes 
involved in inflammatory response that may repress immune response. But how 
activated NF-κB-driven transcriptional activity upon nucleolar stress leads to 





One explanation for these results may be that in SW480 cells, the genes tested are 
under control of another pathways. To test this hypothesis, I further examined gene 
expressions in response to TNFα induction in SW480 cells. Among five NF-κB 
target genes tested, only the expressions of IκBα and FAS genes were found to 
increase in response to TNFα induction (Figure 3.5 A), which suggested in SW480 
cells these two genes are direct targets of the NF-κB pathway.  
Previous studies had shown that NF-κB dependent gene expression dynamically 
changes in response to stimuli due to the periodical oscillation of NF-κB between the 
cytoplasm and nucleus. It was also suggested tha the functional consequence of NF-
κB activation may be dependent on the oscillation pattern (Nelson et al., 2004). 
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Therefore, I performed a siRNA time course experiment to examine the dynamic 
change of NF-κB-controlled gene expression following nucleolar disruption. I found 
TIF-IA knockdown induced and increase in IκBα gene expression in a time 
dependent manner. In contrast, UBF knockdown induced an up-and-down pattern 
with a significant increase at 24 and 48 hours, but a decrease after 56 hours of 
transfection (Figure 3.5 B). Since IκBα is an inhibitor of NF-κB activation, the 
repressed gene expression of many genes observed in (Figure 3.4) may due to this 
negative feedback loop (Figure 3.3 A for protein level, Figure 3.5 B for gene 
transcription)  
Fas gene expression increased in a time dependent manner up to 56 hours following 
transfection, with UBF depletion having a greater effect than TIF-IA depletion 
(Figure 3.5 C).  
Previous results show nucleolar stress caused NF-κB activation is dependent on the 
phosphorylation and degradation of IκBα, and cytoplasmic to nuclear translocation 
of NF-κB. Here I further evidenced NF-κB-targeted IκBα gene expression was up-
regulated by knocking down UBF, but this upregulation was abrogated in cells 
transiently expressing superrepressor IκBSR (Supplementary Figure 3.1).  
Taken together, these results suggested that besides inducing NF-κB driven 
transcription, nucleolar stress also regulates the transcription of NF-κB controlled 
genes. However, this effect was dynamic and highly gene dependent. The dynamic 




3.2.3 Activation of NF-κB pathway is not a consequence of 
inhibition of rDNA transcription 
The above results indicate that siRNA depletion of TIF-IA and UBF inhibit rDNA 
transcription and activate NF-κB transcriptional activity, but the mechanism 
underlying this activation is unknown. Stabilisation of p53 is a common consequence 
of nucleolar stress and is induced by inhibition of rDNA transcription. To determine 
whether activation of NF-κB is also caused by inhibition of rDNA transcription, I 
utilised two novel, highly specific small molecule inhibitors of Pol I, CX-5461 and 
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BMH-21, which are known to stabilize p53 (Drygin et al., 2011) (Peltonen et al., 
2014). I also used low dose of actinomycin D which specifically inhibits Pol I 
activity. I found these agents, which efficiently and dramatically inhibited rDNA 
transcription, had no effect on NF-κB driven-transcriptional activity (Figure 3.6 A). 
This result suggested that, unlike stabilisation of p53, activation of the NF-κB 
pathway is not a consequence of rDNA transcription inhibition.  
3.2.4 CK2 is not involved in Pol I disruption-induced NF-κB 
activation 
From the observations above, it seems NF-κB activation is linked specifically to 
disruption of the Pol I complex and loss of Pol I integrity. Especially, I assumed this 
activation may be an ‘inside-out’ signalling consequence, that disruption of Pol I 
integrity causes relocation of certain proteins in the complex to the cytoplasm where 
it stimulates the upstream signalling cascade that culminates in activation of NF-κB. 
Regarding this hypothesis, the protein kinase casein kinase 2 (CK2) is a favourite 
candidate. CK2 is one of the factors in the Pol I transcription complex, it reportedly 
shuttles between the nucleolus, nucleoplasm and cytoplasm, and modulates NF-κB 
pathway under certain stress condition (Kato et al., 2003). CK2 is a tetramer of two 
α-subunits and two-β subunits, with the α subunits carrying the catalytic kinase 
function. I utilised siRNA against CK2 subunits (CK2α and CK2β), and examined 
their effects on stressed-induced NF-κB activation. I found knocking down CK2 
subunits alone repressed NF-κB activity, in keeping with a role in turnover of the 
protein. Knockdown of UBF had a reduced effect on NF-κB-driven transcription in 
the absence of CK2, but this was still significant (Figure 3.6 B). Thus, this data 
suggested CK2 is not involved in Pol I disruption-induced NF-κB activation, 





In this chapter, I demonstrate that disruption of nucleolar integrity, through 
artificially knocking down critical Pol I factors, stimulates the cytoplasmic NF-κB 
signalling pathway and modulates expression of NF-κB targeted genes. I also 
demonstrated that nucleolar disruption mediated NF-κB activation is not a 
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consequence of rDNA transcription inhibition, but specifically linked to loss of Pol I 
integrity. However, factors that link these two events are yet to be identified. This 
data provides a novel link between nucleolar stress response and modulation of the 
NF-κB signalling pathway. 
NF-κB activation as a downstream consequence of nucleolar stress 
So far, the downstream consequences of nucleolar stress are limited to effects on 
ribosome biosynthesis and stabilisation of p53 (James et al., 2014). Recently studies 
in models lacking p53 and large-scale nucleolar proteomics strongly suggest the 
existence of other signalling pathways that regulate cell phenotype as downstream 
consequences of nucleolar stress. Interestingly, there is a strong correlation between 
stress inducers that cause nucleolar disruption and that stimulate NF-κB (Table 3.1), 
but the potential link between these two events has never been investigated.  
Here, I made the novel observation that the NF-κB pathway is stimulated by 
nucleolar disruption. I demonstrate that specifically depleting Pol I factors causes 
degradation of IκBα, increased NF-κB-driven transcription and modulation on NF-
κB controlled gene expression. This observation is further supported by previous 
findings in the lab that disruption of nucleolar integrity, by means of siRNA interfere 
against Pol I subunits and expression of site-mutated inactive UBF (Flag-UBF-
S388G), enhances phosphorylation of RelA at serine 536 and nuclear translocation of 
RelA. I also show direct evidence that this activation is dependent on the degradation 
of IκBα as this effect is lost in cells expressing a superrepressor form of IκB (IκBSR) 
that retains NF-κB in the cytoplasm (Figure 3.2 B). Furthermore, other members of 
the lab have observed the same phenomenum in other cell types (e.g HeLa cells), 
indicating this activation is a general effect and not just limited to colorectal cancer 
cells. 
UBF and TIF-IA are two indispensable Pol I complex components. The importance 
of them in rDNA transcription and ribosomal biogenesis has been intensively 
explored and impairment of their activities could lead to rDNA transcription 
inhibition and nucleolar disruption (Drygin et al., 2010; Grob et al., 2014; Jin and 
Zhou, 2016). Inhibition of UBF was previously used as a nucleolar stress model in 
106	
	
the very first study demonstrated stabilisation of p53 was the downstream 
consequences of nucleolar stress (Rubbi and Milner, 2003). In my study, I show 
siRNA silencing either TIF-IA or UBF suppress rDNA transcription activates the 
NF-κB pathway and regulates NF-κB target genes. Depletion of UBF had a greater 
effect than depletion of TIF-IA on most of the NF-κB assays. This is in accordance 
with the fact that UBF is present on wide ranges of rDNA genes and is involved in 
multiple steps of rDNA transcription such as initiation, elongation and termination; 
while TIF-IA is primarily important in rDNA transcription initiation and is mainly 
present at the active sites of rDNA (Drygin et al., 2010). This further implies the 
factors that regulate NF-κB activation under Pol I complex disruption is also present 
at the repressed rDNA.  
The molecular mechanism underlying nucleolar stress activation of the NF-
κB pathway 
Despite my data strongly suggesting that nucleolar disruption stimulates the NF-κB 
pathway, I have yet to identify the mechanism underlying this activation. However, 
my data would suggest that this activation is a direct effect of loss nucleolar integrity 
rather than indirect effects from Pol I transcription inhibition. NF-κB is known to be 
activated by cell cycle inhibition, which is a consequence of nucleolar disruption 
(Negi and Brown, 2015; Tsai and Pederson, 2014). However, CX5461 and BMH21, 
which are known to induce cell cycle arrest (Negi and Brown, 2015; Peltonen et al., 
2014), have no effect on the NF-κB pathway (Figure 3.6). This would suggest that in 
this case, stimulation of NF-κB signalling is not a consequence of the cell cycle 
inhibition.  
It is most likely that Pol I complex disruption causes the loss of nucleolar integrity 
and relocation of a specific component of Pol I complex or other nucleolar proteins 
to the cytoplasm where it activates NF-κB signalling pathway. This hypothesis 
parallels the known RP-Mdm2-p53 ribosome biogenesis surveillance pathway, that is: 
nucleolar stress causes release of a subset of RPs (for example RPL5 and RPL11) 
from nucleoli which then bind to MDM2, thus blocking its interaction with p53 and 
subsequently evoking cell arrest or apoptosis (Deisenroth and Zhang, 2010). 
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However, I believe the molecular basis underlying nucleolar stress-mediated 
activation of NF-κB is different from that involved in p53 nucleolar response 
pathway as I found that Pol I chemical inhibitors (BMH-21 and CX-5461) that 
stimulate this pathway have no effect on NF-κB-driven transcriptional activity (Colis 
et al., 2014; Drygin et al., 2011).  
The protein kinase casein kinase 2 (CK2) was thought to be a good candidate for 
linking Pol I complex disruption to NF-κB stimulation. Firstly, CK2 is one of the 
factors in the Pol I transcription complex (Drygin et al., 2010) and so disruption of 
the complex could lead to the release of CK2. Secondly, CK2 is known to be 
modulated by upstream kinase and shuttles between the nucleolus, nucleoplasm and 
cytoplasm in response to cell stress (Bierhoff et al., 2008). Thirdly, and importantly, 
CK2 modulates NF-κB pathway upstream of IκBα under certain stress condition 
(Kato et al., 2003). Therefore, I explored the involvement of CK2 in Pol I disruption-
mediated NF-κB by using siRNA against CK2 subunits. However, I found knocking 
down either of the CK2 subunits had minimal effects on siRNA silencing UBF 
induced NF-κB activation. One of the shortcomings of this experiment is that CK2 
knockdown efficiency was not directly tested by western blot analysis. Further 
experiments using specific CK2 inhibitors or overexpressing inactive form of CK2 
would be desirable to clearly address this question. Another kinase of possible 
involvement is NF-κB inducing kinase (NIK). NIK is a factor regulating the NF-κB 
non-canonical pathway, but is known to shuttle between the cytoplasm, nucleoplasm 
and nucleolus and differentially regulate NF-κB pathway (Birbach et al., 2004). 
Downstream effects of nucleolar stress-induced NF-κB activation  
NF-κB pathway is a pleotropic signalling pathway that plays a critical role in 
regulating immune response and cancer development. It targets and controls the 
expression of a growing list of genes with various functions (website resource: 
http://www.bu.edu/NF-κB/gene-resources/target-genes/, maintained by Thomas 
Gilmore’s laboratory). In order to understand the downstream consequence on gene 
expression or cellular functions of nucleolar stress-activated NF-κB, I tested the 
expression of a set of genes known to be regulated by NF-κB. Consistent with the 
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finding that nucleolar stress activates the NF-κB pathway, western blot analysis 
demonstrated Pol I complex disruption increased the protein level of IκBα and Bcl-
xL (Figure 3.3A), two proteins whose expressions are directly regulated by NF-κB 
activation. The effects of nucleolar disruption on gene expression were studied by 
two methods: gene reporter assay and quantitative RT-PCR. However, these two 
methods initially demonstrated incompatible outcomes. Gene transcription assays, 
where luciferase activity was driven by either synthetic κB binding sites or the full-
length promotor of the IκB gene showed increased transcription (Figure 3.3 B). In 
contrast, qRT-PCR demonstrated a significant decrease in gene expression patterns 
of NF-κB targeted genes under the same conditions (Figure 3.4). There are several 
hypotheses could explain this conflict.  
1) The cell-specific and context dependent activation of NF-κB targeted genes, that is 
NF-κB may directly regulate the expression of certain genes in other cell types but 
not or indirectly through cooperating with other signalling pathways in the cell 
culture system I used. First, in my experimental setting in SW480 cells I found genes 
known to be regulated by NF-κB, such as Bcl-xL, BAX and XIAP, were not activated 
by TNFα (a well-known NF-κB stimuli) (Figure 3.5A), suggesting these genes were 
not direct targets of NF-κB or not only targeted by NF-κB pathway in SW480 cells. 
Others members in the lab have shown that expression of these NF-κB targets are 
increased in another colorectal cancer cell line HCT116 following depletion of TIF-
IA and UBF, supporting the cell type dependent consequences. Second, NF-κB 
pathway has complicated inter-talks with other signalling pathways in regulating 
downstream gene transcription (see section 1.5.1.1). Given the huge change of 
nucleolar proteome in response to stress (Boulon et al., 2010), it is highly possible 
that other pathways are also modulated in response to Pol I complex disruption and 
cooperate with NF-κB to regulate downstream genes.  
2) NF-κB mediated gene expression was shown to dynamically change following 
time after stimuli due to a negative feedback loop driven by NF-κB-regulated IκBα 
transcription, which caused the periodically oscillation of NF-κB between cytoplasm 
and nuclear (Nelson et al., 2004). Therefore, the down-regulations of these NF-κB 
targeted genes I observed in qRT-PCR experiments may just represent the gene 
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transcription status of a specific timing (48 hours of siRNA transfection). Indeed, 
Figure 3.5 shows siRNA interfere against TIF-IA or UBF after 48 hours increased 
the protein level of IκBα, the inhibitor of NF-κB activation, which could be a direct 
clue explaining the gene expression repression shown in Figure 3.4 in the same 
experiment setting. Furthermore, to address the dynamic change of NF-κB-regulated 
gene expression under nucleolar disruption, I performed siRNA time course 
experiment in prior to qRT-PCR analysis. Observations from this experiment, which 
shown the transcription of the two NF-κB directly targeted genes IκBα and Fas were 
dynamically changed after siRNA silencing of TIF-IA or UBF, supporting the 
dynamics of gene expression.  However, this time-course experiment just done once, 
and it would be with great interest to examine the dynamic change of other genes 
under Pol I complex disruption. Moreover, it would be beneficial to generate TIF-IA 
or UBF conditionally knocking-down cell lines and perform gene microarray in these 
cells to address this question. 
3) NF-κB-responsive gene transcription is known to be repressed by NF-κB 
repressing factor (NRF) through interacting with specific negative regulatory DNA 
elements on certain NF-κB targeted genes promoters (Nourbakhsh and Hauser, 1999). 
Most importantly, NRF is dominantly located in nucleolus and is released to 
nucleoplasm under stress condition like actinomycin D treatment (Niedick et al., 
2004). It would be interesting to investigate whether the location of NRF is changed 
and expression of NRF is enhanced following Pol I complex disruption. 
4) Recent studies have shown RNA-binding protein RC3H1 (or ROQUIN) promotes 
mRNA degradation of NF-κB pathway regulators and NF-κB transcriptional targets, 
including TNFα (Leppek et al., 2013), A20 and IκB (Murakawa et al., 2015). RC3H1 
targets these transcripts by recognizing a constitutive decay element (CDE) in the 
3’UTR and recruiting a CCR4-CAF1-NOT deadenylase complex (Murakawa et al., 
2015). Therefore, it would be interesting to know whether RC3H1 also help decay 
the mRNA transcripts of the genes I tested in Figure 3.4 under nucleolar stress. 
Notably, studies have already evidenced RC3H1 accumulated in stress granules, 




One of the initial aims on studying gene expression pattern of NF-κB targeted genes 
was to understand the phenotypic outcome under Pol I complex disruption and to 
determine whether NF-κB required for this outcome. The data on inflammatory 
related gene expression may implicate a repression effect on immune response of 
nucleolar disruption, but the data I obtained did not give us a clear idea whether cell 
apoptosis was directly affected under this disruption. In order to clearly understand 
whether Pol I complex disruption mediated phenotypic outcome is through NF-κB 
activation, further qRT-PCR should be perfomed by knocking down RelA along with 
the Pol I factors.   
 
In summary, the overwhelming evidence demonstrated NF-κB activation is a direct 
downstream consequence of nucleolar disruption. Given the extensive overlap 
between stimuli that activate NF-κB and those that cause nucleolar disruption (Table 
3.1), suggesting a potential central role of nucleolus in linking stress response 
signalling and downstream NF-κB activation. To further examine this relationship, I 






Chapter 4: Results—stress stimuli of NF-κB 
induce degradation of the Pol I transcription 





















In the last chapter I demonstrated that the NF-κB pathway is activated by depletion 
of crucical Pol I factors, a distinct type of nucleolar stress. 
Nucleolar stress is a general term for describing modifications in nucleolar structure 
and function that eventually lead to modulation of cell homeostasis (James et al., 
2014). It is recognised that the varied effects of different stresses on nucleolar 
function induced by different kinds of cellular stresses would lead to different form 
of nucleolar stress, which, for instance, could be distinguished by distinct nucleolar 
morphological changes (reviewed in section 1.4).  
Previous findings in the lab, aimed at identifying the anti-tumour effects of aspirin, 
revealed this agent also causes changes to nucleolar morphology in colorectal cancer 
cells. Interestingly, the observed changes to nucleoli were distinct from other forms 
of nucleolar stress. That is, aspirin caused an increase in nucleolar size, decreased 
nucleolar number and formation of ‘nucleolar caps’ without segregation (that is 
proteins in FC moved to the periphery, but they were not separated from, and were 
still surrounded by, the DFC). The lab also demonstrated these distinct 
morphological changes were paralleled with a reduction in rDNA transcription, 
which preceded the the effects of the agent on the NF-κB pathway. They also found 
that other stress stimuli of NF-κB had similar effects on nucleolar morphology 
suggesting the two events may be linked. However, the molecular mechanism 
driving this morphological change and whether there is a connection between aspirin 
(or other stresses) effects on nucleoli and stimulation of NF-κB were unknown. To 
address this, I next investigated the effects of aspirin as a tool stress stimuli of the 
NF-κB pathway on componets of the Pol I complex.  
As outlined in Chapter 1, components of the Pol I transcription machinery are 
regulated by various upstream pathways in different conditions, mainly by the means 
of post-translational modifications (Drygin et al., 2010). Among these components, 
the regulation of transcriptional initiation factor –IA (TIF-IA) has been extensively 
studied in response to stress. TIF-IA interacts with PolI β and coordinates the 
interaction between Pol I SL-1/TIF-IB to recruit Pol I to the rDNA promoter to 
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assemble the transcription initiation complex. It senses environmental signals, plays 
an important role in cell growth and death, and also controls nucleolar morphology. 
The activity of TIF-IA is mainly regulated by its phosphorylation status. There are 
multiple phosphorylation sites on TIF-IA have been identified regulated by various 
upstream signalling pathway, such as JNK2, mTOR, AMPK, p38 MAPK, in 
coordinating growth signals, stress response and rDNA transcription.  
Although data on the regulation of TIF-IA protein abundance is not profuse, Fatyol 
and Grummt have shown TIF-IA is regulated by ubiquitination dependent 
degradation. They demonstrated 19S proteasome complexes were capable of binding 
to rDNA and 19S proteasome subunit Sug1, a E3 ligase, recognized and bound to the 
94 amino acids on TIF-IA N-terminus thus inducing degradation of this protein 
(Fatyol and Grummt, 2008). One more study demonstrated that MDM2 acts as an 
ubiquitin liagse for TIF-IA, and that phosphorylation of TIF-IA by an Akt-CK2 axis 
prevents MDM2-mediated TIF-IA degradation (Nguyen le and Mitchell, 2013). 
However, to my best knowledge, the dynamics of TIF-IA protein levels following 
cellular stress has never been reported. 
In this chapter, firstly, I demonstrate that aspirin and other stress stimuli of the NF-
κB pathway, such as UV-C and ceramide, cause a reduction in levels of TIF-IA. I 
characterise the molecular mechanisms underlying this reduction. Based on previous 
findings in the lab that inhibition of CDK4 mimics aspirin effects on the NF-κB 
pathway (Thoms et al., 2007b), and data demonstrating CDK4 targets the Pol I 
complex and regulates rDNA transcription (Voit et al., 1999), I considered that 
CDK4 inhibition may play a role in this pathway. Indeed, I confirm that inhibiting 
CDK4 activity mimics stress effects on TIF-IA. 
4.2 Results 
4.2.1 Aspirin induces a reduction in TIF-IA protein levels 
To further understand the connection between stress-induced nucleolar modification 
and stimulation of NF-κB pathway, I set out to explore the molecular changes to 
nucleoli in response to stress stimuli of NF-κB. Given the critical role of the Pol I 
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transcription complex in regulating nucleolar function, especially stress response, I 
firstly examined the effects of stress on protein levels of Pol I factors. 
Western blot analysis performed on whole cell lysates indicated the total level of 
TIF-IA protein rapidly (after 1 hour) decreases in SW480 colorectal cancer cells 
following exposure to aspirin. In contrast, the agent had a minimal effect on levels of 
two other Pol I factors, Pol I subunit RPA194 and UBF, in this time frame (Figure 
4.1 A). In addition, pharmacological relevant low concentration of aspirin (<3mM) 
for two-days treatment displayed the same effects on TIF-IA protein level as the high 
concentration treatment in a short time period (Figure 4.1 B). I excluded the 
possibility that this reduction in protein levels observed by western blot analysis was 
due to the antibody specificity or domain specificity by using two antibodies from 
different species and recognising different domains of TIF-IA (Figure 4.1 A).  
I found that aspirin effects on TIF-IA paralleled effects on nucleolar morphology and 
rDNA transcription (Figure 1.10), suggesting they may be linked. This link was also 
supported by the gene silencing experiments in the previous chapter that siRNA 
against TIF-IA, which caused the reduction in TIF-IA protein level, induced a 
significant reduction in rDNA transcription (Figure 3.1 A). 
Together, these data, suggest aspirin induces a reduction in TIF-IA protein in 
colorectal cancer cells, and that this reduction may lead to the inhibition of rDNA 
transcription. 
It was reported that stress causes re-location of TIF-IA from the nucleolus to 
nucleoplasm and that is causally involved in the inhibition of rDNA transcription 
(Mayer et al., 2005). By immunocytochemistry, I found TIF-IA was present in 
distinct nucleolar foci before aspirin treatment, reminiscent of fibrillar centres. 
However, in response to aspirin TIF-IA was dispersed throughout the nucleus and 
formed ‘nucleolar cap’, which suggested a potential nucleolar fragmentation (Figure 
4.1 C and D). This dispersal was consistent when cells were treated with the agent at 




4.2.2 Stress-specificity of effects on TIF-IA 
I next explored the generality of TIF-IA depletion with regards to stress stimuli of 
the NF-κB pathway.  
I found UV-C exposure also induced TIF-IA reduction prior to degradation of IκBα 
(Figure 4.2 A). However, unlike aspirin effects, this depletion was transient and 
levels were ultimately restored. In contrast to UV-C, the DNA damaging agents 
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camptothecin and hydrogen peroxide had no effect on TIF-IA levels, and didn’t 
induce IκBα degradation in the indicated time frame (Figure 4.2 B and C).  
NF-κB stimuli trigger the generation of ceramide, a crucial lipid second messenger 
that integrates stress signalling with the induction of apoptosis (Rotolo et al., 2005). 
Previous results in the lab found that the soluble forms of ceramide, C2 and C6 
(which can mimic the endogenous ceramide induction following stresses), induced 
enlargement and segregation of nucleoli in a similar fashion to aspirin. They also 
found these effects preceded stimulation of NF-κB signalling and the induction of 
apoptosis. Therefore, I next examined the effects of C2- and C6- ceramides on 
protein levels of TIF-IA. Figure 4.2 D indicates that C2 and C6 induce depletion of 
TIF-IA and that this is not enhanced by concomitant exposure to aspirin (Figure 4.2 
D). These data suggest a potential causal link between nucleolar stress, TIF-IA 
depletion and downstream signalling effects under certain stress conditions.  
To determine whether modulation of TIF-IA levels was restricted to NF-κB stimuli, I 
examined the effects of chemical inhibitors of Pol I transcription, CX-5461, BMH-21 
and low dose actinomycin D, on the protein. I found these agents, which had a 
minimal effect on NF-κB-driven transcription activity, did not cause a reduction in 
TIF-IA protein (Figure 4.2 E). This further demonstrates specificity and also 
indicates TIF-IA depletion is not a consequence of rDNA transcription inhibition. 
Taken together, these data suggest that certain stress stimuli of NF-κB, such as 






4.2.3 Aspirin-induced TIF-IA depletion is not through 
inhibiting TIF-IA gene expression 
Having identified TIF-IA depletion as a putative cause of the effects of stress stimuli, 
on nucleolar structural change, rDNA transcription inhibition and downstream 
stimulation of NF-κB pathway, I wished to elucidate the mechanism involved in this 
reduction in protein levels in order to inhibit this effect and further establish its role 
in these downstream events. 
Aspirin may block the transcription or translation of the TIF-IA gene. To determine 
whether this is the case, aspirin effects on mRNA levels of TIF-IA were examined by 
RT-PCR and qRT-PCR in kinetic studies. Figure 4.3 A and B show that aspirin has a 
minimal effect on TIF-IA mRNA levels in the time frame during which aspirin 
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induces TIF-IA protein reduction. To further explore aspirin’s effects on TIF-IA 
translation, I used cyclohexamide as an inhibitor of protein synthesis. SW480 cells, 
or SW480 cells transfected with exogenous pEGFP-TIF-IA, were exposed to 
cycloheximide in the presence or absence of aspirin. I found that 8 hours exposure to 
cyclohexamide had no effect on endogenous or exogenous TIF-IA protein levels, 
suggesting this protein’s half-life in SW480 cells is longer than 8 hours (Figure 4.3 
C-F). These data contrast with that reported for U2OS cells, in which de novo 
synthesised TIF-IA exhibited a half-life of less than 4 hours (Fatyol and Grummt, 
2008). In contrast, in the presence of aspirin, TIF-IA protein levels were reduced by 
50% in 2 to 4 hours (Figure 4.3 C-F). This result implies that aspirin causes TIF-IA 







4.2.4 Aspirin-induced TIF-IA depletion is due to protein 
degradation 
The above data implies that aspirin-induced TIF-IA depletion is through protein 
degradation. Intracellular protein degradation is mainly executed by two protein 
catabolism machines: proteasome and lysosome (Hideshima et al., 2005). In addition, 
two previous studies have shown that endogenous TIF-IA is regulated by proteasome 
dependent degradation (Fatyol and Grummt, 2008; Nguyen le and Mitchell, 2013).  
To explore the role of proteasome-dependent degradation in aspirin-mediated TIF-IA 
depletion, I used two proteasome inhibitors--MG132 and lactacystin. Although both 
proteasome inhibitors caused an increase in basal levels of TIF-IA, they did not 
completely block aspirin-induced depletion of this protein (Figure 4.4 A-C). In 
contrast, degradation of cyclin D1, an early response of aspirin treatment in 
colorectal cancer cells (Thoms et al., 2007b), was distinctly blocked by proteasome 
inhibitors (Figure 4.4 A-C). This result suggests that proteasome dependent 
degradation regulates the basal levels of TIF-IA as reported (Fatyol and Grummt, 
2008), but cannot fully explain aspirin effects on levels of the protein.  
Lysosome inhibitors quinacrine and bafilomycin were next employed to test the role 
of lysosomes in aspirin-induced TIF-IA depletion. Both of the lysosome inhibitors 
caused increased levels of the control protein, cathepsin D, a lysosomal aspartyl 
protease (Figure 4.4 D-F). Interestingly, basal levels of TIF-IA were also increased 
significantly after lysosome inhibition. However, aspirin-mediated depletion of TIF-
IA was not fully affected by the presence of these inhibitors (Figure 4.4 D-F).  
There are increasing reports of redundancy in degradation pathways in that if one 
pathway is blocked, the protein is degraded by another (Lilienbaum, 2013). 
Therefore, I next examined aspirin effects in the presence of inhibitors of both 
pathways. Interestingly, I found that a combination of both inhibitors significantly 
abrogate aspirin-mediated TIF-IA depletion (Figure 4.5 A-C).  
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Taken together, these results suggest aspirin-induced TIF-IA reduction is through 
promoting protein degradation, mediated by a combination of proteasomal and 








4.2.5 N-terminal 94-204 amino acids of TIF-IA are sufficient 
for aspirin response 
In order to help establish the mechanism by which aspirin affects TIF-IA, I next 
clarified the domains of TIF-IA required for aspirin-induced depletion. TIF-IA 
deletion plasmids were generated from pEGFP-C1-hTIF-IA (kindly supplied by 
Ingrid Grummt, German Cancer Research Centre) (Figure 4.6 A). SW480 cells were 
transfected with the GFP-tagged constructs then anti-GFP western blot analysis used 
to examine aspirin effects on levels of the deleted proteins. It demonstrates aspirin 
induces a significant reduction in levels of all the deletions, even the shortest 
fragment (94 -204 amino acids) (Figure 4.6 B and C). This suggests that the 94-204 
amino acid domain is sufficient for responding to aspirin-mediated stress. 
Next I employed immunocytochemistry to understand the cellular location of the 
deletion proteins. SW480 cells were transfected with the GFP-tagged constructs then 
GFP localisation determined on fixed cells. As observed in Figure 4.6 D, full-length 
TIF-IA was predominately located in nucleolus as expected. The C-terminal (403-
651 amino acids) of TIF-IA, but not N-terminal (1-94 amino acids), are required for 
nucleolar localisation, as constructs with only 1-94 amino acids deleted still 
predominately located in the nucleolus while constructs lacking the C-terminal 250aa 
were predominantly in the cytoplasm (Figure 4.6 D). These data would suggest the 
403-651 amino acids of TIF-IA is critical for the nucleolar localisation of this protein. 
It also suggests that aspirin-induced TIF-IA degradation takes place in the cytoplasm 
as the deleted proteins that localised mainly in the cytoplasm were degraded to the 






4.2.6 The known phosphorylation sites in TIF-IA 94-204aa 
domain are dispensable for aspirin response 
TIF-IA protein has several known phosphorylation sites regulated by mTOR, CK2 
and other pathways. Modulation of TIF-IA phosphorylation status at these sites is 
coupled with changes in cell proliferation and metabolism (Bierhoff et al., 2008; 
Mayer et al., 2004; Nguyen le and Mitchell, 2013; Zhao et al., 2003). Likewise, 
analysis based on TIF-IA protein sequence has predicted several potential 
ubiquitination sites, although no data regarding the bio-function of ubiquitination 
sites on TIF-IA has been published. A number of the known critical phosphorylation 
sites of TIF-IA are located between amino acids 94-204. Therefore, I next used site 
directed mutagenesis to generated mutant pEGFP-C1-hTIF-IA plasmids (Figure 4.7 
A), to determine whether any of these sites have a role in aspirin effects on the 
protein. SW80 cells were transfected with the mutant constructs then anti-TIF-IA 
western blot analysis used to examine aspirin effects on levels of the mutant proteins. 
Figure 4.7 B and C show mutating these phosphorylation sites from Serine (S) or 
Threonine (T) to Alanine (A) (cannot be phosphorylated) or Aspartic (D) acid or 
Glutamic acid (E)) (mimicking phosphorylation) has no effect on TIF-IA depletion in 




In agreement with this result, I found modifying known kinase pathways that have 
been shown to regulate TIF-IA activity through modulation of these phosphorylation 
sites had a minimal effect on aspirin-induced TIF-IA reduction (Figure 4.8 A). 
The mTOR pathway has been shown to regulate serine 44 and serine 199 on TIF-IA 
(Mayer et al., 2004). In addition, previous studies from this institute and others have 
shown that aspirin inhibits mTOR activity and thus, activity of the S6 kinase (Din et 
al., 2012). Therefore, I also further explored this pathway using the inhibitor of 
mTOR, rapamycin. If mTOR/S6k inhibition plays a role I would expect that 
rapamycin would mimic the effects of aspirin. Rather I found rapamycin caused an 
increase in TIF-IA in parallel with decreased phosphorylated S6. Furthermore, this 
agent had no effect on aspirin-mediated TIF-IA degradation (Figure 4.8 B). 
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The CK2 pathway targets serine 170 and 172 on TIF-IA (Bierhoff et al., 2008). A 
previous study demonstrating degradation of TIF-IA had identified a pathway 
involving CK2-regulated phosphorylation on serine 170 and 172 and MDM2-
mediated proteasomal degradation (Nguyen le and Mitchell, 2013). To further 
explore the role of this pathway in aspirin effects on TIF-IA, firstly, I utilised siRNA 
to two subunits of CK2, CK2α and β. I found that transfection with the siRNA had 
no effect on aspirin-mediated TIF-IA degradation (Figure 4.8 C). It did cause a 
reduction in basal levels of NF-κB as previously reported suggesting the siRNA did 
cause protein knockdown (Figure 4.8 D).  
To further examine the role of this previously published pathway I utilised the 
MDM2 inhibitor nutlin-3, which stabilises p53 and reportedly blocks MDM2-
mediated degradation of TIF-IA (Nguyen le and Mitchell, 2013). I found, although 
nutlin-3 treatment caused an accumulation of basal TIF-IA protein level and 
stabilised p53, it had minimal effects on the reduction of TIF-IA protein level in 
respone to aspirin (Figure 4.8 E). To confirm this process is p53-independent, I 
further applied HCT116 cells in which the p53 gene has been deleted (Bunz et al., 
1998). Figure 4.8 F shows aspirin induces similar degradation of TIF-IA both in 
parental and p53 deleted (p53-/-) cells. Therefore, these data suggest aspirin 
mediated TIF-IA depletion is not through the known CK2-MDM2 pathway and is 
irrespective of p53 status. 
Taken together, above data suggested, although the N-terminal 94-204 amino acids 
of TIF-IA was sufficient for aspirin-mediated TIF-IA dedation, known regulatory 




4.2.7 CDK4 lies upstream of stress effects on nucleolus 
To further elucidate the mechanism of TIF-IA depletion under stress stimuli, I next 
examined the upstream signalling involved in this process.  
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Based on previous studies from the lab and published data showing CDK4 targets the 
Pol I complex (See 4.1 introduction), I next determined whether CDK4 inhibition 
lies upstream of stress effects on TIF-IA. 
I utilised a chemical CDK4 inhibitor (CDK4i) to mimic stress effects on 
CyclinD1/CDK4 and found that it caused degradation of TIF-IA (Figure 4.9 A). I 
also confirmed this effect by using a second CDK4 inhibitor (Figure 4.9 B) and 
siRNA to CDK4 (Figure 4.9 C). I also found in the time frame that TIF-IA shown 
dramatic decrease in response to aspirin, CDK4i had no effect on protein levels of 
CDK4 while inducing degradation of cyclin D1 (Figure 4.9 D).  
 
In addition, the 94-204 amino acids domain of TIF-IA, which is sufficient for 
aspirin-mediated degradation of this protein, is also important for degradation 
induced by CDK4 inhibition (Figure 4.10 A), implying that they mediate these 
effects through a common mechanism. Interestingly, although aspirin-induced TIF-
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IA depletion can only be blocked by a combination treatment of proteasome and 
lysosome inhibitors, CDK4i mediated effect was abrogated by either proteasome 
inhibitor MG132, lysosome inhibitor Quinacrine or combination of both (Figure 4.10 
B to D). Furthermore, similar to aspirin treatment, MDM2 inhibitor nutlin-3 had 
minimal effects on the reduction of TIF-IA protein level in respone to CDK4i (Figure 
4.10 E). 
These data, along with previous data from the lab demonstrating that CDK4i 
mimicks aspirin’s effects on nucleolar morphology and rDNA transcription 
inhibition, strongly suggest CDK4 lies upstream and is involved in aspirin-mediated 





In this chapter, I demonstrated for the first time that specific stress stimuli induce the 
degradation of TIF-IA. I also demonstrate this degradation can take place via a 
proteasome or lysosomal pathway. An N-terminal 110 amino acid domain (94-204aa) 
on TIF-IA was found to be sufficient for aspirin-mediated TIF-IA depletion, but the 
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specific modification sites involved are yet to be identified. I demonstrated that a 
reported pathway for TIF-IA degradation involving MDM2 is not involved in stress-
effects on the protein. Furthermore, I demonstrated that is was independent of p53. 
CDK4 inhibition mimicked aspirin’s effects on TIF-IA suggesting this kinase lies 
upstream of TIF-IA in response to aspirin.  
Stress stimuli induce a reduction in TIF-IA protein levels 
Stress that affect rDNA transcription and ribosome biogenesis act predominately by 
modulating the post-translational modifications on Pol I factors and subsequently 
altering their activities (Drygin et al., 2010). Pol I factors were shown overexpressed 
in tumour cells (Negi and Brown, 2015), but studies on the regulation of Pol I factors 
abundance in response to stress are not profuse. Here, I report stress stimuli of NF-
κB induced TIF-IA degradation.  
Aspirin was chosen as a model stress inducer in my study, as we are interested in the 
anti-tumour mechanism of this agent, and the preliminary data in the host laboratory 
have shown it causes nucleolar morphological changes preceding stimulation of NF-
κB pathway. And importantly, in the absence of additional cytokines it stimulates 
NF-κB in a manner characteristic of multiple stress stimuli (Thoms et al., 2007b). 
The dose of aspirin used is a critical criterion in epidemiological studies of this agent, 
therefore this also needs to be considered in in vitro studies. The pharmacological 
related plasma concentration of salicylic acid, the primary hydrolysis product of 
aspirin, is <3mM (Dovizio et al., 2013). I chose to use 10m aspirin in time course 
studies investigating the dynamic change of TIF-IA protein level. Firstly, I was 
convinced I was measuring the direct and primary, but not indirect and secondary, 
effects of this agent. Secondly, the effects of short time periods treatment with 10mM 
aspirin on TIF-IA depletion and cellular localisation have also been observed in the 
long time periods treatment with low dose aspirin (1-5mM).  
Beside aspirin, I also showed other stress stimuli of NF-κB induced similar reduction 
on TIF-IA protein level, including UV-C and ceramide isoforms (Figure 4.2). UV-C 
stress is a well-studied NF-κB stimulus (Wu and Miyamoto, 2007). Previous results 
in the lab have shown UV-C exposure caused the similar nucleolar structure change 
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as aspirin, that is increased nucleolar size and decreased nucleoli numbers. Ceramide 
is a critical lipid second messenger that integrates stress-activated cell apoptosis 
through inducing signalling systems including NF-κB (Kimura et al., 2003). 
Fundamental work in the lab also indicated enlargement/segregation of nucleoli upon 
treating ceramide isoforms. In contrast, chemical Pol I inhibitors, which had no effect 
on NF-κB driven transcriptional activity, did not change the protein level of TIF-IA 
(Figure 4.2). These findings, together with my observation of TIF-IA depletion in 
response to certain stress inducers, suggest regulation on TIF-IA is probably a 
common response to stress stimuli of NF-κB. However, I observed treating cells with 
hydro-peroxide (H2O2) and camptothecin (CPT), which stimulated NF-κB pathway 
(Wu and Miyamoto, 2007) and induced γH2AX foci (done by Lesley Stark), did not 
induce a decrease in TIF-IA protein level but slightly increased it (Figure 4.2). One 
consideration is H2O2 and CPT have been shown cause different forms of nucleolar 
stress from aspirin and UV-C. Al-Baker et.al evidenced H2O2 did not cause the loss 
of nucleolar integrity or nucleolar segregation (Al-Baker et al., 2004), and Kalita 
et.al showed CPT cause nucleolar disruption particularly through inducing the 
disappearance of NPM in the nucleolus in neuros (Kalita et al., 2008). None of these 
studies have shown H2O2 or CPT cause nucleolar enlargement or nucleoli number 
changes as we found under aspirin stress or UV-C exposure. Therefore, depletion of 
TIF-IA may be specifically coupled with a distinct nucleolar stress. I also can not 
completely rule out the possibility that H2O2 or CPT effects on TIF-IA are time- and 
dose- dependent. Further considerations in this setup would be use different 
concentrations of H2O2 and CPT and perform time-course experiments. 
TIF-IA cellular location under stress 
Previous studies in the host laboratory have revealed aspirin increased nucleolar size 
and decreased nucleoli numbers. They also demonstrated aspirin induced a distinct 
‘nucleolar cap’ compared to actinomycin D, that is ‘in response to aspirin the FCs 
and DFC did not completely segregate while there was complete segregation in 
response to Act D’. Using immunocytochemistry, I found in un-treated SW480 cells 
TIF-IA formed foci in the nucleolus. Upon treating aspirin, foci were disrupted and 
TIF-IA became disperse in the nucleolus which was coupled with significant 
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decrease in nucleolar TIF-IA fluorescence intensity. Although there was no clear 
‘TIF-IA nucleolar cap’ observed in response to aspirin, I found these ‘smashed’ foci 
tend to be nucleolar periphery located (Figure 4.1). It was reported TIF-IA was a 
highly dynamic nucleolar factor that shuttles between nucleolus, nucleoplasm and 
cytoplasm and TIF-IA translocated out of nucleolus in certain condition (Mayer et al., 
2005; Mayer et al., 2004; Szymanski et al., 2009). However, my data was not clear 
enough to conclude whether TIF-IA translocated out of nucleolus in response to 
aspirin, with a few of observations supporting an increase of TIF-IA cytoplasmic 
location, while most of the pictures showed TIF-IA foci dispersed and intensity 
decrease but still predominately nucleolar location. Indeed, there are some direct 
supports for the notion that aspirin encourages TIF-IA cytoplasmic translocation 
before degradation. One is my data on domain deletions of TIF-IA. In these 
experiments, I found shorter domain deleted proteins (94-204aa, 94-302aa, 94-
403aa), which still degraded in response to aspirin, were primarily located in 
cytoplasm (Figure 4.6). Another one is the previous observations made by the lab 
members revealed CDK4i, which mimicked most of aspirin effects on nucleolus, 
induced cytoplasmic accumulation of TIF-IA in prior to degradation of this protein. 
Hence, I postulate aspirin does cause TIF-IA to translocate out of nucleolus but my 
images don’t capture this process. One explanation for this is from the imaging 
technical aspect. As reported by Szymański et.al regarding subcellular localisation of 
TIF, in static status, nucleolus appeared as the brightest cellular structure with TIF-
IA and quantifications from single confocal slices showed nucleolus had 23-fold 
higher concentration of TIF-IA foci than cytoplasmic. However, after measuring 
compartment volume using confocal z-stack, the nucleolus only obtained 7% of total 
cellular TIF-IA compared to 48% in cytoplasm and 45% in nucleoplasm (Szymanski 
et al., 2009). Therefore, it would be with great interest to utilize 3D confocal 
microscope to further address the dynamics of TIF-IA in response to aspirin. 
Aspirin-mediated TIF-IA degradation involves proteasomal and lysosomal 
degradation pathway 
In order to further establish the casual link between stress-induced TIF-IA depletion 
and stress-induced rDNA transcription inhibition and NF-κB activation, the 
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mechanism underlying TIF-IA depletion needs to be elucidated. I examined many 
possible mechanisms to explain this degradation. I demonstrated this depletion is 
neither a consequence of TIF-IA gene transcriptional inhibition nor inhibition of TIF-
IA protein synthesis. I found the half-life of TIF-IA protein in SW480 cells is longer 
than 8 hours, which is contrast with a previous report showing the half-life of TIF-IA 
is less than 4 hours in U2OS cells (Fatyol and Grummt, 2008). However, considering 
the different effect arose from different laboratories environment, a more robust 
comparison would be treating U2OS cells with the same dose of cyclohexamide and 
to detect the TIF-IA protein level in the same time duration as did in SW480 cells. 
Moreover, although the cell confluence may influence Pol I transcription and differ 
the drug treatment outcome (Hannan et al., 2000), I found the reduction of TIF-IA in 
response to aspirin treatment was not affected by cell confluence either low 
concentration or over-confluent (Supplementary Figure 4.1 A). Previous data from 
our lab and others indicates ubiquitin proteasome system proteins increase in 
abundance in nucleoli in response to aspirin and proteasome treatment and become 
trapped in nucleolar aggresome containing ubiquitinated proteins. I addressed the 
possibility that TIF-IA was undetectable due to entrapment in insoluble complexes 
by using a buffer that can solve aggresomes and different lysis buffers with different 
detergent concentration followed by western blot analysis (Supplementary Figure 4.1 
B and C). Results ruled out the observed TIF-IA reduction in whole cell extract was 
due to TIF-IA becoming undetectable upon formation of insoluble aggresome in 
response to aspirin. Furthermore, I also exclude the invovlment of caspase dependent 
cleavage in this depletion (Supplementary Figure 4.1 D).  
Observations in the study have pointed the mechanism underlying aspirin-induced 
reduction of TIF-IA protein level to protein degradation. Firstly, cycloheximide 
treatment in SW480 cells indicates the half-life of TIF-IA in this cell is more than 8 
hours, while aspirin induced TIF-IA depletion generally happens 30 minutes to 1 
hour after treatmen, thus implying protein degradation pathways have been triggered 
upon the exposure to this agent. Secondly, although separately using proteasome 
inhibitor and lysosome inhibitor had minor effects on aspirin mediated TIF-IA 
reduction, inhibiting proteasomal and lysosomal activity together completely blocked 
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the observed TIF-IA degradation, again suggesting the involvement of protein 
degradation pathways in this regard. 
Previous studies have demonstrated that endogenous TIF-IA is targeted by 
proteasome dependent degradation, and Sug-1 and MDM2 have previously been 
identified as TIF-IA E3 ligase (Fatyol and Grummt, 2008; Nguyen le and Mitchell, 
2013). However, I found proteasome inhibitors and MDM2 inhibitor nultin-3 had no 
or minimal effects on preventing aspirin-induced TIF-IA degradation. Besides, 
fundamental works in the lab demonstrated aspirin did not change the interaction 
between Sug-1 and TIF-IA, together with my finding that TIF-IA depletion mutant 
lacking reported Sug-1 binding domain (1-94aa) did not affect aspirin-induced 
degradation (Figure 4.6), indicating the reported TIF-IA E3 ligase Sug-1 was also not 
involved in this stress-mediated TIF-IA regulation. Therefore, I postulate it is an 
unknown E3 ligase involved in stress-mediated TIF-IA modification that selectively 
target the protein for proteasomal or lysosomal degradation. Moreover, further 
experiments investigating the ubiquitination of TIF-IA upon aspirin treatment would 
be desirable. 
My study is for the first time to find TIF-IA protein level is regulated by lysosome 
degradation pathway. I also evidenced although separately using proteasomal or 
lysosomal inhibitor has minor effects on stress mediated TIF-IA degradation, 
simultaneously applying these two types of inhibitors can completely abrogate this 
effect. This indicates a possibility that TIF-IA could be targeted by either of the 
degradation pathway under stress. This hypothesis could be supported by recent 
findings showing cooperation between proteasome and lysosome degradation 
pathways in cells in case of protein overloading and degradation pathways 
redundancy. In addition, there are some proteins already known to be substrates of 
both degradation pathways (Lilienbaum, 2013).  
The known phosphorylation sites in TIF-IA 94-204aa domain are 
dispensiable for aspirin response 
A set of studies has elucidated the mechanisms underlying stress-mediated TIF-IA 
inactivation and degradation are through modulation of its phosphorylation status, 
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and a number of phosphorylation sites and responsive upstream kinase have been 
identified (Jin and Zhou, 2016). Unlike these known regulations on TIF-IA, I found 
the stress-stimuli of NF-κB effects on TIF-IA is independent of these known 
regulatory cascades, by applying TIF-IA domain deletion constructs, mutating 
known phosphorylation sites and specifically inhibiting upstream regulative kinase 
pathways.  
Firstly, I applied a set of TIF-IA domain deletion plasmids. In the past decades, 
studies have gradually illustrated the molecular basis of TIF-IA in the regulation of 
RNA polymerase I initiation and cell growth, that characterised domains on this 
protein responsible for certain functions (Figure 4.11). For examples, TIF-IA acts as 
a bridge between Pol I and SL-1 through interacting with two Pol I subunits RPA43 
and PAF67 with its C-terminal 512-609aa whereas associating with SL-1 
components TAFI95 and TAFI68 on a conserved short motif (411-415aa) (Yuan et 
al., 2002). DNA binding of TIF-IA is essential for rDNA transcription, and it has 
been identified TIF-IA binds to rDNA on its 382-400aa (Stepanchick et al., 2013). 
TIF-IA binds Pol I as a monomer but forms dimer in solution, the 335-493aa on this 
protein is required for the dimer interface contact (Blattner et al., 2011). 1-94aa on 
the C-terminus is targeted by E3 ligase Sug-1 for proteasome degradation (Fatyol 
and Grummt, 2008). In my study, I demonstrated 94-204aa of TIF-IA are sufficient 
for aspirin response and 403-651aa of TIF-IA are responsible for nucleolar 




The 94-204 amino acids domain on TIF-IA is with particular interest, as a structure–
function analysis of TIF-IA has revealed a surface serine patch on this protein, which 
ranges from 97-200 amino acids. In vitro and in vivo functional analysis further 
demonstrated this serine patch is critically important in Pol I components recruitment, 
Pol I binding and cell growth (Blattner et al., 2011). In supporting with this finding, 
most of the previously identified TIF-IA phosphorylation sites, which are under 
stress stimuli regulation, locate in this domain. To study the involvement of these 
published phosphorylation sites in aspirin-mediated TIF-IA regulation, I accordingly 
mutated these sites and transfected into SW480 cells, but none of these mutants 
blocked aspirin’s effects. However, to further strength this data, repeat this 
transfection in TIF-IA-null cells would be diserable to exclude the effects of 
endogeneous TIF-IA binding to the mutants. Furthermore, using inhibitors or siRNA 
silencing, I and previous data in the lab have proved inhibiting the activity of kinases 
(mTOR, CK2, JNK, AKT) that regulates these known phosphorylation sites during 
this domain has no effect on aspirin-induced TIF-IA degradation. These data would 
suggest aspirin modulates TIF-IA on a residue that never been identified.  
Another possibility is aspirin’s effects on TIF-IA is a combined effect from 
modulations on multiple sites rather than on a single site. This hypothesis parallels 
139	
	
with the finding that mTOR regulates the activity of TIF-IA is a conjunct effect from 
modifications on two phosphorylation sites serine 44 and serine 199 in the opposite 
way (Mayer et al., 2004). Generation of shorter domain deletion mutants based on 
94-204aa domain would be also help to this question.  
CDK4i lies upstream of stress effects on nucleoli 
Previous publication in the host laboratory have demonstrated that aspirin caused 
degradation of cyclin D1/inhibition of CDK4 through upstream activation of p38, 
and also evidenced this pathway contributes to the nucleolar translocation of NF-
κB/RelA and pro-apoptotic effect of aspirin (Thoms et al., 2007b). The CDK4/cyclin 
D1 complex has been observed modulating the phosphorylation of Pol I factor UBF 
and affects rDNA transcription (Voit et al., 1999). Therefore, I determined whether 
CDK4 inhibition lie upstream of aspirin effects on nucleolus. Interestingly, I found 
CDK4i mimicked aspirin-induced TIF-IA depletion by using siRNA against CDK4 
or chemical CDK4 inhibitors, such as palbociclib, a CDK4/6 inhibitor approved by 
FDA to be used for breast cancer treatment (Sherr et al., 2016). I also found there 
was almost complete overlap in the mechanisms between CDK4i- and aspirin-
mediated TIF-IA degradation (Figure 4.10) i.e. 94-204aa on TIF-IA are essential, is 
dependent on both proteasomal and lysosomal degradation pathways and was 
inhibited in the presence of calyculin A (Figure 6.2D), but not nutlin-3. These results 
are in line with the previous observations in the lab that CDK4i mimicked aspirin 
effects on nucleolar morphological change and rDNA transcription inhibition. Taken 
together, these findings suggest CDK4 inhibition lies upstream of TIF-IA depletion 
and nucleolar stress in response to aspirin, and also reinforce the possibility that 
stress regulation on TIF-IA in prior to effects on nucleolar structure change and 
rDNA transcription inhibition.  
Based on the previous findings in the lab, it was postulated p38 activation dependent 
CDK4i inhibition also the upstream signalling cascade that regulates nucleolar stress 
response. However, fundamental works in the lab revealed that inhibiting p38 
activity, either using chemical inhibitor or siRNA interfere, did not block aspirin’s 
effects on TIF-IA protein levels and rDNA transcription, despite preventing cyclin 
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D1 degradation in the presence of this agent. This suggests the effects of aspirin on 
TIF-IA and nucleolar functions are independent of p38 activation-mediated 
degradation of cyclin D1/CDK4 inhibition. Hence, there are two possibilities: First, 
an alternative pathway rather than p38 is utilized by aspirin to inhibit CDK4 in prior 
to affect nucleolus. For this possibility, p16Ink4A is a great candidate to be 
investigated. p16Ink4A is an inhibitor of CDK4 that through binding to this kinase 
and inhibiting the interaction between this kinase and cyclin D1 thus inhibiting the 
catalytic activity of this complex (Serrano et al., 1993). Interestingly, a cohort study 
has observed the loss of p16Ink4A expression in numbers of colorectal cancers 
through methylation on promoter of this gene (Shima et al., 2011). Therefore, it is 
possible that aspirin induces inhibition of CDK4 through upregulating expression of 
this protein. Indeed, I performed few experiments to examine the p16Ink4A protein 
levels in response to aspirin. However, although this protein level seems upregulated 
in 15 minutes of aspirin treatment, which parallels aspirin induced TIF-IA depletion 
in 30 minutes, this protein appears to be undetectable by whole cell extract based 
western blot analysis in colon cancer cell lines compared to other cell types 
(Supplementary Figure 4.2). It would be great interesting to address this question 
further. Experiments could be designed by using exogenously overexpressing 
p16Ink4A in colon cancer cells or testing the methylation status of this protein in 
response to aspirin. Second, another possibility is that CDK4 is not directly regulated 
by aspirin, instead, CDK4i and aspirin treatment both affect TIF-IA and nucleolar 
function through converging on a common pathway downstream of CDK4/cyclin D1. 
In this regard, it would be good to know whether aspirin treatment directly affect the 
CDK4 kinase activity through operating ELISA. CDK4 mutants that are either 
constitutively active or inactive could also be applied to distinguishes these two 
possibilities. In addition, retinoblastoma protein (pRb), which is phosphorylated by 
CDK4/cyclin D1 in cell cycle progression, is a possible candidate as a common 
target by aspirin and CDK4 inhibition. It has been also shown accumulation of pRb 
in nucleolus inhibited the Pol I transcription through binding and inactivating UBF 
(Cavanaugh et al., 1995). And hyperphosphorylated pRb could be recruited by 
nucleolar protein NPM and translocates to nucleolus (Takemura et al., 2002). Hence, 
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it would be interesting to known whether aspirin promotes the phosphorylation of 
this protein.  
It also need to be noted that, from my observation, aspirin-induced TIF-IA 
degradation could only be blocked by combination of proteasomal and lysosomal 
inhibitors, whereas using either of them efficiently blocked this degradation in the 
presence of CDK4i. This would suggest aspirin has more complicated regulations on 
TIF-IA compared with CDK4i. It is possible that there are other upstream factors 
involved in aspirin’s effects on nucleolus in addition to CDK4.  
Aspirin induced TIF-IA degradation is p53-independent 
p53 and related pathways are central downstream regulator of nucleolar stress, but as 
far as I know, whether p53 is involved in the upstream of nucleolar stress in response 
to stresses is unknown. In my experiment settings using SW480 cells (with three p53 
copies but carrying two point mutations R273H and P309S and with constitutively 
activates p21 (Rochette et al., 2005)), MDM2-p53 interaction inhibitor nutlin-3 and 
HCT116 cells that have mutants with a disabled TP53 gene (HCT116 p53-/-), I 
proved aspirin’s effects on TIF-IA depletion is p53 independent. Besides, the 
previous findings in the lab have shown p53 is dispensable for aspirin effects on NF-
κB pathway that lies downstream of nucleolar disruption (Chapter 3), and the 
subsequent induction of cellular apoptosis (Din et al., 2004). Therefore, I believe, in 
this context, nucleolar stress response and downstream consequences is in a p53-
independent way. Notably, a study demonstrated a potent CDKs inhibitor RGB-
286638 induced cell death in p53-null multiple myeloma cells, indicated the exsit of 
p53-independent mechanisms underlying the anti-tumour effect of CDKs inhibitors 
(Cirstea et al., 2013).  
 
Taken together, data in this chapter strongly suggest TIF-IA degradation is a parallel 
stress effect with rDNA transcription inhibition and nucleolar structure changes, and 
provide further insight to understand the molecular link between stress signalling, 
nucleolar stress and NF-κB activation. 
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Chapter 5: Results—p14ARF-UBF axis 
mediates aspirin-induced TIF-IA degradation 




















Having found distinct disruption of Pol I complex activates NF-κB signalling 
(Chapter 3) and stress-stimuli of NF-κB induce rDNA transcription suppression in 
line with reduction of Pol I factor TIF-IA protein levels (Chapter 4), in this chapter, I 
set out to find molecular clues about the nucleolar factors involved in stress-induced 
TIF-IA depletion and rDNA transcription inhibition, in order to demonstrate a 
functional relationship between stress-mediated effects on TIF-IA and NF-κB 
activation. 
In order to fully understand the anti-tumour mechanism of aspirin, a related study in 
the host laboratory involving stable isotope labelling by amino acids in Cell Culture 
(SILAC) study plus sub-compartmental fraction analysis characterised aspirin effects 
on the nucleolar proteome (by Ian T. Lobb, unpublished data). Compared to 
conventional western blotting and image analysis, SILAC is a more powerful tool to 
answer the biological questions about nucleolar stress. Notably, a number of studies 
from the Lamond lab have established that the nucleolar proteome is complex and 
dynamic by using this technology (reviewed in section 1.2).  
Using SILAC based quantitative proteomics, the host laboratory investigated aspirin 
effects on the nucleolar proteome. They identified 749 nucleolar proteins of which 21 
were significantly increased (>1.6 fold change at 6 hours and 10 hours aspirin 
treatment relative to 0 hour control) while only five proteins demonstrated a 
significant decrease in abundance in response to aspirin. The p14ARF tumour 
suppressor, a critical nucleolar modulator of MDM2/p53, is among these proteins. 
p14ARF is a tumoursuppressor that is a critical regulator of the MDM2/p53 pathway. 
It is generally held in the nucleolus due to interactions with nucleolar proteins such 
as nucleophosmin (NPM) and MDM2 (James et al., 2014). The interaction between 
p14ARF and NPM mainly controls the activity and stability of p14ARF, in that NPM 
prevents ubiquitin-mediated degradation of p14ARF in non-stressed cells (Chen et al., 
2010). The formation of a stable complex between p14ARF and MDM2 in the 
nucleolus contributes to its tumour suppressor properties. p14ARF prevents MDM2 
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from binding to p53, thus stabilising p53 and initiating p53-mediated cell cycle arrest 
and apoptosis (Pomerantz et al., 1998).  
Although acting as a key activator of p53 signaling pathway under nucleolar stress, 
studies also shown p14ARF plays a more intricate role in response to stress and in 
tumour surveillance, and could act independently of the p53 pathway. For example, 
in order to elucidate the mechanism of p14ARF-regulated nucleolar function in 
response to stress, a proteomic study had been carried out using wild type or 
p14ARF-/- mouse embryonic fibroblasts and revealed a RNA helicase-DDX5 (also 
known as p68) as a p53-independent p14ARF target in ribosomal biosynthesis. They 
demonstrated, upon p14ARF depletion, DDX5 was enriched in nucleoli, increasingly 
associated with UBF and bound to rDNA promoter thus promoting rDNA 
transcription (Saporita et al., 2011). 
p14ARF has also been shown to play a direct role in regulating rDNA transcription 
and ribosome biogenesis. For example, Sugimoto et.al demonstrated induction of 
p19ARF in mouse NIH 3T3 fibroblasts retarded the processing of rRNA (Sugimoto 
et al., 2003). In the same system, another study found that besides the 
aforementioned NPM, p14ARF interacts with another 20 ribosomal biogenesis 
related proteins, suggesting a negative regulatory role for ARF in ribosomal 
biosynthesis regulation independent on MDM2 and p53 (Bertwistle et al., 2004). 
p14ARF was also shown to directly associate with 60 S preribosomal particles and 
regulated cell growth (Rizos et al., 2006). Moreover, there is direct evidence 
demonstrating p14ARF negatively regulates rDNA transcription by binding to the 
rDNA promoter and interacting with Pol I transcription factors. For example, UBF 
was identified as a p14ARF binding partner and was shown to be 
hypophosphorylated by overexpression of p14ARF, which caused inhibition of 
rDNA transcription (Ayrault et al., 2006). Additionally, RNA polymerase I 
transcription termination factor TTF-I shuttles between nucleoplasm and nucleolus. 
p14ARF binds to its nucleolar localization sequence thus inhibiting its nucleolar 
import causing it to accumulate in the nucleoplasm (Lessard et al., 2010).  
These data indicate a p53-independent role of p14ARF in the regulation of cell 
growth and cell death, which is at least in part through suppression of ribosomal 
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DNA transcription and synthesis. It also underlines the importance of identification 
of novel p14ARF-binding proteins in understanding the p53 independent functions of 
p14ARF and nucleolar stress response.  
p14ARF has also been shown be involved in NF-κB regulation. Studies by Rocha 
et.al have revealed that upon oncogenic stress, p14ARF inhibits the NF-κB pathway 
to prevent cell transformation irrespective of MDM2 and p53 status. It does this by 
inducing an association between NF-κB RelA and the histone deacetylase HDAC1, 
which results in repression of RelA-dependent gene expression (Rocha et al., 2003). 
In addition, they found p14ARF induced the serine/threonine-protein kinase ATR 
and its downstream kinase Chk1 mediated phosphorylation of RelA at the 
transactivation domain, thus repressing the transcriptional activation domain of RelA. 
(Rocha et al., 2005). 
Based on the proteomics studies in the host laboratory that identified p14ARF as a 
downstream regulator of aspirin, and the proficient evidence of p14ARF’s 
involvement in rDNA transcription, ribosomal biogenesis and NF-κB regulations, I 
decided to investigate the role of p14ARF in stress effects on TIF-IA, nucleoli and 
NF-κB pathway.  
Firstly, I demonstrated p14ARF is required for aspirin-effects on TIF-IA. Secondly, I 
found that blocking aspirin- and CDK4i induced TIF-IA reduction by modulation on 
p14ARF abrogates nucleolar stress, NF-κB stimulation and apoptosis. Furthermore, I 
identified another Pol I factor UBF was involved in the regulation of TIF-IA by 
aspirin, postulating a novel nucleolar p14ARF-UBF-TIF-IA complex in responding 





5.2.1 p14ARF regulates aspirin-mediated degradation of TIF-
IA 
In order to determine whether p14ARF plays a role in aspirin effects on TIF-IA, I 
first tested the effects of aspirin on p14ARF protein levels. Consistent with the 
observation in previous SILAC data which indicated p14ARF is reduced in all cell 
compartments in response to aspirin, I found the protein level of p14ARF was 
reduced at lower dose aspirin treatment (3mM) for 24 hours (Figure 5.1 A) in SW480 
cells. However, higher dose of aspirin (10mM), which reduced TIF-IA protein level 
in a rapid manner, had minor effects on p14ARF protein level after 2-4 hours (Figure 
5.1 B and C). This suggests aspirin effects on TIF-IA are an earlier event than on 
p14ARF levels. Next, I determined whether p14ARF could directly interact with 
TIF-IA. Indeed, co-immunoprecipitation assay revealed that p14ARF interactes with 
TIF-IA in SW480 cells and demonstrated that this interaction was enhanced by 




This interesting result made me further postulate that TIF-IA depletion under aspirin 
treatment may be directly regulated by p14ARF. To further test this suggestion, 
siRNA against p14ARF was utilised.  SW480 cells were transfected with control or 
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p14ARF siRNA prior to treatement with aspirin in dose studies. Western blot 
analysis performed on whole cell extracts indicated that, compared to control siRNA, 
siRNA depletion of p14ARF attenuated aspirin-induced TIF-IA reduction (Figure 5.2 
A and B). Immunocytochemistry analysis confirmed the significant reduction in TIF-
IA observed in response to aspirin in cells transfected with control siRNA, was lost 
in cells transfected with siRNA to p14ARF. Importantly, observations suggested 
TIF-IA accumulated within nucleoli in p14ARF depleted cells, suggesting a role for 
p14ARF in nucleolar location or shuttling of this protein (Figure 5.2 C). In keeping 
with a role for p14ARF, I found that overexpressing the protein enhanced aspirin-
induced depletion of TIF-IA (Figure 5.2 D). Together, these data demonstrate 
p14ARF is involved in aspirin-mediated TIF-IA degradation  
p14ARF is located in nucleolus due to its association with nucleophosmin (NPM) 
(James et al., 2014), it also known that p14ARF regulates rDNA transcription and 
ribosome biosynthesis through this association (Bertwistle et al., 2004). Therefore, I 
tested whether the involvement of p14ARF in aspirin-mediated TIF-IA depletion is 
also through its association with NPM. NPM was depleted from SW480 cells with 
siRNA interfere, however, this depletion had no effect on TIF-IA depletion or 
p14ARF reduction upon aspirin treatment, suggesting p14ARF facilitated TIF-IA 





p14ARF is differentially expressed in different colorectal cancer cell lines (Figure 
5.3 A). To further test the importance of p14ARF in regulating aspirin-mediated TIF-
IA depletion, I examined aspirin response in four types of colon cancer cell lines: 
SW480 and HCT116 (high p14ARF expression), HRT18 and RKO (low/absent ARF 
expression). Cells were exposed to 1.5mM or 3mM aspirin for 24 hours then whole 
cell extracts prepared for western blot analysis. Results demonstrate that in response 
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to aspirin treatment, there was a more robust depletion of TIF-IA in p14ARF 
expressing cell types (SW480 and HCT116) than the ones without p14ARF 
expression, supporting the hypothesis that p14ARF is involved in aspirin-induced 
TIF-IA depletion (Figure 5.3 B and C). 
Taken together, these lines of data revealed p14ARF interacts with TIF-IA in 
response to aspirin and is a regulator of TIF-IA depletion induced by this agent.  
 
5.2.2 p14ARF mediated depletion of TIF-IA links nucleolar 
stress response and NF-κB modulation 
Having demonstrated p14ARF is a mediator of TIF-IA depletion in response to 
aspirin stress, I further studied whether this effect links stress signalling, nucleolar 
disruption and downstream consequences on the NF-κpathway. Firstly, qRT-PCR 
analysis revealed siRNA depletion of p14ARF abrogated the repression of rDNA 
transcription in response to aspirin (Figure 5.4 A and B). In keeping with this finding, 
immunocytochemistry demonstarted that depletion of p14ARF also blocked the 
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effects of aspirin on nucleolar morphological changes (Figure 5.4 C and D). These 
data suggest a causal link between p14ARF-TIF-IA depletion and aspirin-induced 
nucleolar stress.   
 
Additionally, I found inhibiting TIF-IA depletion using p14ARF siRNA blocked 
aspirin-mediated activation of the NF-κB pathway, as evidenced by inhibition of 
IκBα degradation (Figure 5.5 A and B). The effects of p14ARF depletion on TIF-IA 
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and IκBα were further tested using an independent siRNA to p14ARF, which 
confirmed that depleting this protein blocks both TIF-IA and IκBα degradation 
(Figure 5.5 A and B).  
Previous data from the lab indicated repression of NF-κB driven-transcription is a 
downstream consequence of aspirin-mediated IκBα degradation and RelA nucleolar 
translocation (Stark and Dunlop, 2005). Indeed, 24 hours exposure to 3mM aspirin 
significantly inhibited NF-κB-driven transcription activity while TNFα (positive 
control) dramatically enhanced it (Figure 5.5 C). However, knocking down p14ARF 
significantly attenuated aspirin-induced NF-κB transcriptional inhibition (Figure 5.5 
D).  
Since previous studies demonstrated p14ARF regulates nuclear NF-κB activity 
(Rocha et al., 2003) (Rocha et al., 2005), I did consider that depletion of p14ARF 
could affect stress-mediated NF-κB activation regardless of its regulatory role on 
TIF-IA. To test this possibility, I examined whether knocking down p14ARF altered 
the increase in NF-κB activity induced by Pol I complex disruption. Previously, I 
demonstrated mimicking nucleolar stress by disrupting Pol I complex (siRNA 
against TIF-IA and UBF) activated the NF-κB pathway (Chapter 3). Here, I found 
this activation was not changed in the absence of p14ARF, suggesting that in this 
NF-κB pathway, the role of p14ARF is upstream of Pol I complex disruption (Figure 
5.5 E). 
Furthermore, in keeping with previous studies showing aspirin-mediated TIF-IA 
depletion, NF-κB activation and apoptosis are independent of p53, I found that the 
effects of p14ARF knockdown blocked aspirin effects on TIF-IA and IκBα are 
independent of p53 (Figure 5.5 F). 
Taken together, these findings indicate p14ARF-facilatied TIF-IA degradation is 
central to sense aspirin or other stresses and convert stress signalling to nucleolar 







5.2.3 CDK4 lies upstream of p14ARF-facilitated TIF-IA 
depletion 
Previous results suggested CDK4 kinase inhibition lies upstream of aspirin-mediated 
degradation of TIF-IA. Therefore, I next examined the role of p14ARF in CDK4i-
mediated TIF-IA degradation. In keeping with this suggestion, I found that siRNA 
depletion of p14ARF in SW480 cells blocked CDK4i-mediated TIF-IA degradation 
(Figure 5.6 A and B). In further support for a role of TIF-IA degradation in stress-
mediated activation of the NF-κB pathway, I found that siRNA to p14ARF blocked 
CDK4i-mediated nuclear translocation of RelA (Figure 5.6 C).  
 
To further examine the relationship between CDK4i effects on TIF-IA and p14ARF, 
I examined CDK4i-mediated TIF-IA degradation in cell lines with variable cellular 
levels of p14ARF expression (Figure 5.7 A). I found that like aspirin, CDK4i-
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induced TIF-IA depletion is in accordance with the cellular protein level of p14ARF. 
For example, compare the effects of CDK4i on TIF-IA in SW480 cells with high 
levels of p14ARF and U2OS cells with low levels of this protein (Figure 5.7 B and 
C). In keeping with a connection between TIF-IA degradation and CDK4i-mediated 
activation of the NF-κB pathway, I found that CDK4i-induced IκBα degradation was 
attenuated in U2OS cells (Figure 5.7 B and D). 
Therefore, in addition to the previous observations that CDK4 acts as an upstream 
mediator of stress-mediated TIF-IA depletion and nucleolar stress, these findings 
further demonstrate CDK4 induced TIF-IA depletion is p14ARF dependent and 




5.2.4 UBF is involved as an intermediate in p14ARF-
dependent TIF-IA degradation 
The Pol I transcription complex contains several factors that associate with each 
other to orchestrate and modulate the activity of rDNA transcription. Of these, UBF 
is particularly interesting as it is critical for Pol I-driven transcription and is a direct 
target for both CDK4 and p14ARF. Indeed, CDK4 has been shown to phosphorylate 
UBF on serine 484, impairment of which halts rDNA transcription and causes cell 
cycle arrest (Voit et al., 1999). 
To determine the role of this protein I firstly examined the phosphorylation status in 
response to aspirin and CDK4i. I found that depletion of TIF-IA was paralleled by 
the dephosphorylation of UBF at this known s484 phosphorylation site (Figure 5.8 
A), suggesting modification on this site may be required for the aspirin stress 
response.  
To further examine the role of this protein I next used siRNA to UBF. I demonstrated 
that TIF-IA depletion in response to aspirin and CDK4i is blocked in the absence of 
UBF, while siRNA silencing of another Pol I subunit, RPA194, had no effect on 
levels of the protein (Figure 5.8 B and C). This suggests that stress effects on TIF-IA 
may occur indirectly though modulation of UBF but not Pol I subunit.  
The above data indicated a role for UBF in this stress response pathway. To 
determine whether serine 484 was necessary, we utilised an expression plasmid that 
expresses a serine to alanine mutation at this site and therefore cannot be 
phosphorylated. If phosphorylation was important I would have expected that this 
mutant would mimick the effects of CDK4i/aspirin on TIF-IA levels, or at least 
enhance the effects of this agent. SW480 cells were transfected with control or UBF 
siRNA alongside WT UBF or a UBF S484A mutant. Results show that the inhibition 
of CDK4i-mediated TIF-IA depletion observed in the absence of UBF is rescued by 
overexpression of wild type UBF. However, expression of the mutant actually 




To definitively establish a connection between inhibition of CDK4 activity, 
disruption of the Pol I complex and activation of the NF-κB pathway I next 
examined whether this UBF-S484A mutant could modulate CDK4i effects on NF-κB 
activation. SW480 cells were transfected with control or UBF siRNA prior to 
overexpression of Flag-UBF-WT or -S484A as above. Immunocytochemistry 
(picture taken by Dr. Lesley Stark) revealed that for both control and UBF siRNA, 
CDK4i induced a significant increase in nuclear levels of RelA in cells transfected 
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with wild type UBF, but not in those transfected with the S484A phospho-mutant 
(Figure 5.9).  
Taken together, these results suggest UBF acts as an accessory in aspirin- and 
CDK4i- mediated TIF-IA depletion and NF-κB activation. They also suggest a role 
for S484 of UBF although whether phosphorylation at this site is involved remains 
unclear. 
 
5.2.5 Relationship between p14ARF-facilitated TIF-IA 
degradation and pro-apoptotic effects of aspirin 
Previous studies in this lab have shown that degradation of IκBα is absolutely 
required for aspirin and CDK4i-mediated apoptosis. To investigate the relationship 
between the identified nucleolar stress response pathway and pro-apoptotic activity 
of aspirin, I performed apoptosis assay. In SW480 cells, p14ARF was silenced by 
siRNA prior to aspirin treatment for 24 hours. Apoptotic cells were then determined 
by positive Annexin V staining. I found knocking down p14ARF, basally attenuated 
cell apoptosis. Aspirin treatment significantly enhanced apoptosis in control cells, 
which was completely inhibited in cells in which p14ARF was silenced (Figure 5.10 
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A). Whole cell extracts were also prepared from cells in the same experiment setup 
for western blot analysis, revealing aspirin induced a reduction of pro-caspase 3 level, 
a hallmark of apoptosis, in paralleled with TIF-IA depletion, and importantly, both of 
effects were blocked by siRNA silencing p14ARF (Figure 5.10 B). This was further 
confirmed by an independent p14ARF siRNA, which also suggested this effect was 
coupled with aspirin effects on NF-κB activation (Figure 5.10 C). 
Taken together, these data suggest a potential connection between aspirin-mediated 
p14ARF-facilitated degradation of TIF-IA, activation of NF-κB pathway and pro-






In this chapter, I elucidated a novel nucleolar stress response pathway that through 
regulating a CDK4-UBF-p14ARF-TIF-IA axis culminates in the activation of the 
NF-κB pathway. I demonstrated p14ARF interacts with TIF-IA in response to stress, 
and is a mediator of aspirin/CDK4i mediated TIF-IA degradation. Blocking TIF-IA 
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degradation through siRNA silencing of p14ARF abrogated stress effects on rDNA 
transcription inhibition, nucleolar morphological changes, stimulation of NF-κB and 
most importantly, the induction of cell apoptosis. I also revealed UBF was involved 
as an intermediate and serine 484 on UBF was required in this regulation. Taken 
together, these data proposed a novel nucleolar stress response pathway that lies 
upstream of NF-κB activation, and this could potentially explain the anti-tumour 
effects of aspirin in colorectal cancer.  
p14ARF plays a role in stress-mediated TIF-IA degradation and rDNA 
transcription inhibition 
Since aspirin treatment down-regulates p14ARF in nucleolus, I initially postulated 
that reduced p14ARF was linked to TIF-IA depletion. However, contrary to this 
expectation, western blot analysis revealed siRNA silencing of p14ARF actually 
abrogated aspirin-mediated degradation of TIF-IA, especially at lower concentration 
of this agent (Figure 5.2). In contrast, overexpression of p14ARF enhanced TIF-IA 
degradation in the presence of aspirin (Figure 5.2). This seems counterintuitive, but 
the experiments on the detailed kinetic studies on TIF-IA and p14ARF protein level 
and immunoprecipitation indicated aspirin-mediated degradation of TIF-IA precedes 
loss of p14ARF (Figure 5.1), and these two proteins actually associated upon aspirin 
exposure. Immunocytochemistry analysis further confirmed p14ARF was a mediator 
of TIF-IA degradation, and we found although TIF-IA degradation was blocked in 
the cells transfected with p14ARF siRNA, TIF-IA foci was trend to accumulate at 
the periphery of nucleoli rather than in the central as found in control cells (Figure 
5.2 C). pEGFP-p14ARF plasmids were also employed to study the co-localization of 
TIF-IA and p14ARF. I found p14ARF was predominately accumulated in nucleolar 
and nucleoplasm in SW480 cells, but it was not clear to conclude whether p14ARF 
and TIF-IA co-localised and travelled out of nucleolus in response to aspirin from 
these results (Data not shown). Further experiments on 3D confocal imaging would 
help address this question. Taken together, these data would suggest that p14ARF 
contributes to TIF-IA degradation in response to aspirin possibly through binding 




The association between p14ARF and nucleolar protein NPM contributes to the 
nucleolar location of p14ARF and regulation on rDNA transcription and ribosome 
biosynthesis of this protein (Bertwistle et al., 2004; James et al., 2014). I found this 
association was not required for p14ARF in mediating TIF-IA degradation in stress 
condition. However, I did interestingly observe the basal level of TIF-IA was 
decreased in the presence of siRNA against NPM and aspirin-induced degradation of 
TIF-IA was slightly enhanced by knocking down NPM. This would suggest an 
interesting possibility that depletion of NPM actually disrupted its interaction with 
p14ARF thus releasing p14ARF to bind TIF-IA for degradation. This possibility 
should be further explored in future experiments. 
Taken together, previous studies have suggested p14ARF is a negative regulator of 
rDNA transcription in a p53/MDM2 independent manner, and a few nucleolar 
proteins have been identified as p14ARF partners in this regulation. Here I 
demonstrate another mechanism of p14ARF regulating rDNA transcription under 
stress conditions is through facilitating TIF-IA degradation. 
CDK4i-p14ARF-UBF axis regulates stress effects on TIF-IA  
In chapeter 4, I provided data to show that CDK4 inhibition mimics aspirin effects on 
TIF-IA and NF-κB activation, and discussed the possibility that CDK4 lies upstream 
of nucleolar stress in response to aspirin. Here, I conclude that the UBF-p14ARF axis 
lies downstream of CDK4i effects on TIF-IA. This conclusion is supported by a line 
of observations. First, CDK4i causes p14ARF depletion. Second, siRNA against 
p14ARF blocked CDK4i-induced TIF-IA degradation and NF-κB activation. Third, 
CDK4i and aspirin induce decrease of UBF phosphorylation on serine 484. Fourth, 
knocking down UBF and introducing UBF-S484A mutant abrogated CDK4i-
mediated TIF-IA degradation. Taken together, these results would suggest aspirin 
and CDK4i induce TIF-IA degradation through a common pathway involving UBF-
p14ARF-TIF-IA axis. Now it would be imperitive to show that aspirin exert 
nucleolar stress directly through regulation on CDK4 by demonstrating aspirin has 




RNA polymerase I transcription machinery contains several components that have 
complicated interactions with each other to coordinate the function of rDNA 
transcription. Therefore, it is possible that stress-mediated TIF-IA degradation is 
‘assisted’ by TIF-IA’s ‘teammates’. Among them, I demonstrated UBF is involved. 
Firstly, I found siRNA silencing UBF in SW480 cells completly blocked aspirin- and 
CDK4i- induced TIF-IA degradation (Figure 5.8). Secondly, aspirin and CDK4i both 
down-regulate phosphorylation of UBF at serine 484, and introducing UBF-S484A 
mutant abrogates TIF-IA degradation in the presence of these agents (Figure 5.8). 
Thirdly, and importantly, expressing UBF-S484A mutant impaired CDK4i induced 
NF-κB activation (Figure 5.9). These data suggest the involvement of UBF and 
requirement of modification on serine 484 of UBF in this regulation.   
Having found aspirin and CDK4i cause a reduction of UBF phosphorylation and that 
siRNA against UBF activates NF-κB to a larger extent than siRNA against TIF-IA 
(Figure 3.1 and Figure 5.8), it could be arguing that it is stress effects on UBF, rather 
than TIF-IA, that are critical for downstream stimulation of NF-κB. However, 
evidence here indicates that loss of p14ARF abrogates both aspirin and CDK4i 
mediated activation of NF-κB which is coupled with inhibition of TIF-IA 
degradation. Therefore, I propose TIF-IA degradation is critical in stress response 
and connecting stress signalling to downstream activation of NF-κB, while disruption 
of other Pol I components could mimic the consequences of TIF-IA degradation 
It will now be of considerable interest to elucidate how UBF is involved in the 
interaction between p14ARF and TIF-IA and what the role of S484 is. Interestingly, 
Ayrault et.al revealed one of the nucleolar partner of p14ARF is UBF, and UBF was 
hypophosphorylated and lost the ability to recruit other Pol I components to rDNA 
promoter upon overexpressing of p14ARF, suggesting an association between these 
two proteins in regulating rDNA transcription (Ayrault et al., 2006). Therefore, I 
postulate that hypophosphorylation of UBF, probably serine 484, or a switch of 
phosphorylation status at this residue, is required to mediate the interaction between 
p14ARF and TIF-IA. To test this expectation, further experiments using co-
immunoprecipitation to examine the association between p14ARF and TIF-IA under 
stress in the presence of UBF siRNA or UBF-S484A mutant, or vice versa would be 
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helpful. Based on the observations from Ayrault et.al (Ayrault et al., 2006), another 
possibility could be that p14ARF actually lies upstream of UBF. That is, stress-
enhanced interaction between p14ARF and TIF-IA promotes p14ARF-induced 
hypophosphorylation of UBF, and this hypophosphorylation impairs the rDNA 
recruitment of Pol I components including TIF-IA, thus inducing the disassociation 
of this protein from rDNA and translocation out of nucleolus for degradation. Further 
experiments designing to test the phosphorylation status of UBF in the presence of 
siRNA against p14ARF and Chromatin immunoprecipitation (ChIP) assay of Pol I 
components on rDNA, especially TIF-IA, are desirable to address this hypothesis.  
Based on my data, I conclude that UBF-p14ARF axis lies upstream of TIF-IA 
degradation. I suggest this pathway is only active in response to specific stresses as 
overexpression of p14ARF or siRNA silencing p14ARF or UBF has minimal effects 
on TIF-IA basal protein levels. Although my data suggests that p14ARF-facilitated 
TIF-IA degradation is a mechanism linking stress, NF-κB activation, and aspirin-
induced apoptosis, based on my data so far I cannot rule out the possibility that other 
nucleolar pathways are involved in this process. Especially as I found that in some 
cell lines with very low levels of p14ARF, aspirin and CDK4i still induce TIF-IA 
degradation to a reasonable level (although not as significant as the cell lines with 
p14ARF expression). 
TIF-IA degradation is directly linked to stimulation of NF-κB pathway 
Previous chapters in the thesis have demonstrated nucleolar disruption activate NF-
κB pathway and stress stimuli of NF-κB induce TIF-IA degradation in prior to 
effects on NF-κB pathway. In this chapter I have provided evidence to prove stress-
mediated TIF-IA degradation is directly linked to nucleolar enlargement and 
stimulation of the NF-κB pathway. For example, siRNA against p14ARF, which 
blocked stress-mediated TIF-IA degradation, also blocked stress effects on rDNA 
transcription inhibition, nucleolar enlargement and NF-κB activation. Applying 
UBF-S484A mutant, that abrogated CDK4i-mediated TIF-IA degradation, also 
prevented CDK4-induced RelA nuclear accumulation. In addition to these cell line 
studies, observations made from clinical samples strongly support this notion. 
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Biopsies of fresh surgically resected human colorectal tumours were exposed to 
pharmacological dose of aspirin (100uM) for 1 hour. Western blot analysis revealed 
aspirin induced significant decrease of TIF-IA protein level in 4 out of 7 tumours, 
meanwhile quantitative immunohistochemistry analysis found significant increase of 
pRelAs536 staining in 3 out of 6 tumours. Importantly, they found there was a strong 
inverse relationship (r2=-0.85, n=6) between aspirin-induced TIF-IA protein level 
changes and the percentage of cells with phosphorylated RelA. These data in the 
primary human tumours confirm the strong relationship between aspirin-induced 
TIF-IA degradation and activates NF-κB pathway, and indicate the clinical 
significance of this nucleolar stress response pathway.  
Previous studies have shown nucleolar fragmentation and stabilisation of p53 is a 
downstream consequence of inactivating TIF-IA through alteration on its 
phosphorylation status (Mayer and Grummt, 2005). Here, based on the findings 
mentioned above, the observations that TIF-IA degradation was always associated 
with nucleolar enlargement and NF-κB activation under certain stress stimuli of NF-
κB (aspirin, UV-C, ceramide), and siRNA silencing TIF-IA alone enhanced NF-κB-
driven transcriptional activity, I propose the downstream consequences of 
inactivating TIF-IA through stress-mediated degradation are nucleolar enlargement 
and NF-κB activation. 
Nucleolar stress response pathway containing UBF-p14ARF-TIF-IA axis 
plays a role in the pro-apoptotic effect of aspirin 
There are overwhelming evidence supporting that aspirin is effective in prevention 
and treatment of cancers, especially colorectal cancer (discussed in Chapter 1). 
Although numbers of molecular mechanisms have been proposed for the anti-tumour 
effects of this agent, molecular markers could be efficiently applied for predicting the 
potential side effects and anti-tumour outcome of this agent are very limited. This 
study was aimed to make progression on this area, and I did suggest this novel 
nucleolar stress response pathway containing UBF-p14ARF-TIF-IA axis plays a role 
in the pro-apoptotic effect of aspirin, through observations on pro-caspase 3 
immunoblot analysis and apoptosis assay in the presence of p14ARF siRNA under 
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aspirin exposure (Figure 5.10). Besides, works done by other lab members in 
colorectal tumour ex vivo model, which indicate a strong inverse relationship 
between aspirin-mediated TIF-IA degradation and percentage of cells with 
phosphorylated RelA, have also shown the clinical significance of this pathway. The 
significance of this nucleolar stress response pathway in the pro-apoptotic effect of 


















Chapter 6: Results—Other signals regulating 





















6.1.1 Mass spectrometry shows other signals regulate TIF-IA 
in response to aspirin 
Results above suggest the nucleolar response pathway containing UBF-p14ARF-
TIF-IA directly links stress signals to NF-κB activation and also induction of cell 
apoptosis. However, I cannot completely rule out the possibility that other factors or 
pathways are involved in this process. It would be also interesting to find unknown 
signals that regulate the relationship between UBF-p14ARF-TIF-IA. Therefore, we 
next used label-free quantification (MaxLFQ) to investigate TIF-IA interacting 
proteins under aspirin treatment. This approach is ideal as MaxLFQ intensities not 
only accurately represent dynamic changes in protein interactions, but can also be 
used to rank the proteins in terms of likely relative abundance.  
I immunoprecipitated endogenous TIF-IA and specifically detected it at high 
intensity using LC-MS/MS. Generally, SW480 cells were exposed to 10mM aspirin 
before harvesting and whole cell lysates prepared with NP-40 cell lysis buffer. 
Antibodies against TIF-IA (or IgG control) were used as baits for potential TIF-IA 
associated factors (Figure 6.1 A). Immunoprecipitation (IP)-mass spectrometry for 
protein-protein interactions and initial raw data process using MaxQuant platform 
were carried out by the Edinburgh Cancer Research Centre (ECRC) facility with 
support from Jimi Wells (ECRC) and Alex von Kreigsheim (ECRC), who is an 
expert in this technology (Turriziani et al., 2014). Three independent experiments 
and quantifications were applied.  
From the total interactomes, the lists of potential proteins specifically interacting 
with TIF-IA in the absence or presence of aspirin (ASA- or ASA+ respectively) were 
identified based on data analysis using average LFQ intensity ratio and T-test p value. 
Basically, proteins having the TIF-IA/IgG ratio of average LFQ intensity (relative 
LFQ ratio) higher than 2 and p value less than 0.05 were considered to specifically 
interact with TIF-IA. Using this cut-off I identified 26 proteins that specifically 
interact with TIF-IA in the absence of aspirin and 20 proteins in the presence of 
aspirin (Figure 6.1 C and E, Appendix Table 8.1 and 8.2).  
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STRING database, which is a web resource predicting protein-protein interactions 
mainly based on experimental evidence, computional prediction and textmining of 
published abstract (Szklarczyk et al., 2017), was applied to visualize the associations 
between these identified proteins (Figure 6.1 B and D). As expected, the majority of 
these were ribosomal proteins (including TIF-IA (RRN3)) and subunits of RNA 
polymerase that have known or predicted interactions with TIF-IA, thus confirming 
the specificity of the technique. However, I also identified some novel TIF-IA 
interactors, such as the BRCA1-A complex subunit Abraxas (encoded by FAM175A 
gene) in the absence of aspirin, which would be with great interest for further study 




To identify factors that are differentially binding to TIF-IA under aspirin treatment, I 
compared the proteins that specifically bound to TIF-IA in ASA- and ASA+ 
conditions. There were 17 candidates shared by ASA- and ASA+ lists. While there 
were 9 proteins specifically interacting with TIF-IA in ASA-, and 3 proteins in 
ASA+, indicating a dynamic fluctuations of TIF-IA interactors in the presence and 
absence of aspirin. (Figure 6.2A). Among these proteins specifically interact with 
TIF-IA in the absence of aspirin, majority of which are subunits of RNA polymerase 
I, suggesting this agent disrupted the Pol I-TIF-IA interaction and potential TIF-IA-
involved complexs (Figure 6.2 A and B). With particular interest, 14-3-3 protein eta 
(encoded by YWHAH gene) and WD repeat-containing protein 43, also known as 
Utp5 (encoded by WDR43 gene) were two proteins displaying most significant and 
consistent decrease of relative LFQ intensity under aspirin treatment (Figure 6.2 B 
and 6.1C). 14-3-3 protein eta belongs to 14-3-3 proteins family, which involved in 
the regulation of multiple aspects of signalling pathways through recognizing and 
binding to phosphoserine or phosphothreonine motif. WDR43 is involved in 
ribosomal biogenesis and is mainly localized in fibrillar centre of the nucleolus. The 
proteins specifically interact with TIF-IA under aspirin treatment include Ubiquinol-
cytochrome c reductase, Rieske iron-sulfur polypeptide 1 (encoded by UQCRFS1 
gene), which known to be located in mitochondria and involved in respiratory chain; 
and Polypyrimidine tract-binding protein 1 (encoded by PTBP1 gene), which is a 
nuclear ribonucleoproteins (hnRNPs) and involved in pre-mRNA processing 




6.1.2 Mass spectrometry identified phosphorylation on serine 
44 of TIF-IA is modulated by aspirin treatment 
I have shown that proteasomal degradation (which is dependent on ubiquitination) is 
required for aspirin-mediated TIF-IA degradation (Figure 4.5). I have also shown this 
is dependent on p14ARF, which generally influences the activity of interacting 
proteins through modulation of their sumoylation status. Therefore, I postulate a key 
role for post-transcriptional modifications (PTMs) in this regulation. Label-free 
quantification (MaxLFQ) can simultaneously investigate TIF-IA PTMs and 
interacting proteins. Alex von Kreigsheim (ECRC) has recently used a similar 
approach to identify substrates of PHD3 and FIH20 (Rodriguez et al., 2016). 
Surprisingly, data analysis identified serine 44 on TIF-IA as the only active 
phosphorylation sites modified by aspirin. Phosphoryaltion at this site was 
significantly reduced in response to aspirin treatment (Figure 6.2 A). This seems 
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incompatible with my previous results show 94-204 amino acids of TIF-IA protein 
are sufficient for aspirin response. To confirm the role of this residue, I applied two 
previously generated site-mutated TIF-IA plasmids as described in Chapter 4 (4.2.6): 
a serine to alanine mutation at residue 44 TIF-IA (GFP-TIF-IA S/A) that cannot be 
phosphorylated and a serine to aspartic acid (GFP-TIF-IA S/D) mutation that mimics 
phosphorylation. These constructs were transfected into SW480 cells then treated 
with aspirin in dose response studies. I found that mutating S44 to alanine (A) 
slightly enhanced aspirin-mediated degradation of TIF-IA while mutating the residue 
to aspartic acid (D) partially attenuated this effect (Figure 6.2 B). These results 
suggest that dephosphorylation at this site is important in aspirin-mediated TIF-IA 
degradation. 
To further examine whether de-phosphorylation was involved in aspirin-mediated 
effects on TIF-IA, I applied general serine/threonine phosphatase inhibitor Calyculin 
A. I found both high dose (50nM) Calyculin A and low dose (5nM) Calyculin A 
completely abrogated TIF-IA’s reduction under aspirin or CDK4i treatment, 
suggesting de-phosphorylation process was required for this modulation (Figure 6.2 
C and D).  
Therefore, these observations suggests that aspirin-mediated de-phosphorylation of 





Although my data suggest that a UBF-p14ARF-TIF-IA axis plays a role in stress-
mediated degradation of TIF-IA, there are still a number of questions need to be 
answered regarding this pathway. For example, the factors mediate Pol I complex 
disruption and NF-κB activation are still unknown; and the detailed mechanism 
underlying the interplay between UBF, p14ARF and TIF-IA is unknown. To identify 
novel proteins and post-translational modifications involved, I ustilised ‘on-beads 
digestion in conjuction with data-dependent mass spectrometry’. These data 
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suggested a number of novel TIF-IA interactions in response to aspirin. Among them, 
14-3-3 protein eta is with most significant changes, and with most interesting due to 
their known celluar functions. 14-3-3 protein eta is a member of the 14-3-3 proteins 
family which are highly conserved and widely expressed across eukaryotic 
organisms. 14-3-3 proteins recognize and bind to the phosphoserine and 
phosphothreonine motif of their targeted proteins or kinases, thus regulating their 
kinase activities, cellular location or protein interactions. The role of 14-3-3 proteins 
in regulating cell cycle progression has been extensively studied. In particular, 14-3-
3 protein eta was shown to regulate mitotic progression, and deletion of it resulted in 
enhanced mitotic cell death and sensitized tumour cells to microtubule inhibitor, 
suggesting this protein as a potential target for cancer therapy (Lee et al., 2013). 14-
3-3 protein eta was also shown to regulate the cell cycle through interacting with 
CDC25, a dual phosphatase that regulates and activates CDKs (Mils et al., 2000). 
Furthermore, a study revealed colon cancer cells (HCT116) with a 14-3-3 protein eta 
deficiency were more sensitive to p14ARF-induced apoptosis, indicating a potential 
link between 14-3-3 protein eta and p14ARF, which has not been investigated so far 
(Hemmati et al., 2008).  
Besides the well-studied role in cell cycle regulation, 14-3-3 proteins are also 
involved in the regulation of other signaling pathways, some of them, particularly 
MDM2 and mTOR, are with great interest regarding this study. Wood NT. et.al have 
shown 14-3-3 proteins interact with Pim kinase phosphorylated MDM2 (Wood et al., 
2009), which implies a potential role of 14-3-3 proteins in mediating protein 
degradation. Therefore, further experiments in this study investigating whether 14-3-
3 protein eta is involved in aspirin-induced TIF-IA depletion will be beneficial. 14-3-
3 proteins were also known to be involved in mTOR pathway regulation under 
hypoxia through associating with mTOR inhibitory proteins (DeYoung et al., 2008). 
Notably, mass spectrometry analysis also identified aspirin induced the 
hypophosphorylation of serine 44 of TIF-IA, a site known to be dephosphorylated by 
mTOR activity inhibition (Mayer et al., 2004). Consistent with this, I found aspirin-
induced TIF-IA depletion was completely abrogated in the presence of phosphatase 
inhibitor calyculin A, suggesting phosphorylation status alterations were involved in 
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this regulation. A previous study has shown that aspirin inhibits mTOR activity (Din 
et al., 2012), which would suggest an aspirin-mTOR-TIF-IA/S44 dephosphorylation 
regulation cascade regulates the degradation of this protein. However, I applied the 
mTOR inhibitor--rapamycin, it caused an increase in the basal TIF-IA protein levels 
and had no effect on aspirin-mediated TIF-IA degradation (Figure 4.8 B). This 
implies aspirin may simultaneously regulate other kinase pathways in addition to 
mTOR for the modification of serine 44 on TIF-IA and the regulation of TIF-IA 
degradation. In addition, further experiments using the cells have constitutively 
activated mTOR pathway would help to understand the involvement of mTOR 
inhibiton in this regulation. Furthermore, since mass spectrometry results suggest the 
serine 44 is the only phosphorylation site modulated by aspirin treatment, it will be 
very interesting to use the phosphomimetic mutations constructs on this residue 
(Figure 6.3) to understand whether this mutations blocked aspirin’s effects on 
nucleolar stress, the NF-κB pathway activation and even aspirin-induced cancer cell 
apoptosis. Mechanistically, it will be also interesting to know whether this residue is 
important for TIF-IA-p14ARF binding. 
In summary, based on this preliminary finding from mass spectrometry analysis, 
future studies with detailed investigation would help to identify signals that regulate 
p14ARF-TIF-IA binding and the interaction partners/post-translational modifications 




























Based on the previous observations in the lab that aspirin and other stresses effects 
on nucleolus precede stimulation of NF-κB pathway, this thesis primarily aims to 
establish the molecular connection between stress signalling, nucleolar response and 
NF-κB modulation. With a view to build on the molecular mechanisms underlying 
the pro-apoptotic effect of aspirin, which has been established in the host laboratory. 
The work presented in this thesis generally achieved these goals and has great 
significance, as I demonstrate for the first time that nucleolar stress can activate NF-
κB signalling pathway and characterise a novel nucleolar stress response pathway 
that lies upstream of this activation. Furthermore, I demonstrate that this pathway is 
involved in aspirin-induced apoptosis, which together with the observations in the 
lab indicating the clinical significance of this pathway, propose a novel mechanism 
of anti-tumour action of aspirin. 
Summarised work in this thesis, I propose the nucleolar stress response model 
outlined in Figure 7.1. I suggest that stress stimuli of NF-κB (including aspirin, UV-
C radiation and ceramide), directly or indirectly through inhibiting CDK4 kinase 
activity, enable TIF-IA-p14ARF interaction within the nucleolus. The de-
phosphorylation on serine 44 of TIF-IA could be an important modification for this 
interaction. I also suggest p14ARF then transports TIF-IA outside nucleolus for 
degradation. UBF acts as an accessory and phosphorylation status on serine 484 of 
UBF is essential for this process. As a consequence of this nucleolar disruption in 
response to stress, specific proteins are probably released from nucleoli into the 






Pol I complex disruption activates the NF-κB pathway 
Compared to conventional activation of NF-κB induced by cytokines such as TNFα, 
stresses stimulate the NF-κB with a delayed kinetics. Therefore, stress stimulation of 
NF-κB could go through a different pathway involving components that are distinct 
from the known factors/kinases participating in the cytokine-activated NF-κB. 
Preliminary work in the lab had evidenced that stress-induced disruption of nucleoli 
preceded the activation of NF-κB pathway and nucleolar translocation of NF-κB 
RelA (Figure 1.10). They also interestingly found almost all the stress stimuli of NF-
κB modulate nucleolar functions based on a literature review (Table 3.1). These 
findings strongly suggest a casual link between these two events. 
In chapter 3, I made the novel observations that nucleolar stress activated the NF-κB 
pathway. To establish the link between nucleolar disruption and p53, Rubbi and 
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Miller artificially disrupted the Pol I complex then examined p53 stability (Rubbi 
and Milner, 2003). Therefore, I firstly used this approach to examine the link 
between nucleolar disruption and activation of NF-κB. I demonstrated that disrupting 
Pol I complex, using siRNA to Pol I components induced increased NF-κB activity. 
This was not observed in cells expressing super-repressor IκBα, indicating Pol I 
complex disruption stimulates the cytoplasmic pathway (Figure 3.1 and 3.2). 
I also observed the Pol I complex disruption regulated the expressions of NF-κB 
directly targeted genes, and probably with a dynamic property (Figure 3.3-3.5), 
which was termed as ‘NF-κB oscillation’ due to the upregulation of IκBα protein 
level upon NF-κB activation (Nelson et al., 2004). Despite the phenotypic 
consequences of nucleolar stress activation of NF-κB are not clear based on my gene 
expression studies, according to my results and the function of NF-κB pathway, I 
postulate nucleolar stress activation of NF-κB modulating inflammatory response 
and cell growth/death. Further studies using gene microarray upon inducibly 
knocking down Pol I componetns would accurately answer this question in depth.  
I have yet to identify the molecular mechanism underlying nucleolar disruption 
activated NF-κB pathway, but I demonstrate this activation is specifically through 
disruption of Pol I complex rather than a general effect upon inhibition of rDNA 
transcription. Since the chemical inhibitors targeting rDNA transcription had no 
effects on the NF-κB pathway (Figure 3.6). Therefore, this would distinguish the 
mechanism underlying the novel nucleolar stress activation of NF-κB from the well-
established nucleolar stress stabilisation of p53. In parallel with the relocation of 
ribosome proteins (e.g. RPL5/RPL11) results in the stabilisation of p53 as a 
downstream consequence of nucleolar stress (Deisenroth and Zhang, 2010), I 
postulate Pol I complex disruption causes the loss of nucleolar integrity and 
relocation of specific components of Pol I complex or other nucleolar proteins to the 
cytoplasm where it activates NF-κB signalling pathway. I tested the potential role of 
CK2 in this regulation, as CK2 is one of the components in the Pol I transcription 
complex, known to shuttle between subcellular compartments and modulates NF-κB 
under stress (Bierhoff et al., 2008; Drygin et al., 2010; Kato et al., 2003). I found the 
activated NF-κB-driven transcriptional activity by siRNA silencing UBF was slightly 
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repressed in the presence of siRNA against CK2 subunits (Figure 3.6). However, due 
to the uncertain of CK2 knock-down efficiencies, this data is not conclusive to prove 
the involvement of CK2 in connecting Pol I complex disruption and NF-κB 
activation.  
Taken together, these data suggest a novel consequence of nucleolar stress is NF-κB 
activation, allow further studies to pinpoint the phenotypic consequences of nucleolar 
disruption stimulation of NF-κB and to explore the exact molecular mechanisms by 
which loss of nucleolar integrity activates NF-κB pathway.  
Stress induce degradation of Pol I components, TIF-IA  
In order to understand the role of nucleolus in stress-stimulation of NF-κB, I further 
investigated the molecular changes in the nucleolus in response to stress, and made 
the novel observation that stress induce degradation of Pol I transcription initiation 
factor, TIF-IA.  
TIF-IA, Rrn3 in mice, is a basal component of the Pol I initiation complex that is 
indispensiable for regulating cell growth (Jin and Zhou, 2016). In chapter 4, I 
evidenced certain stress stimuli of NF-κB, such as aspirin, UV-C and ceramide 
isoforms, induce the reduction of TIF-IA protein level (Figure 4.1 and 4.2). This is 
the first study to show the depletion of this protein under stress. It is distinct from the 
reported mechanisms of stress regulations on TIF-IA that inactivate TIF-IA through 
modulation its phosphorylation status without significant change on its protein level 
(Drygin et al., 2010).  
Although several mechanisms have been considered could explain stress-induced 
TIF-IA depletion, I demonstrated this depletion is due to stress-mediated protein 
degradation, rather than inhibition on TIF-IA gene transcription or translation (Figure 
4.3-4.5). However, our results revealed the known TIF-IA regulation pathways that 
involve ubiqutination-mediated proteasomal degradation are not applied for this 
situation. Instead, my study shows for the first time that TIF-IA degraded by 
lysosome. In addition, only combination both proteasomal and lysosomal inhibitors 
can completely abrogate aspirin-induced degradation of this protein, suggesting a 
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cooperation of these two protein degradation pathways under stress condtion (Figure 
4.5). Interestingly, there are studies have evidenced the redundancy of the 
degradation pathway, and shown some proteins are degraded by boths pathways 
(Lilienbaum, 2013). Futhermore, the fact that only blocking both degradation 
pathways completely abrogates aspirin effects on TIF-IA would also suggest a 
hypothesis that proteasome and lysosome targets different kinase or phosphatase 
upstream of TIF-IA degradation in the presence of this agent. And these two 
pathways may be required sequentially in the pathway rather than directly targeting 
TIF-IA simultaneously. 
I characterised 94-204 amino acids domain on TIF-IA is sufficient for the stress 
response of this protein, but the modification sites have yet to be identified (Figure 
4.6-4.8). However, finding from the mass spectrometry analysis revealed the 
phosphorylation on serine 44 of TIF-IA protein was down-regulated by aspirin 
treatment (Figure 6.2). Serine 44 and serine 199 of TIF-IA are both regulated by 
mTOR pathway and phosphorylation on these two sites has opposite effects on 
rDNA transcription and cell function (Mayer et al., 2004). This suggests a hypothesis 
that aspirin could induce kinase cascades that regulates multiple phosphorylation 
sites on TIF-IA preceding the degradation of this protein. 
I observed the cellular location of TIF-IA was changed under stress, which became 
disperse in the nucleolus (Figure 4.1). Although some of my data have suggested 
aspirin induces TIF-IA translocated into cytoplasm where it would be degraded, we 
have yet to prove it directly from our immunocytochemistry experiments that to see 
cytoplasmic accumulation of this protein in the presence of aspirin. However, further 
3D confocoal with quantifications would help address this question. As reported by a 
study investigating subcellular localisation of TIF-IA, although nucleolus appeared 
as the brightest cellular compartment with TIF-IA from the 2D confocal slices, it just 
occupied 7% of total celluar TIF-IA after quantified under 3D images and taking 
compartment volume into consideration (Szymanski et al., 2009). Besides, despite 
the preliminary results in the lab have evidenced stress stimuli of NF-κB exert 
distinct nucleolar morphological change (increased nucleli size, decreased nucleoli 
number and nucleolar components segregation), we have yet to characterize whether 
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these changes drive TIF-IA degradation or vice versa. The nature of nucleoli 
formation is nucleoli forming around rDNA termed nucleolar organizer regions 
(NORs) and active rDNA transcription are thought to maintain nucleoar structure. 
Notbaly, there was a study suggested the density of the proteins within nucleoli make 
it act like a ‘liquid droplet’, which could simply alter sizes and shapes under stresses 
by accumulating or dispersing nucleolar factors (Brangwynne et al., 2011). Therefore, 
one hypothesis in this regard is aspirin could target nucleolar factors that affect the 
structure of the acrocentric chromosomes, which caused the ‘droplet’ spread. Further 
experiments to test the structure of acrocentric chromosomes and the association 
between TIF-IA and other Pol I factors with rDNA under aspirin stress condition 
would be with great interest. 
UBF-p14ARF-TIF-IA axis links stress signalling, nucleolar response and 
stimulation of NF-κB pathway 
Having found TIF-IA degradation is a response to stress-stimuli of NF-κB, I further 
demonstrate this degradation is directly linked with stress effects on nucleolus and 
NF-κB stimulation. Based on the analysis from the previous aspirin-nucleolar SILAC 
data in the lab, I revealed p14ARF was a regulator of stress-mediated degradation of 
TIF-IA. Blocking aspirin-induced TIF-IA degradation in the presence of p14ARF 
siRNA also abrogated the nucleolar enlargement, NF-κB activation and induction of 
cell apoptosis in response to this agent (Figure 5.2-5.5 and Figure 5.10). Besides, I 
demonstrated UBF acts as an accessory of this regulation, with phosphorylation 
status of serine 484 on this protein is required (Figure 5.8 and 5.9). I have yet to 
illustrate the relationship between UBF and p14ARF in this process, but given the 
known regulation that p14ARF associates with UBF in nucleolus and modulate its 
phosphorylation (Ayrault et al., 2006), I propose the phosphorylation status of UBF 
is essential for the interaction between p14ARF and TIF-IA or the degradation of 
TIF-IA.  
In terms of the upstream pathways regulating stress-mediated nucleolar response, I 
addressed the involvement of CDK4 kinase in this regulation by showing CDK4 
inhibition mimics TIF-IA degradation and shared the similar mechanism of this 
degradation as aspirin, particularly through modulation on the UBF-p14ARF axis 
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(Figure 4.9-4.10 and 5.6-5.7). These data are in consistent with the fundamental 
works in the lab showing CDK4 inhibition replicates aspirin-caused nucleolar 
enlargement and rDNA transcription inhibition, thus suggesting the importance of 
CDK4 inhibition in this nucleolar response pathway. Notbaly, I also observed 
although aspirin-induced TIF-IA degradation can only be abrogated by applying both 
proteasomal and lysosomal inhibitors, either of it can efficiently block CDK4 
inhibitor-induced TIF-IA degradation. This could suggest aspirin triggers a number 
of pathways, which includes CDK4-mediated pathway. However, whether CDK4 is a 
direct regulator of aspirin-induced stress response need to be further addressed. 
From my results, I can not completely rule out the possibility that other 
factors/pathways besides UBF/p14ARF are involved in this regulation. Firstly, 
depletion of UBF/p14ARF did not completely block aspirin/CDK4i-mediated TIF-IA 
degradation. Secondly, aspirin/CDK4i causes TIF-IA degradation to a reasonable 
extent in cells without or low expression of p14ARF. Thirdly, mass spectrometry 
analysis implies involvement of other signals in this process. However, based on my 
observations of siRNA against p14ARF significantly blocking aspirin effects on 
nucleolar morphology, NF-κB activation and cell apoptosis, I propose this UBF-
p14ARF-TIF-IA axis is central in regulating stress-stimulation of NF-κB and plays a 
role in the pro-apoptotic effects of aspirin. I also believe this nucleolar response 
pathway is not dependent on p53 pathway, which has been well-studied as a 
regulator in nucleolar stress response. As evidenced in my data that aspirin induced 
TIF-IA degradation both in p53 wile type or p53 null cells (Figure 4.8 F), and the 
block effects of siRNA p14ARF on aspirin-mediated TIF-IA degradation do not 
change in the presence siRNA against p53 (Figure 5.5 F). Furthermore, previous 
publication in the lab have clarified aspirin effects on NF-κB activation and 
induction of colorectal cancer apoptosis is unrelated to the p53 status (Din et al., 
2004).  
The significance of this nucleolar stress response pathway in the pro-apoptotic 
effect of aspirin. 
Nucleolus and Pol I transcription have been emerging as exciting targets for cancer 
therapy (Reviewed in 1.3.2). Above data I presented, which revealed a nucleolar 
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response pathway results in the inhibition of rDNA transcription, proposed a novel 
pathway that could be exploited for therapeutic purpose.  
Firstly, our study has found ceramide isoforms mimic aspirin effects on nucleolar 
morphological change, NF-κB activation and importantly, TIF-IA degradation 
(Figure 4.2). Interestingly, previous study investigating the anti-tumour effects of 
aspirin had suggested the inhibition of COX, a direct target of aspirin, mediated 
cancer cell apoptosis by causing an increase in ceramide levels (Chan et al., 1998). 
This implies a possibility that the pro-apoptotic effect of aspirin is through 
upregulating ceramide and subsequently inducing downstream TIF-IA degradation 
and NF-κB activation.  
Secondly, I also suggest that this nucleolar pathway is indeed utilised by aspirin for 
anti-tumour effects by demonstrating siRNA against p14ARF, which blocks aspirin-
mediated degradation of TIF-IA and rDNA transcription inhibition, also blocks the 
decrease of pro-caspase 3 and induction of colorectal cancer cell apoptosis in 
response to this agent (Figure 5.10). In supporting with this finding, aspirin treatment 
in biopsies of fresh resected colon tumour from clinical patients has indicated a 
strong relationship between aspirin-induced TIF-IA degradation and aspirin effects 
on phosphorylation of RelA (not published data in the lab). Therefore, this thesis 
proposes a new mode of the anti-tumour action of aspirin that through modulation on 
nucleolar response and rDNA transcription inhibition. Further ex vivo works in this 
context would help on the potential utilisation of this model for predicting the cancer 
prevention outcome of aspirin in individuals. Interestingly, an aspirin-induced 
genome-wide expression study in colon cancer HT-29 cells strongly support the 
significance of nucleolar response in anti-tumour action of this agent, as they 
revealed the most marked effects of aspirin were on genes encoding proteins function 
on ribosome assembly and rRNA metabolism (Yin et al., 2006).  
Furthermore, in my study, I demonstrated CDK4 inhibition mimics aspirin effects on 
this nucleolar response pathway, that is cause UBF/p14ARF-facilitated TIF-IA 
degradation, inhibition of rDNA transcription and stimulation of NF-κB pathway. 
Defects in the cyclin D1/CDK4 pathways is common in human cancer, which result 
in the uncontrolled G1/S cell cycle progression and lead to excessive proliferation in 
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tumour cells (Peurala et al., 2013). There is a great interest in targeting CDK4 for 
cancer therapy. However, most of these inhibitors shown efficiency in inhibition 
CDK4 activity have unclear anti-tumour mechanism (Sherr et al., 2016). Here, the 
data I presented suggest CDK4 inhibitor could repress the dysregulated nucleolar 
activity, thus proposing a novel mechanism by which CDK4 inhibition could reduce 
cancer cell growth.  
 
Taken together, these works have made steps forward in understanding the molecular 
basis underlying the anti-tumour effects of aspirin. Based on these new aspects and 
previously identified molecular mechanisms, I propose a new model that summarise 
the significance of the host laboratory findings in understanding the anti-tumour 
action of aspirin, with a view for developing novel therapeutic targets against colon 
cancer (Figure 7.2). This model also addressed the central role of nucleolus and NF-
κB pathway in aspirin response.  
 
1) Aspirin induces degradation of IκBα, NF-κB nuclear translocation, which is linked 
with cell growth inhibition (Stark et al., 2001).   
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2) NF-κB component RelA is sequestered in the nucleolus following aspirin 
treatment, as well as other stimuli such as UV-C and serum starvation, but not by 
cytokines like TNFα and TRAIL. As a result of this sequestration, NF-κB driven 
transcriptional activity in nuclear is repressed and NF-κB targeted genes expression 
is decreased, which consequently induce cell apoptosis. A N-terminal motif (27-30 
amino acids) of RelA has been identified as nucleolar localisation signal (NoLS) 
(Stark and Dunlop, 2005).  
3) Upstream molecular pathway responsible for nucleolar targeting of RelA under 
aspirin stress was characterised (Thoms et al., 2007b). The host laboratory revealed 
aspirin stimulated the p38 mitogen-activated protein kinase (MAPK) pathway in 
prior to degradation of Cyclin D1 and inhibition of CDK4 activity. They also 
demonstrated this upstream signalling cascade preceded the activation of NF-κB 
pathway and nuclear/nucleolar translocation of RelA. CDK4 inhibition reproduced 
aspirin’s effects on NF-κB pathway and cell apoptosis through a common 
mechanism involving the N-terminal NoLS of RelA (Thoms et al., 2007b). 
4) Molecular mechanisms underlying aspirin-induced RelA nucleolar accumulation 
were further determined. That is, ubiquitination of RelA is essential for this process 
and NoLS on this protein is critical for ubiquitination modification. Moreover, a 
scaffold protein COMMD1was identified interacts with RelA and promotes its 
ubiquitination following aspirin treatment (Thoms et al., 2010). Further study also 
revealed aspirin upregulates COMMD1 protein level through promoting p300-
mediated acetylation of COMMD1 which protects COMMD1 from XIAP-mediated 
proteasomal degradation (O'Hara et al., 2014).  
5) In this thesis, I demonstrated aspirin/CDK4 inhibition induced degradation of Pol I 
factor TIF-IA through regulation on a UBF-p14ARF axis. And this nucleolar stress 
response pathway lies upstream of stress-mediated activation of NF-κB and cell 
apoptosis.  
6) The mechanism of how nucleolar disruption activates NF-κB has yet been 
characterised, with some potential candidate factors been proposed for further study.  
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7) Based on previous and my studies, I propose the nucleolus is central for cellular 
aspirin response. First, aspirin-induced nucleolar stress response precedes its effect 
on activation of cytoplasmic NF-κB. Second, nucleolar sequestration of RelA NF-κB 
is a downstream consequence of aspirin treatment and directly linked with cell 
apoptosis. It would be bold but interesting to hypothesis there was a link between this 
novel nucleolar stress response pathway identified in this thesis and nucleolar 
sequestration of RelA in response to aspirin, which formed a feedback loop to 
regulate the activity of NF-κB pathway and anti-tumour effects of aspirin.  
8) Previous study in the lab also indicated another pathway mediated aspirin-induced 
cell apoptosis which was not dependent on NF-κB driven transcription activity. They 
found nucleolar accumulation of RelA promoted relocation of nucleolar protein 
NPM to the cytoplasm, which consequently facilitated the accumulation of BAX in 
mitochondrial and resulted in enhanced cell apoptotic activity (Khandelwal et al., 
2011).  
9) The knowledge of genetic markers that could predict the anti-tumour effects of 
aspirin in individuals will be essential to forward the cancer-prevention application 
of aspirin into personalized clinical assessment and practice (see Chapter 1 section 
1.6). Considering the close relationships between the NF-κB pathway and current 
identified genetic markers (TNFR2, IL-16, PI3K, BRAF, Chapter 1 section 1.6), it 
would be interesting to know whether the activation of NF-κΒ is directly related to 
the outcome of aspirin treatment in colorectal cancer prevention.  
 
In summary, work carried out in this thesis demonstrated for the first time that 
nucleolar stress activates NF-κB pathway. I also illustrated how the nucleolus 
appears to be central in the cells response to stress stimuli of NF-κB and a novel 
nucleolar pathway containing CDK4-UBF-p14ARF-TIF-IA axis was identified in 
this regard. My work has already highlighted the complexity of this nucleolar stress 
response pathway and addressed the orientations for further investigations in 
elucidating this pathway. Furthermore, I indicated the potential role of this pathway 
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in the anti-tumour effects of aspirin, and believe future works are worthwhile to be 
focused on deeply understanding the role and its significance in clinical practice.  
Conclusion – nucleolus is central for sensing stress-stimuli of NF-κB which is most 
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